llipinggg的个人主页 - 老虎社区

llipinggg

暂无个人介绍

IP属地：未知

207关注

20粉丝

0主题

0勋章

2021-11-15

Like

These are the next three mega-cap tech stocks you’ll be hearing more about

2021-12-24

Like

Japan health panel approves Merck's oral COVID-19 treatment

2021-11-01

Like

Federal Reserve decision, October jobs report: What to know this week

2021-10-21

Like

Portillo's stock soared more than 40% after it opened at $26.00 above $20 IPO price

2021-11-27

Like

Dow plunges 905 points in Black Friday selloff, books worst day in over a year as WHO declares new COVID 'variant of concern'

2021-11-25

Like

7 stocks with the most Thanksgiving exposure, according to Bank of America

2021-10-28

Like

‘Sticky’ Inflation May Drive Gold to New Peak, Agnico CEO Says

2021-10-24

Like

US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week

2021-09-30

Like

What You Need to Know About IBM's $19 Billion Spinoff

2021-12-27

Like

Novavax shares dropped 8% in morning trading

2021-12-16

Loke

Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron

2021-10-10

Like

Is the stock market open on Columbus Day? Yes! But the bond market isn't--Here's why

2021-09-25

K

7 Best Stocks To Buy for Investors Building a ‘Brands’ Portfolio

2021-12-23

Like

U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19

2021-12-15

Like

U.S. stock market kicks off lackluster start on Fed decision day,S&P 500 gains 0.1%

2021-12-09

Like

2 Short-Squeeze Candidates That Could Go Parabolic Soon

2021-10-20

Like

PayPal Said to Explore Purchase of Social Media Firm Pinterest

2021-10-19

Like

Morgan Stanley’s Kushma Says Bond Yields Climbing Too Quickly

2021-10-12

Like

Another Earnings Season Is Here. What to Expect This Time.

2021-10-02

Like

3 Stocks That Can Double Again in the Fourth Quarter

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3576377533433583,"uuid":"3576377533433583","gmtCreate":1613285558478,"gmtModify":1613285558478,"name":"llipinggg","pinyin":"llipinggg","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":20,"headSize":207,"tweetSize":250,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":692016294,"gmtCreate":1640790929927,"gmtModify":1640790930233,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692016294","repostId":"1147073840","repostType":4,"repost":{"id":"1147073840","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640786111,"share":"https://www.laohu8.com/m/news/1147073840?lang=&edition=full","pubTime":"2021-12-29 21:55","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1147073840","media":"Benzinga","summary":"Tigress Financial lifted the price target on McDonald's Corporation (NYSE:MCD) from $271 to $314. Mc","content":"<html><head></head><body><p>Tigress Financial lifted the price target on McDonald&#39;s Corporation (NYSE:MCD) from $271 to $314. McDonald&#39;s shares fell 0.1% to close at $267.88 on Tuesday.</p><p>Argus Research boosted the price target on Cintas Corporation (NASDAQ:CTAS) from $410 to $490. Cintas shares rose 0.5% to close at $444.10 on Tuesday.</p><p>Needham boosted Tenable Holdings, Inc. (NASDAQ:TENB) price target from $62 to $66. Tenable shares fell 0.8% to close at $55.46 on Tuesday.</p><p>B of A Securities cut Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) price target from $37 to $34. Kiniksa Pharmaceuticals shares rose 1.8% to $12.35 in pre-market trading.</p><p>HC Wainwright &amp; Co. raised Dynavax Technologies Corporation (NASDAQ:DVAX) price target from $23 to $28. Dynavax Technologies shares gained 1.4% to $14.40 in pre-market trading.</p><p>Needham cut the price target on Cellebrite DI Ltd. (NASDAQ:CLBT) from $12 to $9.5. Cellebrite DI shares rose 5.2% to close at $8.35 on Tuesday.</p><p>Compass Point boosted Bluerock Residential Growth REIT, Inc. (NYSE:BRG) price target from $14.5 to $27. Bluerock Residential Growth shares fell 1.7% to $26.22 in pre-market trading.</p><p>Needham lowered the price target for <a href=\"https://laohu8.com/S/NABL\">N-able, Inc.</a> (NASDAQ:NABL) from $17 to $13.5. N-able shares fell 2.9% to $10.89 in pre-market trading.</p><p>Argus Research raised the price target for Edison International (NYSE:EIX) from $68 to $73. Edison International shares rose 0.1% to $68.21 in pre-market trading.</p><p>Needham lifted <a href=\"https://laohu8.com/S/MSP\">Datto Holding Corp.</a> (NYSE:MSP) price target from $29 to $32. Datto Holding shares fell 3.5% to $26.00 in pre-market trading.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-29 21:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Tigress Financial lifted the price target on McDonald&#39;s Corporation (NYSE:MCD) from $271 to $314. McDonald&#39;s shares fell 0.1% to close at $267.88 on Tuesday.</p><p>Argus Research boosted the price target on Cintas Corporation (NASDAQ:CTAS) from $410 to $490. Cintas shares rose 0.5% to close at $444.10 on Tuesday.</p><p>Needham boosted Tenable Holdings, Inc. (NASDAQ:TENB) price target from $62 to $66. Tenable shares fell 0.8% to close at $55.46 on Tuesday.</p><p>B of A Securities cut Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) price target from $37 to $34. Kiniksa Pharmaceuticals shares rose 1.8% to $12.35 in pre-market trading.</p><p>HC Wainwright &amp; Co. raised Dynavax Technologies Corporation (NASDAQ:DVAX) price target from $23 to $28. Dynavax Technologies shares gained 1.4% to $14.40 in pre-market trading.</p><p>Needham cut the price target on Cellebrite DI Ltd. (NASDAQ:CLBT) from $12 to $9.5. Cellebrite DI shares rose 5.2% to close at $8.35 on Tuesday.</p><p>Compass Point boosted Bluerock Residential Growth REIT, Inc. (NYSE:BRG) price target from $14.5 to $27. Bluerock Residential Growth shares fell 1.7% to $26.22 in pre-market trading.</p><p>Needham lowered the price target for <a href=\"https://laohu8.com/S/NABL\">N-able, Inc.</a> (NASDAQ:NABL) from $17 to $13.5. N-able shares fell 2.9% to $10.89 in pre-market trading.</p><p>Argus Research raised the price target for Edison International (NYSE:EIX) from $68 to $73. Edison International shares rose 0.1% to $68.21 in pre-market trading.</p><p>Needham lifted <a href=\"https://laohu8.com/S/MSP\">Datto Holding Corp.</a> (NYSE:MSP) price target from $29 to $32. Datto Holding shares fell 3.5% to $26.00 in pre-market trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CTAS":"信达思","BRG":"Bluerock Residential Growth REIT Inc","TGT":"塔吉特","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4504":"桥水持仓","NABL":"N-able, Inc.","KNSA":"Kiniksa Pharmaceuticals Ltd.","BK4532":"文艺复兴科技持仓","BK4114":"综合货品商店","EIX":"爱迪生国际","MCD":"麦当劳","TENB":"Tenable Holdings Inc.","CLBT":"Cellebrite","DVAX":"德纳维制药","MSP":"Datto Holding Corp."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147073840","content_text":"Tigress Financial lifted the price target on McDonald's Corporation (NYSE:MCD) from $271 to $314. McDonald's shares fell 0.1% to close at $267.88 on Tuesday.Argus Research boosted the price target on Cintas Corporation (NASDAQ:CTAS) from $410 to $490. Cintas shares rose 0.5% to close at $444.10 on Tuesday.Needham boosted Tenable Holdings, Inc. (NASDAQ:TENB) price target from $62 to $66. Tenable shares fell 0.8% to close at $55.46 on Tuesday.B of A Securities cut Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) price target from $37 to $34. Kiniksa Pharmaceuticals shares rose 1.8% to $12.35 in pre-market trading.HC Wainwright & Co. raised Dynavax Technologies Corporation (NASDAQ:DVAX) price target from $23 to $28. Dynavax Technologies shares gained 1.4% to $14.40 in pre-market trading.Needham cut the price target on Cellebrite DI Ltd. (NASDAQ:CLBT) from $12 to $9.5. Cellebrite DI shares rose 5.2% to close at $8.35 on Tuesday.Compass Point boosted Bluerock Residential Growth REIT, Inc. (NYSE:BRG) price target from $14.5 to $27. Bluerock Residential Growth shares fell 1.7% to $26.22 in pre-market trading.Needham lowered the price target for N-able, Inc. (NASDAQ:NABL) from $17 to $13.5. N-able shares fell 2.9% to $10.89 in pre-market trading.Argus Research raised the price target for Edison International (NYSE:EIX) from $68 to $73. Edison International shares rose 0.1% to $68.21 in pre-market trading.Needham lifted Datto Holding Corp. (NYSE:MSP) price target from $29 to $32. Datto Holding shares fell 3.5% to $26.00 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696265797,"gmtCreate":1640705548538,"gmtModify":1640705548821,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/696265797","repostId":"1118096605","repostType":4,"repost":{"id":"1118096605","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640702927,"share":"https://www.laohu8.com/m/news/1118096605?lang=&edition=full","pubTime":"2021-12-28 22:48","market":"us","language":"en","title":"Meta Platforms Stock Climbed More Than 1% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1118096605","media":"Tiger Newspress","summary":"Meta Platforms stock climbed more than 1% in morning trading as Facebook stock could get a big boost","content":"<p>Meta Platforms stock climbed more than 1% in morning trading&nbsp;as&nbsp;Facebook stock could get a big boost from surging Oculus sales,analyst&nbsp;said.</p>\n<p><img src=\"https://static.tigerbbs.com/e2ae2b8db56f2dada813c9b14eab1bc1\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Meta's latest Oculus VR handset dubbed the Quest 2 appears to have been a hot gift this holiday season, underscoring one reason why shares of the social media giant remain a buy, says Jefferies analyst&nbsp;Brent Thill.</p>\n<p>Based on new research by Thill on Tuesday, the Oculus app was the number one most downloaded app in the App store on Christmas Day. Oculus downloads and daily active users on Christmas Day surged 70% and 90%, respectively, from the prior year.</p>\n<p>The gains are impressive in the sense the Quest 2 isn't cheap at nearly $400.</p>\n<p>\"We view this massive uptick in app usage as evidence that the improved slate of games and experiences is resonating with users and that Quest 2 sales are likely to surprise. Quest 2s were popular gifts in our households this Christmas with 'SuperHot' and 'Eleven Table Tennis' among our favorite games,\" Thill said.</p>\n<p>Added Thill, \"As teens spend an increasing amount of time on services like SNAP, TikTok, RBLX, and Fortnite it is becoming more challenging for FB to attract and retain younger users. We believe that Quest 2 could serve as an on-ramp for attracting these users, as they can more easily be introduced to FB's diverse offering of games, experiences, and social platforms. We also see Oculus' mainstream success as a potential catalyst for game developers to work more closely with FB.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b5fc51977410835f4bf21d41b7b66fa\" tg-width=\"960\" tg-height=\"604\" width=\"100%\" height=\"auto\"><span>Oculus was a hot seller this holiday season.</span></p>\n<p>Thill — a long-time Meta bull — maintained a Buy rating on Meta with a price target of $420.</p>\n<p>While Thill acknowledges headline risk to Meta's stock from privacy concerns, he contends valuation is too compelling to ignore in light of key fundamental drivers such as Oculus.</p>\n<p>\"Our most recent advertiser checks point to a healthy environment for digital ad spending. Additionally, recent Mastercard data indicates that online retail Holiday sales were up 11% year-over-year (and 61% vs. 2019), providing further evidence that holiday ad demand was likely robust. With the stock trading at just 20x FY23E earnings per share (vs. Nasdaq comparable 26x), we see plenty of opportunity for a higher stock over the next 12 months,\" Thill concluded.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Stock Climbed More Than 1% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Stock Climbed More Than 1% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-28 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Meta Platforms stock climbed more than 1% in morning trading&nbsp;as&nbsp;Facebook stock could get a big boost from surging Oculus sales,analyst&nbsp;said.</p>\n<p><img src=\"https://static.tigerbbs.com/e2ae2b8db56f2dada813c9b14eab1bc1\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Meta's latest Oculus VR handset dubbed the Quest 2 appears to have been a hot gift this holiday season, underscoring one reason why shares of the social media giant remain a buy, says Jefferies analyst&nbsp;Brent Thill.</p>\n<p>Based on new research by Thill on Tuesday, the Oculus app was the number one most downloaded app in the App store on Christmas Day. Oculus downloads and daily active users on Christmas Day surged 70% and 90%, respectively, from the prior year.</p>\n<p>The gains are impressive in the sense the Quest 2 isn't cheap at nearly $400.</p>\n<p>\"We view this massive uptick in app usage as evidence that the improved slate of games and experiences is resonating with users and that Quest 2 sales are likely to surprise. Quest 2s were popular gifts in our households this Christmas with 'SuperHot' and 'Eleven Table Tennis' among our favorite games,\" Thill said.</p>\n<p>Added Thill, \"As teens spend an increasing amount of time on services like SNAP, TikTok, RBLX, and Fortnite it is becoming more challenging for FB to attract and retain younger users. We believe that Quest 2 could serve as an on-ramp for attracting these users, as they can more easily be introduced to FB's diverse offering of games, experiences, and social platforms. We also see Oculus' mainstream success as a potential catalyst for game developers to work more closely with FB.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b5fc51977410835f4bf21d41b7b66fa\" tg-width=\"960\" tg-height=\"604\" width=\"100%\" height=\"auto\"><span>Oculus was a hot seller this holiday season.</span></p>\n<p>Thill — a long-time Meta bull — maintained a Buy rating on Meta with a price target of $420.</p>\n<p>While Thill acknowledges headline risk to Meta's stock from privacy concerns, he contends valuation is too compelling to ignore in light of key fundamental drivers such as Oculus.</p>\n<p>\"Our most recent advertiser checks point to a healthy environment for digital ad spending. Additionally, recent Mastercard data indicates that online retail Holiday sales were up 11% year-over-year (and 61% vs. 2019), providing further evidence that holiday ad demand was likely robust. With the stock trading at just 20x FY23E earnings per share (vs. Nasdaq comparable 26x), we see plenty of opportunity for a higher stock over the next 12 months,\" Thill concluded.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118096605","content_text":"Meta Platforms stock climbed more than 1% in morning trading as Facebook stock could get a big boost from surging Oculus sales,analyst said.\n\nMeta's latest Oculus VR handset dubbed the Quest 2 appears to have been a hot gift this holiday season, underscoring one reason why shares of the social media giant remain a buy, says Jefferies analyst Brent Thill.\nBased on new research by Thill on Tuesday, the Oculus app was the number one most downloaded app in the App store on Christmas Day. Oculus downloads and daily active users on Christmas Day surged 70% and 90%, respectively, from the prior year.\nThe gains are impressive in the sense the Quest 2 isn't cheap at nearly $400.\n\"We view this massive uptick in app usage as evidence that the improved slate of games and experiences is resonating with users and that Quest 2 sales are likely to surprise. Quest 2s were popular gifts in our households this Christmas with 'SuperHot' and 'Eleven Table Tennis' among our favorite games,\" Thill said.\nAdded Thill, \"As teens spend an increasing amount of time on services like SNAP, TikTok, RBLX, and Fortnite it is becoming more challenging for FB to attract and retain younger users. We believe that Quest 2 could serve as an on-ramp for attracting these users, as they can more easily be introduced to FB's diverse offering of games, experiences, and social platforms. We also see Oculus' mainstream success as a potential catalyst for game developers to work more closely with FB.\nOculus was a hot seller this holiday season.\nThill — a long-time Meta bull — maintained a Buy rating on Meta with a price target of $420.\nWhile Thill acknowledges headline risk to Meta's stock from privacy concerns, he contends valuation is too compelling to ignore in light of key fundamental drivers such as Oculus.\n\"Our most recent advertiser checks point to a healthy environment for digital ad spending. Additionally, recent Mastercard data indicates that online retail Holiday sales were up 11% year-over-year (and 61% vs. 2019), providing further evidence that holiday ad demand was likely robust. With the stock trading at just 20x FY23E earnings per share (vs. Nasdaq comparable 26x), we see plenty of opportunity for a higher stock over the next 12 months,\" Thill concluded.","news_type":1},"isVote":1,"tweetType":1,"viewCount":681,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696382108,"gmtCreate":1640618475036,"gmtModify":1640618475276,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696382108","repostId":"1103486686","repostType":4,"repost":{"id":"1103486686","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640616531,"share":"https://www.laohu8.com/m/news/1103486686?lang=&edition=full","pubTime":"2021-12-27 22:48","market":"us","language":"en","title":"Novavax shares dropped 8% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1103486686","media":"Tiger Newspress","summary":"Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.","content":"<p>Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.</p>\n<p><img src=\"https://static.tigerbbs.com/d6627c5ec391aa02c9ec15dfc36c8f87\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares dropped 8% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares dropped 8% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-27 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.</p>\n<p><img src=\"https://static.tigerbbs.com/d6627c5ec391aa02c9ec15dfc36c8f87\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103486686","content_text":"Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698733350,"gmtCreate":1640531626103,"gmtModify":1640531626339,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698733350","repostId":"1166698166","repostType":4,"repost":{"id":"1166698166","pubTimestamp":1640484465,"share":"https://www.laohu8.com/m/news/1166698166?lang=&edition=full","pubTime":"2021-12-26 10:07","market":"us","language":"en","title":"Clover Health Is Not the $2 Billion Stock to Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1166698166","media":"InvestorPlace","summary":"Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth ","content":"<p><b>Clover Health</b>(NASDAQ:<b><u>CLOV</u></b>) finished its first day of trading in early January with CLOV stock worth approximately$7 billion. It had just completed its merger with Social Capital Hedosophia III, the special purpose acquisition company (SPAC) sponsored by “Silicon Valley venture capitalist” Chamath Palihapitiya.</p>\n<p>Today, as I write this, it’s worth approximately $1.94 billion, 74% less than it’s $7 billion valuation.</p>\n<p>When I last wrote about Clover Health in early December,I suggested,“only the most speculative investors ought to be anywhere near this healthcare stock.” Since then, CLOV stock has lost another 9% as we approach the end of the year.</p>\n<p>While CLOV stock is trading for pennies over $4, here are three similarly-valued stocks to buy for 2022.</p>\n<p>Forget CLOV Stock — Buy This Instead</p>\n<p>According to<i>Finviz.com,</i>there are64 stocks&nbsp;with a market capitalization between $1.9 billion and $2 billion. My three picks grow sales, generate profits, and possess solid balance sheets. If you’re lucky, at least one will pay a decent dividend.</p>\n<p>Ultimately, all three are, in my opinion, safer bets than CLOV in 2022.</p>\n<p><b>Sonic Automotive</b>(NYSE:<b><u>SAH</u></b>) is my first pick. It has a current market cap of $2 billion. Its stock is up 25.77% year-to-date (YTD), 258 basis points less than the<b>S&amp;P 500</b>.</p>\n<p>Sonic is one of the top automotive retailers in America. Its&nbsp;119 dealerships&nbsp;are located in 17 states and represent more than 25 brands. In its latest fiscal year, it sold 93,000 new vehicles and 159,000 used vehicles, generating $9.8 billion in revenue.&nbsp; It expects to grow its revenue to $25 billion by 2025.</p>\n<p>From a brand breakdown, luxury accounts for 55% of its sales with BMW, Mercedes, and Audi accounting for 71% of its luxury vehicle sales.</p>\n<p>In 2021’s third-quarter, its revenues grew by 20.6% to $3.07 billion. Its net income rose 46.9% to $84.7 million and its total debt is$1.97 billion&nbsp;or 56% of its total assets.</p>\n<p>The company’s Echo Park used car business should be a big contributor as it pushes to $25 billion in sales by 2025.</p>\n<p>The Second Alternative to CLOV Stock</p>\n<p><b>Sally Beauty Holdings</b>(NYSE:<b><u>SBH</u></b>) business and the stock bounced back in 2021. That’s great news for long-time shareholders. Up 42.8% YTD, SBH’s five-year return looks a little better as a result. However, it’s down 29% on a cumulative basis over the past 60 months.</p>\n<p>Back in May 2017, I compared&nbsp;Sally Beauty and&nbsp;<b>Ulta Beauty Holdings</b>(NASDAQ:<b><u>ULTA</u></b>). ULTA was on a bit of a roll, while SBH was stumbling and bumbling. So, wisely, I said ULTA was the better stock to buy. Ulta is up 28.2% since — it’s also had its ups and downs — while SBH is up 3.8% over the same period.</p>\n<p>However, I thought Sally Beauty’s restructuring at the time was gaining traction. While Covid-19 didn’t help its business, its most recent results are encouraging.</p>\n<p>For all of fiscal 2021, its&nbsp;sales increased10.3% to $3.87 billion with 10.2% same-store sales growth. Its operating earnings grew 44.2% in 2021 to $622.7 million, and it managed to reduce its debt by $420 million in the past year. That puts its long-term debt at $1.38 billion or 48% of its total assets.</p>\n<p>On Oct. 1, board member Denise Paulonistook over as chief executive officer (CEO)of the company. She is tasked with growing sales and profits after previous CEO Chris Brinkman thoroughly modernized its beauty business during his six-year tenure.</p>\n<p>A Final Possibility</p>\n<p>My final alternative is&nbsp;<b>Goldman Sachs BDC</b>(NYSE:<b><u>GSBD</u></b>). It was founded in 2012 to make debt and equity investments in middle-market companies — defined as earnings before interest, taxes, depreciation and amortization (EBITDA) earnings of$5 million to $200 million— and merged with Goldman Sachs Middle Market Lending Corp. (MMLC) in October 2020.</p>\n<p>As a result of the merger, GSBD’s asset base more than doubled to$3.5 billion. The MMLC shareholders received 1.1336 GSBD shares for every share of MMLC.</p>\n<p>GSBD had $3.11 billion in investments and $401.8 million in unfunded commitments for111 portfolio companies&nbsp;across 37 industries at the end of September. Approximately 84% of its assets are first lien loans with an average yield of 8.4%.</p>\n<p>It’s essential to remember that this is an investment focused on income rather than capital appreciation. The BDC’s current quarterly distribution of $0.50 yields a very high 10.4%.</p>\n<p>Do not buy GSBD if you’re expecting capital appreciation. However, if you’re willing to take on more risk than a guaranteed investment, it’s an excellent way to boost your income portfolio.</p>\n<p>None of these three alternatives to CLOV stock are a sure thing. But, that said, I don’t believe they possess the same amount of risk as Clover Health.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health Is Not the $2 Billion Stock to Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health Is Not the $2 Billion Stock to Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth approximately$7 billion. It had just completed its merger with Social Capital Hedosophia III, the ...</p>\n\n<a href=\"https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/12/clover-health-and-clov-stock-is-not-the-2-billion-stock-to-buy-for-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166698166","content_text":"Clover Health(NASDAQ:CLOV) finished its first day of trading in early January with CLOV stock worth approximately$7 billion. It had just completed its merger with Social Capital Hedosophia III, the special purpose acquisition company (SPAC) sponsored by “Silicon Valley venture capitalist” Chamath Palihapitiya.\nToday, as I write this, it’s worth approximately $1.94 billion, 74% less than it’s $7 billion valuation.\nWhen I last wrote about Clover Health in early December,I suggested,“only the most speculative investors ought to be anywhere near this healthcare stock.” Since then, CLOV stock has lost another 9% as we approach the end of the year.\nWhile CLOV stock is trading for pennies over $4, here are three similarly-valued stocks to buy for 2022.\nForget CLOV Stock — Buy This Instead\nAccording toFinviz.com,there are64 stocks with a market capitalization between $1.9 billion and $2 billion. My three picks grow sales, generate profits, and possess solid balance sheets. If you’re lucky, at least one will pay a decent dividend.\nUltimately, all three are, in my opinion, safer bets than CLOV in 2022.\nSonic Automotive(NYSE:SAH) is my first pick. It has a current market cap of $2 billion. Its stock is up 25.77% year-to-date (YTD), 258 basis points less than theS&P 500.\nSonic is one of the top automotive retailers in America. Its 119 dealerships are located in 17 states and represent more than 25 brands. In its latest fiscal year, it sold 93,000 new vehicles and 159,000 used vehicles, generating $9.8 billion in revenue.  It expects to grow its revenue to $25 billion by 2025.\nFrom a brand breakdown, luxury accounts for 55% of its sales with BMW, Mercedes, and Audi accounting for 71% of its luxury vehicle sales.\nIn 2021’s third-quarter, its revenues grew by 20.6% to $3.07 billion. Its net income rose 46.9% to $84.7 million and its total debt is$1.97 billion or 56% of its total assets.\nThe company’s Echo Park used car business should be a big contributor as it pushes to $25 billion in sales by 2025.\nThe Second Alternative to CLOV Stock\nSally Beauty Holdings(NYSE:SBH) business and the stock bounced back in 2021. That’s great news for long-time shareholders. Up 42.8% YTD, SBH’s five-year return looks a little better as a result. However, it’s down 29% on a cumulative basis over the past 60 months.\nBack in May 2017, I compared Sally Beauty and Ulta Beauty Holdings(NASDAQ:ULTA). ULTA was on a bit of a roll, while SBH was stumbling and bumbling. So, wisely, I said ULTA was the better stock to buy. Ulta is up 28.2% since — it’s also had its ups and downs — while SBH is up 3.8% over the same period.\nHowever, I thought Sally Beauty’s restructuring at the time was gaining traction. While Covid-19 didn’t help its business, its most recent results are encouraging.\nFor all of fiscal 2021, its sales increased10.3% to $3.87 billion with 10.2% same-store sales growth. Its operating earnings grew 44.2% in 2021 to $622.7 million, and it managed to reduce its debt by $420 million in the past year. That puts its long-term debt at $1.38 billion or 48% of its total assets.\nOn Oct. 1, board member Denise Paulonistook over as chief executive officer (CEO)of the company. She is tasked with growing sales and profits after previous CEO Chris Brinkman thoroughly modernized its beauty business during his six-year tenure.\nA Final Possibility\nMy final alternative is Goldman Sachs BDC(NYSE:GSBD). It was founded in 2012 to make debt and equity investments in middle-market companies — defined as earnings before interest, taxes, depreciation and amortization (EBITDA) earnings of$5 million to $200 million— and merged with Goldman Sachs Middle Market Lending Corp. (MMLC) in October 2020.\nAs a result of the merger, GSBD’s asset base more than doubled to$3.5 billion. The MMLC shareholders received 1.1336 GSBD shares for every share of MMLC.\nGSBD had $3.11 billion in investments and $401.8 million in unfunded commitments for111 portfolio companies across 37 industries at the end of September. Approximately 84% of its assets are first lien loans with an average yield of 8.4%.\nIt’s essential to remember that this is an investment focused on income rather than capital appreciation. The BDC’s current quarterly distribution of $0.50 yields a very high 10.4%.\nDo not buy GSBD if you’re expecting capital appreciation. However, if you’re willing to take on more risk than a guaranteed investment, it’s an excellent way to boost your income portfolio.\nNone of these three alternatives to CLOV stock are a sure thing. But, that said, I don’t believe they possess the same amount of risk as Clover Health.","news_type":1},"isVote":1,"tweetType":1,"viewCount":517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698513920,"gmtCreate":1640445196090,"gmtModify":1640445196363,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698513920","repostId":"2193917872","repostType":4,"repost":{"id":"2193917872","pubTimestamp":1640398248,"share":"https://www.laohu8.com/m/news/2193917872?lang=&edition=full","pubTime":"2021-12-25 10:10","market":"us","language":"en","title":"3 Best Buffett Stocks to Buy for the Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193917872","media":"Motley Fool","summary":"Each of these three big pharma stocks are featured in Berkshire Hathaway's massive portfolio.","content":"<p>Since Warren Buffett took full control of <b>Berkshire Hathaway</b> in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.</p>\n<p>The Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.</p>\n<h2>1. Johnson &amp; Johnson</h2>\n<p>The first pharma stock within Berkshire's portfolio to contemplate purchasing is <b>Johnson &amp; Johnson</b> (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.</p>\n<p>J&amp;J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.</p>\n<p>J&amp;J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&amp;J's $69 billion in net sales.</p>\n<p>These drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.</p>\n<p>J&amp;J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.</p>\n<p>Income investors can scoop up J&amp;J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.</p>\n<h2>2. Bristol Myers Squibb</h2>\n<p>Another Buffett stock that could be a great fit in your portfolio is <b>Bristol Myers Squibb</b> (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.</p>\n<p>Bristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with <b>Pfizer</b> (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.</p>\n<p>What matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.</p>\n<p>As a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.</p>\n<p>Yield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.</p>\n<h2>3. AbbVie</h2>\n<p>Finally, a Buffett stock that'd also be a good fit for income investors is <b>AbbVie</b> (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.</p>\n<p>It's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.</p>\n<p>AbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.</p>\n<p>AbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3.&nbsp;This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Best Buffett Stocks to Buy for the Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Best Buffett Stocks to Buy for the Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","BMY":"施贵宝","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193917872","content_text":"Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.\nThe Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.\n1. Johnson & Johnson\nThe first pharma stock within Berkshire's portfolio to contemplate purchasing is Johnson & Johnson (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.\nJ&J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.\nJ&J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&J's $69 billion in net sales.\nThese drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.\nJ&J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.\nIncome investors can scoop up J&J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.\n2. Bristol Myers Squibb\nAnother Buffett stock that could be a great fit in your portfolio is Bristol Myers Squibb (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.\nBristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with Pfizer (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.\nWhat matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.\nAs a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.\nYield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.\n3. AbbVie\nFinally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.\nIt's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.\nAbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.\nAbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3. This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698850170,"gmtCreate":1640346574159,"gmtModify":1640346574440,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698850170","repostId":"2193127176","repostType":4,"repost":{"id":"2193127176","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640345481,"share":"https://www.laohu8.com/m/news/2193127176?lang=&edition=full","pubTime":"2021-12-24 19:31","market":"us","language":"en","title":"Japan health panel approves Merck's oral COVID-19 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2193127176","media":"Reuters","summary":"TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COV","content":"<p>TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck &amp; Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.</p>\n<p>The panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.</p>\n<p>Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.</p>\n<p>In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill&nbsp;developed by Pfizer Inc. And Japan's Shionogi &amp; Co is expected to soon file for approval of its own treatment&nbsp;supplying another 1 million doses by early next year.</p>\n<p>U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.</p>\n<p>Countries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.</p>\n<p>Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan health panel approves Merck's oral COVID-19 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan health panel approves Merck's oral COVID-19 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck &amp; Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.</p>\n<p>The panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.</p>\n<p>Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.</p>\n<p>In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill&nbsp;developed by Pfizer Inc. And Japan's Shionogi &amp; Co is expected to soon file for approval of its own treatment&nbsp;supplying another 1 million doses by early next year.</p>\n<p>U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.</p>\n<p>Countries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.</p>\n<p>Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","MRK":"默沙东","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4516":"特朗普概念","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193127176","content_text":"TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck & Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.\nThe panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.\nJapan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.\nIn addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill developed by Pfizer Inc. And Japan's Shionogi & Co is expected to soon file for approval of its own treatment supplying another 1 million doses by early next year.\nU.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.\nCountries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.\nJapan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":901,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698937949,"gmtCreate":1640273647428,"gmtModify":1640273647655,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698937949","repostId":"1192623075","repostType":4,"repost":{"id":"1192623075","pubTimestamp":1640269891,"share":"https://www.laohu8.com/m/news/1192623075?lang=&edition=full","pubTime":"2021-12-23 22:31","market":"us","language":"en","title":"U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=1192623075","media":"SeattleTimes","summary":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea","content":"<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p>\n<p>The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p>\n<p>As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p>\n<p>The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p>\n<p>Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p>\n<p>The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p>\n<p>The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p>\n<p>Some experts question whether there will be much of a role for the Merck drug in the U.S.</p>\n<p>“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p>\n<p>For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p>\n<p>The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p>\n<p>Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p>\n<p>The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p>\n<p>Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p>","source":"lsy1640271591192","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. adds Merck pill as 2nd easy-to-use drug against COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 22:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/><strong>SeattleTimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug ...</p>\n\n<a href=\"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192623075","content_text":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.\nAs a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.\nThe Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.\nKnown as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.\nThe restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.\nThe Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.\nSome experts question whether there will be much of a role for the Merck drug in the U.S.\n“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”\nFor now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.\nThe FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.\nFederal officials have agreed to purchase enough of the drug to treat 3.1 million people.\nThe U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.\nMerck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691641564,"gmtCreate":1640187931332,"gmtModify":1640187931554,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691641564","repostId":"1169752126","repostType":4,"repost":{"id":"1169752126","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640186708,"share":"https://www.laohu8.com/m/news/1169752126?lang=&edition=full","pubTime":"2021-12-22 23:25","market":"us","language":"en","title":"Why Paychex Shares Are Making New All-Time Highs Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1169752126","media":"Benzinga","summary":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal seco","content":"<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p>\n<p>Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p>\n<p>Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p>\n<p>\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p>\n<p>Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p>\n<p><b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p>\n<p>The stock was up 5.54% at $133.44.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Paychex Shares Are Making New All-Time Highs Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Paychex Shares Are Making New All-Time Highs Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 23:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p>\n<p>Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p>\n<p>Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p>\n<p>\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p>\n<p>Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p>\n<p><b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p>\n<p>The stock was up 5.54% at $133.44.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PAYX":"沛齐"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169752126","content_text":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.\nPaychex reported quarterly adjusted earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.\nPaychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.\n\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said Martin Mucci, chairman and CEO of Paychex.\nPaychex is a leading provider of payroll, human capital management and insurance solutions servicing small and midsize clients primarily in the United States.\nPAYX Price Action:Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.\nThe stock was up 5.54% at $133.44.","news_type":1},"isVote":1,"tweetType":1,"viewCount":683,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691029236,"gmtCreate":1640099683076,"gmtModify":1640099683337,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691029236","repostId":"2193154031","repostType":4,"repost":{"id":"2193154031","pubTimestamp":1640099220,"share":"https://www.laohu8.com/m/news/2193154031?lang=&edition=full","pubTime":"2021-12-21 23:07","market":"us","language":"en","title":"Tesla Sends S&P 500 Crowd on a Wild Ride of Surges and Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2193154031","media":"Bloomberg","summary":" -- There was a sense among Wall Street types a year ago that Tesla Inc.’s entrance into the S&P 500 Index would calm the stock. Sure, it would still have sporadic moments of Elon Musk-driven swings -- up 5% Tuesday, down 5% Wednesday -- but overall, it would behave more like a proper, staid member of the blue-blooded community it was joining.In the 12 months since it was added to the index, Tesla’s stock has been every bit as volatile as it was in 2018 and 2019. . On a typical day, the electric","content":"<p>(Bloomberg) -- There was a sense among Wall Street types a year ago that Tesla Inc.’s entrance into the S&amp;P 500 Index would calm the stock. Sure, it would still have sporadic moments of Elon Musk-driven swings -- up 5% Tuesday, down 5% Wednesday -- but overall, it would behave more like a proper, staid member of the blue-blooded community it was joining.</p>\n<p>They were wrong.</p>\n<p>In the 12 months since it was added to the index, Tesla’s stock has been every bit as volatile as it was in 2018 and 2019. (The start of the pandemic, and the wild swings it sparked, makes comparisons to 2020 meaningless.)</p>\n<p>On a typical day, the electric-vehicle maker’s price swings are more than four times greater those of the S&amp;P 500. This is remarkable for a company that is the fifth-most valuable stock in the index. Its peers of large size -- the Nvdias, the <a href=\"https://laohu8.com/S/FB\">Meta Platforms</a>, the Berkshire Hathaways -- are markedly less, not more, volatile than Tesla.</p>\n<p>All of which has given the S&amp;P 500 a little taste of the meme fever that has become to represent the stock mania that swept through the country this past year.</p>\n<p>“When companies get bigger, we tend to think of volatility as declining, since bigger means more stable. But that hasn’t happened with Tesla,” said Nicholas Colas, co-founder of DataTrek Research, who compared the company’s gyrations to those of Bitcoin. “Tesla, Bitcoin - they are still call options on a given future” that has yet to arrive, contributing to fluctuations.</p>\n<p>Along the way, Tesla has handed investors a 29% return, beating the index by 6 percentage points over the past 12 months. The shares were up 1.7% in premarket trading on Tuesday after a stee[ drop on Monday.</p>\n<p>There’s little consensus on whether that outperformance will continue in 2022 -- the company faces lots of challenges and its valuation is sky-high -- but there’s <a href=\"https://laohu8.com/S/AONE.U\">one</a> thing nearly all seem to agree on now: The volatility is here to stay.</p>\n<p>“We increasingly live in a trader’s world as opposed to an investor’s world, and Tesla is a poster-child of that,” said David Trainer, founder of New Constructs research firm.</p>\n<p>Retail investors’ devotion to Tesla predates the company’s arrival to the S&amp;P 500, with thousands of early backers committing their savings accounts to Musk’s vision of an all-electric vehicle world.</p>\n<p>Excitement around the stock is on display across social media platforms and chatrooms daily. Musk himself turned to <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> on Nov. 6 before embarking on a share selling spree to ask users whether he should offload part of his stake in the car maker. The response? “Yes”.</p>\n<p>Tesla’s spokesperson didn’t &nbsp;return a request for comment about volatility in the company’s shares.</p>\n<p>While Musk’s zaniness is often embraced by the retail crowd, such unpredictable moves are new for institutional managers and investors that buy blue-chip stocks. Still, some analysts see an upshot to the persistent volatility of Tesla, currently the fifth-biggest stock in the S&amp;P and the world’s biggest automaker by market capitalization.</p>\n<p>Its inclusion in the index led to more “open-mindedness” among traders about volatile stocks that offer faster growth and strong returns, said Matt Weller, global head of market research at Forex.com.</p>\n<p>Index of the Future</p>\n<p>Analysts expect the volatility in Tesla to continue. After all, a gauge of expected one-month volatility in the electric-vehicle maker hovers in the 83rd percentile of its readings going back a decade ago.</p>\n<p>While there are varying views on Wall Street as to whether shares are a buy, hold or sell, on average analysts expect the stock to be at $845 12 months from now, a 6% decline from the current level.</p>\n<p>Tesla posted its ninth straight quarter of profits in the three months through September, solidifying the stock’s rally and propelling it to new highs. The share advance has also left some sell-side analysts wondering if the rally left the shares overvalued.</p>\n<p>Read more: Tesla Shows Progress on Profit as Investors Seek Perfection</p>\n<p>But retail investors, who have shown an appetite for risk and a capacity to weather swings in valuation, are likely to extend their links to the company and its stock -- regardless of what the Wall Street establishment thinks.</p>\n<p>“At the end of the day, having stocks that move in different ways in response to different catalysts is really what brings the diversity that indexes seek to offer,” Forex.com’s Weller said. “Indexes of the future won’t just consist exclusively of the old-school, conservative CEOs.”</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Sends S&P 500 Crowd on a Wild Ride of Surges and Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Sends S&P 500 Crowd on a Wild Ride of Surges and Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tesla-sends-p-500-crowd-120000678.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- There was a sense among Wall Street types a year ago that Tesla Inc.’s entrance into the S&P 500 Index would calm the stock. Sure, it would still have sporadic moments of Elon Musk-...</p>\n\n<a href=\"https://finance.yahoo.com/news/tesla-sends-p-500-crowd-120000678.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","TSLA":"特斯拉","SPXU":"三倍做空标普500ETF","BK4504":"桥水持仓",".SPX":"S&P 500 Index","OEX":"标普100","OEF":"标普100指数ETF-iShares","BK4099":"汽车制造商","BK4548":"巴美列捷福持仓","SPY":"标普500ETF","IVV":"标普500指数ETF","UPRO":"三倍做多标普500ETF","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","SDS":"两倍做空标普500ETF","SH":"标普500反向ETF","BK4559":"巴菲特持仓","BK4527":"明星科技股","SSO":"两倍做多标普500ETF","BK4550":"红杉资本持仓","BK4551":"寇图资本持仓"},"source_url":"https://finance.yahoo.com/news/tesla-sends-p-500-crowd-120000678.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193154031","content_text":"(Bloomberg) -- There was a sense among Wall Street types a year ago that Tesla Inc.’s entrance into the S&P 500 Index would calm the stock. Sure, it would still have sporadic moments of Elon Musk-driven swings -- up 5% Tuesday, down 5% Wednesday -- but overall, it would behave more like a proper, staid member of the blue-blooded community it was joining.\nThey were wrong.\nIn the 12 months since it was added to the index, Tesla’s stock has been every bit as volatile as it was in 2018 and 2019. (The start of the pandemic, and the wild swings it sparked, makes comparisons to 2020 meaningless.)\nOn a typical day, the electric-vehicle maker’s price swings are more than four times greater those of the S&P 500. This is remarkable for a company that is the fifth-most valuable stock in the index. Its peers of large size -- the Nvdias, the Meta Platforms, the Berkshire Hathaways -- are markedly less, not more, volatile than Tesla.\nAll of which has given the S&P 500 a little taste of the meme fever that has become to represent the stock mania that swept through the country this past year.\n“When companies get bigger, we tend to think of volatility as declining, since bigger means more stable. But that hasn’t happened with Tesla,” said Nicholas Colas, co-founder of DataTrek Research, who compared the company’s gyrations to those of Bitcoin. “Tesla, Bitcoin - they are still call options on a given future” that has yet to arrive, contributing to fluctuations.\nAlong the way, Tesla has handed investors a 29% return, beating the index by 6 percentage points over the past 12 months. The shares were up 1.7% in premarket trading on Tuesday after a stee[ drop on Monday.\nThere’s little consensus on whether that outperformance will continue in 2022 -- the company faces lots of challenges and its valuation is sky-high -- but there’s one thing nearly all seem to agree on now: The volatility is here to stay.\n“We increasingly live in a trader’s world as opposed to an investor’s world, and Tesla is a poster-child of that,” said David Trainer, founder of New Constructs research firm.\nRetail investors’ devotion to Tesla predates the company’s arrival to the S&P 500, with thousands of early backers committing their savings accounts to Musk’s vision of an all-electric vehicle world.\nExcitement around the stock is on display across social media platforms and chatrooms daily. Musk himself turned to Twitter on Nov. 6 before embarking on a share selling spree to ask users whether he should offload part of his stake in the car maker. The response? “Yes”.\nTesla’s spokesperson didn’t  return a request for comment about volatility in the company’s shares.\nWhile Musk’s zaniness is often embraced by the retail crowd, such unpredictable moves are new for institutional managers and investors that buy blue-chip stocks. Still, some analysts see an upshot to the persistent volatility of Tesla, currently the fifth-biggest stock in the S&P and the world’s biggest automaker by market capitalization.\nIts inclusion in the index led to more “open-mindedness” among traders about volatile stocks that offer faster growth and strong returns, said Matt Weller, global head of market research at Forex.com.\nIndex of the Future\nAnalysts expect the volatility in Tesla to continue. After all, a gauge of expected one-month volatility in the electric-vehicle maker hovers in the 83rd percentile of its readings going back a decade ago.\nWhile there are varying views on Wall Street as to whether shares are a buy, hold or sell, on average analysts expect the stock to be at $845 12 months from now, a 6% decline from the current level.\nTesla posted its ninth straight quarter of profits in the three months through September, solidifying the stock’s rally and propelling it to new highs. The share advance has also left some sell-side analysts wondering if the rally left the shares overvalued.\nRead more: Tesla Shows Progress on Profit as Investors Seek Perfection\nBut retail investors, who have shown an appetite for risk and a capacity to weather swings in valuation, are likely to extend their links to the company and its stock -- regardless of what the Wall Street establishment thinks.\n“At the end of the day, having stocks that move in different ways in response to different catalysts is really what brings the diversity that indexes seek to offer,” Forex.com’s Weller said. “Indexes of the future won’t just consist exclusively of the old-school, conservative CEOs.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":876,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693693721,"gmtCreate":1640010977750,"gmtModify":1640010978004,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Lime","listText":"Lime","text":"Lime","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693693721","repostId":"1139958745","repostType":4,"repost":{"id":"1139958745","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640010639,"share":"https://www.laohu8.com/m/news/1139958745?lang=&edition=full","pubTime":"2021-12-20 22:30","market":"us","language":"en","title":"Dow falls 500 points to start the week as omicron continues to spook markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1139958745","media":"Tiger Newspress","summary":"Stocks fell on Monday at the start of a holiday-shortened week of trading, with investors considerin","content":"<p>Stocks fell on Monday at&nbsp;the start of a holiday-shortened week of trading, with investors considering renewed virus-related restrictions overseas and prospects that a significant social policy bill may be scuttled.</p>\n<p>The S&amp;P 500, Dow Nasdaq each dropped more than 1%. Treasury yields fell as investors piled into safe haven assets, and the benchmark 10-year yield held below 1.4%. The CBOE Volatility Index,or VIX,spiked more than 20% to hover above 25.</p>\n<p>U.S. crude oil prices sank 3% to trade below $69 per barrel as restrictions mounted in Europe, stoking jitters around energy demand. Countries from&nbsp;Germany to Irelandimposed curfews or travel restrictions in recent days given the rapidly spreading new variant. And the Netherlands over the weekend&nbsp;announced a nationwide lockdown of non-essential stores, bars and restaurants&nbsp;until Jan. 14. As of this weekend, the Omicron variant&nbsp;had been reported in about 89 countries,with cases doubling every 1.5 to 3 days.</p>\n<p>Renewed fears over the economic impact of the Omicron variant compounded with last week's concerns for investors around the prospects of tighter monetary policy, with the Federal Reserve accelerating its rate of asset-purchase tapering and signaling three interest rate hikes could be coming next year. Last week, each of the three major indexes posted steep weekly losses. The Nasdaq Composite fell 3% and the S&amp;P 500 and Dow each dropped by nearly 2% for the week.</p>\n<p>Still, other updates around the effect of current COVID-19 vaccines on the variant were more upbeat. Moderna (MRNA)said Monday that a booster,or a third dose, of its shot increased Omicron neutralizing antibody levels. This echoed results from&nbsp;Pfizer (PFE) and BioNTech (BNTX) from earlier this month&nbsp;about the effectiveness of their vaccine's third dose on neutralizing Omicron. Shares of Moderna gained more than 7% ahead of the opening bell.</p>\n<p>Investors also digested the unexpected news that Senator Joe Manchin (D., W. Va.) would not support President Joe Biden's $1.75 billion Build Back Better social policy bill. Manchin, speaking onFox News Sunday, said he had discussed with Democratic House and Senate leaders and Biden, but was unable to come to an agreement on the bill given concerns about inflation, the national debt and ongoing pandemic.</p>\n<p>White House Press Secretary Jen Psakireleased a statement&nbsp;calling Manchin's comments \"a sudden and inexplicable reversal in his position,\" and said the administration would work to move forward with the legislation next year.</p>\n<p>Still, Goldman Sachs this weekend&nbsp;slashed its quarter GDP forecasts for 2022following Manchin's withdrawal of support for the bill. The economists, led by Jan Hatzius, said they expected the \"fiscal impulse will be somewhat more negative\" than previously expected next year, in absence of the spending on social and climate-related policies included in the bill. The firm lowered its U.S. GDP forecast to 2% from 3% for the first quarter of 2022, to 3% from 3.5% for the second quarter, and to 2.75% from 3% for the third quarter.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow falls 500 points to start the week as omicron continues to spook markets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow falls 500 points to start the week as omicron continues to spook markets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-20 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stocks fell on Monday at&nbsp;the start of a holiday-shortened week of trading, with investors considering renewed virus-related restrictions overseas and prospects that a significant social policy bill may be scuttled.</p>\n<p>The S&amp;P 500, Dow Nasdaq each dropped more than 1%. Treasury yields fell as investors piled into safe haven assets, and the benchmark 10-year yield held below 1.4%. The CBOE Volatility Index,or VIX,spiked more than 20% to hover above 25.</p>\n<p>U.S. crude oil prices sank 3% to trade below $69 per barrel as restrictions mounted in Europe, stoking jitters around energy demand. Countries from&nbsp;Germany to Irelandimposed curfews or travel restrictions in recent days given the rapidly spreading new variant. And the Netherlands over the weekend&nbsp;announced a nationwide lockdown of non-essential stores, bars and restaurants&nbsp;until Jan. 14. As of this weekend, the Omicron variant&nbsp;had been reported in about 89 countries,with cases doubling every 1.5 to 3 days.</p>\n<p>Renewed fears over the economic impact of the Omicron variant compounded with last week's concerns for investors around the prospects of tighter monetary policy, with the Federal Reserve accelerating its rate of asset-purchase tapering and signaling three interest rate hikes could be coming next year. Last week, each of the three major indexes posted steep weekly losses. The Nasdaq Composite fell 3% and the S&amp;P 500 and Dow each dropped by nearly 2% for the week.</p>\n<p>Still, other updates around the effect of current COVID-19 vaccines on the variant were more upbeat. Moderna (MRNA)said Monday that a booster,or a third dose, of its shot increased Omicron neutralizing antibody levels. This echoed results from&nbsp;Pfizer (PFE) and BioNTech (BNTX) from earlier this month&nbsp;about the effectiveness of their vaccine's third dose on neutralizing Omicron. Shares of Moderna gained more than 7% ahead of the opening bell.</p>\n<p>Investors also digested the unexpected news that Senator Joe Manchin (D., W. Va.) would not support President Joe Biden's $1.75 billion Build Back Better social policy bill. Manchin, speaking onFox News Sunday, said he had discussed with Democratic House and Senate leaders and Biden, but was unable to come to an agreement on the bill given concerns about inflation, the national debt and ongoing pandemic.</p>\n<p>White House Press Secretary Jen Psakireleased a statement&nbsp;calling Manchin's comments \"a sudden and inexplicable reversal in his position,\" and said the administration would work to move forward with the legislation next year.</p>\n<p>Still, Goldman Sachs this weekend&nbsp;slashed its quarter GDP forecasts for 2022following Manchin's withdrawal of support for the bill. The economists, led by Jan Hatzius, said they expected the \"fiscal impulse will be somewhat more negative\" than previously expected next year, in absence of the spending on social and climate-related policies included in the bill. The firm lowered its U.S. GDP forecast to 2% from 3% for the first quarter of 2022, to 3% from 3.5% for the second quarter, and to 2.75% from 3% for the third quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139958745","content_text":"Stocks fell on Monday at the start of a holiday-shortened week of trading, with investors considering renewed virus-related restrictions overseas and prospects that a significant social policy bill may be scuttled.\nThe S&P 500, Dow Nasdaq each dropped more than 1%. Treasury yields fell as investors piled into safe haven assets, and the benchmark 10-year yield held below 1.4%. The CBOE Volatility Index,or VIX,spiked more than 20% to hover above 25.\nU.S. crude oil prices sank 3% to trade below $69 per barrel as restrictions mounted in Europe, stoking jitters around energy demand. Countries from Germany to Irelandimposed curfews or travel restrictions in recent days given the rapidly spreading new variant. And the Netherlands over the weekend announced a nationwide lockdown of non-essential stores, bars and restaurants until Jan. 14. As of this weekend, the Omicron variant had been reported in about 89 countries,with cases doubling every 1.5 to 3 days.\nRenewed fears over the economic impact of the Omicron variant compounded with last week's concerns for investors around the prospects of tighter monetary policy, with the Federal Reserve accelerating its rate of asset-purchase tapering and signaling three interest rate hikes could be coming next year. Last week, each of the three major indexes posted steep weekly losses. The Nasdaq Composite fell 3% and the S&P 500 and Dow each dropped by nearly 2% for the week.\nStill, other updates around the effect of current COVID-19 vaccines on the variant were more upbeat. Moderna (MRNA)said Monday that a booster,or a third dose, of its shot increased Omicron neutralizing antibody levels. This echoed results from Pfizer (PFE) and BioNTech (BNTX) from earlier this month about the effectiveness of their vaccine's third dose on neutralizing Omicron. Shares of Moderna gained more than 7% ahead of the opening bell.\nInvestors also digested the unexpected news that Senator Joe Manchin (D., W. Va.) would not support President Joe Biden's $1.75 billion Build Back Better social policy bill. Manchin, speaking onFox News Sunday, said he had discussed with Democratic House and Senate leaders and Biden, but was unable to come to an agreement on the bill given concerns about inflation, the national debt and ongoing pandemic.\nWhite House Press Secretary Jen Psakireleased a statement calling Manchin's comments \"a sudden and inexplicable reversal in his position,\" and said the administration would work to move forward with the legislation next year.\nStill, Goldman Sachs this weekend slashed its quarter GDP forecasts for 2022following Manchin's withdrawal of support for the bill. The economists, led by Jan Hatzius, said they expected the \"fiscal impulse will be somewhat more negative\" than previously expected next year, in absence of the spending on social and climate-related policies included in the bill. The firm lowered its U.S. GDP forecast to 2% from 3% for the first quarter of 2022, to 3% from 3.5% for the second quarter, and to 2.75% from 3% for the third quarter.","news_type":1},"isVote":1,"tweetType":1,"viewCount":829,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699715775,"gmtCreate":1639894589596,"gmtModify":1639894589813,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699715775","repostId":"2192903248","repostType":4,"repost":{"id":"2192903248","pubTimestamp":1639886588,"share":"https://www.laohu8.com/m/news/2192903248?lang=&edition=full","pubTime":"2021-12-19 12:03","market":"us","language":"en","title":"5 Stocks You Can Confidently Invest $500 in Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2192903248","media":"Motley Fool","summary":"These stocks have a high probability of producing attractive returns.","content":"<p>The stock market has been a bit more volatile than usual lately. Several factors have made investors nervous, including inflation worries and the omicron variant of the coronavirus. This stock market volatility might be making you feel less confident about putting more money to work.</p>\n<p>However, there are safer stocks you can confidently buy right now. Here are five great options for those with a few hundred dollars to invest.</p>\n<h4><a href=\"https://laohu8.com/S/O\"><b>Realty Income</a></b></h4>\n<p><b>Realty Income</b> lives up to its name. The real estate investment trust (REIT) has a long history of producing dependable income. It has made 617 consecutive monthly dividend payments throughout its history. The REIT has also increased its payout 113 times, including by 5.1% over the past year. It currently offers a dividend yield of 4.4%.</p>\n<p>Realty Income owns a diversified portfolio of commercial real estate, focusing on freestanding retail properties with triple net leases to tenants that are resistant to economic downturns and e-commerce pressures. That portfolio and lease structure enable it to generate steady cash flow. It also has <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the strongest financial profiles in the sector, giving it the flexibility to continue expanding its portfolio. This combination of diversification and financial flexibility has enabled Realty Income to consistently deliver double-digit total shareholder returns with minimal volatility.</p>\n<h4><a href=\"https://laohu8.com/S/BIPC\">Brookfield Infrastructure</a></h4>\n<p><b>Brookfield Infrastructure</b> operates a globally diversified portfolio of infrastructure businesses across the utility, transportation, energy midstream, and data sectors. These businesses tend to generate relatively steady cash flow; that allows Brookfield to pay an attractive dividend yielding 3.5% right now.</p>\n<p>The company has a long history of growing its cash flow and dividend. It expects both to continue rising, projecting annual per-share growth in the mid- to upper single digits for several years. Brookfield sees a few factors powering this outlook, including rising contract rates, expansion projects, and new additions to its portfolio. Brookfield Infrastructure recently completed another needle-moving deal, acquiring a Canadian midstream company that should fuel growth for the next few years. That positions it to continue producing attractive total returns.</p>\n<h4><a href=\"https://laohu8.com/S/WM\">Waste Management</a></h4>\n<p><b>Waste Management</b> (NYSE:WM) turns trash into cash. The waste collection and recycling company expects to produce between $2.5 billion and $2.6 billion of free cash flow this year. That's giving it more money to return to shareholders. It recently boosted its dividend by 13% and authorized an additional $1.5 billion in share repurchases.</p>\n<p>One factor driving its rising cash flow is its recent acquisition of Advanced Disposal. The company expects that combination to save it $150 million annually. Waste Management is also investing in new and upgraded recycling facilities, enabling it to recycle more materials, helping drive additional cash flow growth. With a strong balance sheet and a business that's generating lots of cash, Waste Management should be able to continue producing steady returns for investors.</p>\n<h4><a href=\"https://laohu8.com/S/NEE\">NextEra Energy </a></h4>\n<p><b>NextEra Energy</b> operates the largest utility in Florida. It also owns a vast portfolio of energy infrastructure assets, including natural gas pipelines, wind farms, transmission lines, solar-energy facilities, and energy storage. These assets generate stable cash flow, giving it money to invest in expanding its operations and pay a growing dividend.</p>\n<p>The company expects to grow its earnings per share at or near the upper end of its 6% to 8% annual target range through at least 2023. That should support dividend growth of around 10% through 2022. This growth should help it continue to produce above-average total returns in the coming years.</p>\n<h4><a href=\"https://laohu8.com/S/STAG\">STAG Industrial</a></h4>\n<p><b>STAG Industrial</b> is a REIT that owns a diversified portfolio of industrial properties it leases under long-term contracts. That supplies it with steady income to cover its monthly dividend, which now yields 3.2%.</p>\n<p>One thing that makes STAG Industrial stand out in the crowded industrial REIT sector is its relatively low valuation. Because it's cheaper, it offers more downside protection in today's heated market.</p>\n<p>STAG Industrial also offers attractive growth prospects. Thanks to the growing demand for industrial real estate, the average rental rate on new and renewal leases at its existing properties jumped 14.7% in the third quarter. Meanwhile, the company has lots of financial flexibility to expand its portfolio via acquisitions. Combined with its high-yield dividend, that growth should enable STAG Industrial to produce attractive total returns in the coming years.</p>\n<h4>Solid investment options</h4>\n<p>If you have a few hundred dollars to invest, you might not want to risk that money on stocks that could see large price declines in today's volatile market. However, instead of staying on the sidelines, you might want to consider spreading your money around a few lower-risk and less volatile stocks like the five above.</p>\n<p>Realty Income, Brookfield Infrastructure, NextEra Energy, Waste Management, and STAG Industrial are all growing cash flow at healthy rates, enabling them to pay steadily rising dividends. Those factors should help these stocks produce attractive total returns in the coming years, making them look like solid buys right now.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks You Can Confidently Invest $500 in Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks You Can Confidently Invest $500 in Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 12:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/18/5-stocks-you-can-confidently-invest-500-in-right-n/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market has been a bit more volatile than usual lately. Several factors have made investors nervous, including inflation worries and the omicron variant of the coronavirus. This stock market ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/18/5-stocks-you-can-confidently-invest-500-in-right-n/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4197":"燃气公用事业","BK4080":"零售业房地产投资信托","O":"Realty Income Corp","NEE":"新纪元能源","BK4120":"环境与设施服务","BK4081":"电力公用事业","BK4550":"红杉资本持仓","BIPC":"Brookfield Infrastructure Corp","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4171":"工业房地产投资信托","BK4566":"资本集团","BK4208":"复合型公用事业","STAG":"STAG Industrial","REIT":"ALPS Active REIT ETF","WM":"美国废物管理","BIP":"布鲁克菲尔德公共建设"},"source_url":"https://www.fool.com/investing/2021/12/18/5-stocks-you-can-confidently-invest-500-in-right-n/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192903248","content_text":"The stock market has been a bit more volatile than usual lately. Several factors have made investors nervous, including inflation worries and the omicron variant of the coronavirus. This stock market volatility might be making you feel less confident about putting more money to work.\nHowever, there are safer stocks you can confidently buy right now. Here are five great options for those with a few hundred dollars to invest.\nRealty Income\nRealty Income lives up to its name. The real estate investment trust (REIT) has a long history of producing dependable income. It has made 617 consecutive monthly dividend payments throughout its history. The REIT has also increased its payout 113 times, including by 5.1% over the past year. It currently offers a dividend yield of 4.4%.\nRealty Income owns a diversified portfolio of commercial real estate, focusing on freestanding retail properties with triple net leases to tenants that are resistant to economic downturns and e-commerce pressures. That portfolio and lease structure enable it to generate steady cash flow. It also has one of the strongest financial profiles in the sector, giving it the flexibility to continue expanding its portfolio. This combination of diversification and financial flexibility has enabled Realty Income to consistently deliver double-digit total shareholder returns with minimal volatility.\nBrookfield Infrastructure\nBrookfield Infrastructure operates a globally diversified portfolio of infrastructure businesses across the utility, transportation, energy midstream, and data sectors. These businesses tend to generate relatively steady cash flow; that allows Brookfield to pay an attractive dividend yielding 3.5% right now.\nThe company has a long history of growing its cash flow and dividend. It expects both to continue rising, projecting annual per-share growth in the mid- to upper single digits for several years. Brookfield sees a few factors powering this outlook, including rising contract rates, expansion projects, and new additions to its portfolio. Brookfield Infrastructure recently completed another needle-moving deal, acquiring a Canadian midstream company that should fuel growth for the next few years. That positions it to continue producing attractive total returns.\nWaste Management\nWaste Management (NYSE:WM) turns trash into cash. The waste collection and recycling company expects to produce between $2.5 billion and $2.6 billion of free cash flow this year. That's giving it more money to return to shareholders. It recently boosted its dividend by 13% and authorized an additional $1.5 billion in share repurchases.\nOne factor driving its rising cash flow is its recent acquisition of Advanced Disposal. The company expects that combination to save it $150 million annually. Waste Management is also investing in new and upgraded recycling facilities, enabling it to recycle more materials, helping drive additional cash flow growth. With a strong balance sheet and a business that's generating lots of cash, Waste Management should be able to continue producing steady returns for investors.\nNextEra Energy \nNextEra Energy operates the largest utility in Florida. It also owns a vast portfolio of energy infrastructure assets, including natural gas pipelines, wind farms, transmission lines, solar-energy facilities, and energy storage. These assets generate stable cash flow, giving it money to invest in expanding its operations and pay a growing dividend.\nThe company expects to grow its earnings per share at or near the upper end of its 6% to 8% annual target range through at least 2023. That should support dividend growth of around 10% through 2022. This growth should help it continue to produce above-average total returns in the coming years.\nSTAG Industrial\nSTAG Industrial is a REIT that owns a diversified portfolio of industrial properties it leases under long-term contracts. That supplies it with steady income to cover its monthly dividend, which now yields 3.2%.\nOne thing that makes STAG Industrial stand out in the crowded industrial REIT sector is its relatively low valuation. Because it's cheaper, it offers more downside protection in today's heated market.\nSTAG Industrial also offers attractive growth prospects. Thanks to the growing demand for industrial real estate, the average rental rate on new and renewal leases at its existing properties jumped 14.7% in the third quarter. Meanwhile, the company has lots of financial flexibility to expand its portfolio via acquisitions. Combined with its high-yield dividend, that growth should enable STAG Industrial to produce attractive total returns in the coming years.\nSolid investment options\nIf you have a few hundred dollars to invest, you might not want to risk that money on stocks that could see large price declines in today's volatile market. However, instead of staying on the sidelines, you might want to consider spreading your money around a few lower-risk and less volatile stocks like the five above.\nRealty Income, Brookfield Infrastructure, NextEra Energy, Waste Management, and STAG Industrial are all growing cash flow at healthy rates, enabling them to pay steadily rising dividends. Those factors should help these stocks produce attractive total returns in the coming years, making them look like solid buys right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699519882,"gmtCreate":1639836907253,"gmtModify":1639836907506,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699519882","repostId":"1116106959","repostType":4,"repost":{"id":"1116106959","pubTimestamp":1639785552,"share":"https://www.laohu8.com/m/news/1116106959?lang=&edition=full","pubTime":"2021-12-18 07:59","market":"us","language":"en","title":"Wall Street ends down after mostly negative week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116106959","media":"Reuters","summary":" - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.The S","content":"<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.</p>\n<p>All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.</p>\n<p>Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&amp;P 500 and Nasdaq.</p>\n<p>The S&amp;P 500 growth index lost 0.7% and the value index declined 1.4%.</p>\n<p>All of the 11 major S&amp;P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.</p>\n<p>Adding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.</p>\n<p>Traders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.</p>\n<p>\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"</p>\n<p>Heavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&amp;P 500 index gained around 23% in the same period.</p>\n<p>In Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&amp;P 500 lost 1.03% to 4,620.64.</p>\n<p>The Nasdaq Composite dropped 0.07% to 15,169.68.</p>\n<p>On a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.</p>\n<p>With options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.</p>\n<p>For the week, the S&amp;P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.</p>\n<p>In Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.</p>\n<p>FedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down after mostly negative week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down after mostly negative week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116106959","content_text":"(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.\nAll three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.\nNvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.\nThe S&P 500 growth index lost 0.7% and the value index declined 1.4%.\nAll of the 11 major S&P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.\nAdding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.\nTraders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.\n\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"\nHeavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&P 500 index gained around 23% in the same period.\nIn Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&P 500 lost 1.03% to 4,620.64.\nThe Nasdaq Composite dropped 0.07% to 15,169.68.\nOn a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.\nWith options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.\nFor the week, the S&P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.\nIn Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.\nFedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.\nThe S&P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699351782,"gmtCreate":1639751943080,"gmtModify":1639751943400,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699351782","repostId":"2192973737","repostType":4,"repost":{"id":"2192973737","pubTimestamp":1639751189,"share":"https://www.laohu8.com/m/news/2192973737?lang=&edition=full","pubTime":"2021-12-17 22:26","market":"us","language":"en","title":"3 No-Brainer Stocks To Buy in a Market Correction","url":"https://stock-news.laohu8.com/highlight/detail?id=2192973737","media":"Motley Fool","summary":"These tech stocks have economic moats and growth catalysts, but they're a bit expensive right now.","content":"<p>The next stock market correction might just be the best thing that ever happens for your stock portfolio. Corrections and crashes are inevitable in the stock market -- it's a matter of when they will happen, not if.</p>\n<p>During the next downturn, your favorite stocks might go on sale. Don't miss the opportunity to buy great stocks at attractive prices for long-term returns. Here are three stocks that are a bit expensive at the moment, but could make great investments when a correction shakes things up.</p>\n<h2>1. Microsoft</h2>\n<p>As a company, <b>Microsoft</b> (NASDAQ:MSFT) is enjoying a renaissance, and its business success has led to the stock being somewhat expensive as a result.</p>\n<p>This 46-year-old company is the second-most-valuable publicly traded company in the world (trading places with No. 1 <b>Apple</b> a couple of times in 2021), and it's still delivering fantastic growth. In its most recent quarterly results, revenue was up 22% year over year. That's extremely rare, and it's only possible with a strong economic moat along with a commitment to entering new growth markets.</p>\n<p>Microsoft has dominated the PC operating system market for decades, and its Office suite also holds nearly 90% market share. Viable competitors and alternatives exist, but Microsoft's traditional products have the brand strength, user familiarity, and overall quality to ensure that the company will be a major player in those lanes for years to come.</p>\n<p>Microsoft used that foundation as a launchpad, repeatedly showing its willingness to wade into the next wave of growth industries. It's an established leader in the gaming market, with Xbox. Azure has nearly 20% of the cloud computing market. Outlook is a popular email client, especially for businesses, and it's built a number of customer relationship management (CRM) tools to extend its email and productivity software. Microsoft has enjoyed real success in the device business with its Surface products. Bing has a 3% global search engine market share. Even though it was eventually scrapped, Microsoft even showed initiative in the early days of the smartphone industry by developing a Windows Phone.</p>\n<p>Microsoft is diversified as a leader in multiple tech categories, and it's shrewdly moved to the front of several high-growth industries. Azure's growth rate is above 50%, and the company's cloud segment produces more than a third of its revenue. Investors can be confident that Microsoft has incredible staying power and that it will continue to invest in new growth opportunities as they arise.</p>\n<p>All that said, its stock is expensive. Microsoft's forward P/E ratio is around 36 now. A lot of strong performance is built into the share price, and any stumbles are likely to cause a drawdown. This is a stock to monitor. If that forward P/E ratio gets below 30 and the enterprise-value-to-EBITDA (earnings before interest, taxes, depreciation, and amortization) ratio gets down around 20, then Microsoft is a must-buy stock.</p>\n<h2>2. Veeva Systems</h2>\n<p><b>Veeva Systems</b> (NYSE:VEEV) is the cloud software leader in the life sciences industry. It has more than 1,000 customers, many of whom are large pharmaceutical and biotech companies. Veeva's products support customers in drug development, data management, regulatory compliance, CRM, sales, and quality assurance.</p>\n<p>By focusing on pharmaceutical and life sciences customers, Veeva is more valuable to customers than competitors whose products are designed for a broader range of industries. It reported 124% net subscription revenue retention last year, meaning that it not only keeps its customers but also expands its relationships with them. That competitive advantage is nearly impossible to topple in the foreseeable future, and its target customers' market is expected to grow 10%-15% annually over the next decade.</p>\n<p>Veeva's annual sales growth rate is above 25%, but its valuation ratios are less attractive. The stock trades at a forward P/E ratio of 65 and price-to-sales ratio approaching 25. Even its strong growth outlook can't stop Veeva's PEG ratio from approaching 3, which is high. I can't wait to buy more of this stock if it gets cheaper.</p>\n<h2>3. <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a></h2>\n<p>Cybersecurity stocks were hot this year, and <b>Palo Alto Networks</b> (NASDAQ:PANW) was right at the front of that wave. The stock price is up around 120% since the start of 2020.</p>\n<p>Palo Alto Networks provides a variety of enterprise security software and services. It's a major player in firewall and network security, cloud-native applications, and the up-and-coming secure access service edge (SASE), which is essential for organizations that have employees accessing their corporate software remotely. Hacks, ransomware, data theft, and a host of other issues are more prominent than ever before, and every enterprise is coming to grips with the burden of protecting themselves along with their customers.</p>\n<p>That's driving incredible demand across the entire cybersecurity industry, and Palo Alto is one of the biggest benefactors. The company's sales rose 25% in its last fiscal year, and it followed that up with a 32% expansion in its most recent quarter. Palo Alto Networks isn't profitable on a GAAP basis, but it produces a ton of free cash flow -- equal to more than 30% of its revenue. This company has nearly unstoppable growth catalysts for the next few years, and it has the financial resources to invest in growth and acquisitions to stay competitive.</p>\n<p>Unfortunately, those great returns in recent years have made Palo Alto Networks a tad expensive. It trades at a price-to-sales ratio above 10, and a price-to-free-cash-flow ratio close to 30. Those ratios aren't crazy in today's market, but this becomes a slam dunk if it gets just a bit cheaper.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 No-Brainer Stocks To Buy in a Market Correction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 No-Brainer Stocks To Buy in a Market Correction\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/3-no-brainer-stocks-to-buy-in-market-correction/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The next stock market correction might just be the best thing that ever happens for your stock portfolio. Corrections and crashes are inevitable in the stock market -- it's a matter of when they will ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/3-no-brainer-stocks-to-buy-in-market-correction/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4561":"索罗斯持仓","BK4097":"系统软件","BK4505":"高瓴资本持仓","MSFT":"微软","BK4560":"网络安全概念","BK4504":"桥水持仓","PANW":"Palo Alto Networks","BK4548":"巴美列捷福持仓","BK4528":"SaaS概念","CRM":"赛富时","BK4516":"特朗普概念","BK4023":"应用软件","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4525":"远程办公概念","BK4535":"淡马锡持仓","BK4167":"医疗保健技术","BK4527":"明星科技股","BK4538":"云计算","BK4550":"红杉资本持仓","VEEV":"Veeva Systems Inc.","BK4503":"景林资产持仓"},"source_url":"https://www.fool.com/investing/2021/12/17/3-no-brainer-stocks-to-buy-in-market-correction/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192973737","content_text":"The next stock market correction might just be the best thing that ever happens for your stock portfolio. Corrections and crashes are inevitable in the stock market -- it's a matter of when they will happen, not if.\nDuring the next downturn, your favorite stocks might go on sale. Don't miss the opportunity to buy great stocks at attractive prices for long-term returns. Here are three stocks that are a bit expensive at the moment, but could make great investments when a correction shakes things up.\n1. Microsoft\nAs a company, Microsoft (NASDAQ:MSFT) is enjoying a renaissance, and its business success has led to the stock being somewhat expensive as a result.\nThis 46-year-old company is the second-most-valuable publicly traded company in the world (trading places with No. 1 Apple a couple of times in 2021), and it's still delivering fantastic growth. In its most recent quarterly results, revenue was up 22% year over year. That's extremely rare, and it's only possible with a strong economic moat along with a commitment to entering new growth markets.\nMicrosoft has dominated the PC operating system market for decades, and its Office suite also holds nearly 90% market share. Viable competitors and alternatives exist, but Microsoft's traditional products have the brand strength, user familiarity, and overall quality to ensure that the company will be a major player in those lanes for years to come.\nMicrosoft used that foundation as a launchpad, repeatedly showing its willingness to wade into the next wave of growth industries. It's an established leader in the gaming market, with Xbox. Azure has nearly 20% of the cloud computing market. Outlook is a popular email client, especially for businesses, and it's built a number of customer relationship management (CRM) tools to extend its email and productivity software. Microsoft has enjoyed real success in the device business with its Surface products. Bing has a 3% global search engine market share. Even though it was eventually scrapped, Microsoft even showed initiative in the early days of the smartphone industry by developing a Windows Phone.\nMicrosoft is diversified as a leader in multiple tech categories, and it's shrewdly moved to the front of several high-growth industries. Azure's growth rate is above 50%, and the company's cloud segment produces more than a third of its revenue. Investors can be confident that Microsoft has incredible staying power and that it will continue to invest in new growth opportunities as they arise.\nAll that said, its stock is expensive. Microsoft's forward P/E ratio is around 36 now. A lot of strong performance is built into the share price, and any stumbles are likely to cause a drawdown. This is a stock to monitor. If that forward P/E ratio gets below 30 and the enterprise-value-to-EBITDA (earnings before interest, taxes, depreciation, and amortization) ratio gets down around 20, then Microsoft is a must-buy stock.\n2. Veeva Systems\nVeeva Systems (NYSE:VEEV) is the cloud software leader in the life sciences industry. It has more than 1,000 customers, many of whom are large pharmaceutical and biotech companies. Veeva's products support customers in drug development, data management, regulatory compliance, CRM, sales, and quality assurance.\nBy focusing on pharmaceutical and life sciences customers, Veeva is more valuable to customers than competitors whose products are designed for a broader range of industries. It reported 124% net subscription revenue retention last year, meaning that it not only keeps its customers but also expands its relationships with them. That competitive advantage is nearly impossible to topple in the foreseeable future, and its target customers' market is expected to grow 10%-15% annually over the next decade.\nVeeva's annual sales growth rate is above 25%, but its valuation ratios are less attractive. The stock trades at a forward P/E ratio of 65 and price-to-sales ratio approaching 25. Even its strong growth outlook can't stop Veeva's PEG ratio from approaching 3, which is high. I can't wait to buy more of this stock if it gets cheaper.\n3. Palo Alto Networks\nCybersecurity stocks were hot this year, and Palo Alto Networks (NASDAQ:PANW) was right at the front of that wave. The stock price is up around 120% since the start of 2020.\nPalo Alto Networks provides a variety of enterprise security software and services. It's a major player in firewall and network security, cloud-native applications, and the up-and-coming secure access service edge (SASE), which is essential for organizations that have employees accessing their corporate software remotely. Hacks, ransomware, data theft, and a host of other issues are more prominent than ever before, and every enterprise is coming to grips with the burden of protecting themselves along with their customers.\nThat's driving incredible demand across the entire cybersecurity industry, and Palo Alto is one of the biggest benefactors. The company's sales rose 25% in its last fiscal year, and it followed that up with a 32% expansion in its most recent quarter. Palo Alto Networks isn't profitable on a GAAP basis, but it produces a ton of free cash flow -- equal to more than 30% of its revenue. This company has nearly unstoppable growth catalysts for the next few years, and it has the financial resources to invest in growth and acquisitions to stay competitive.\nUnfortunately, those great returns in recent years have made Palo Alto Networks a tad expensive. It trades at a price-to-sales ratio above 10, and a price-to-free-cash-flow ratio close to 30. Those ratios aren't crazy in today's market, but this becomes a slam dunk if it gets just a bit cheaper.","news_type":1},"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690230103,"gmtCreate":1639668050409,"gmtModify":1639668050659,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Loke","listText":"Loke","text":"Loke","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/690230103","repostId":"1108384523","repostType":4,"repost":{"id":"1108384523","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639667369,"share":"https://www.laohu8.com/m/news/1108384523?lang=&edition=full","pubTime":"2021-12-16 23:09","market":"us","language":"en","title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","media":"Tiger Newspress","summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108384523","content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","news_type":1},"isVote":1,"tweetType":1,"viewCount":184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607482798,"gmtCreate":1639579232175,"gmtModify":1639579232441,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607482798","repostId":"1153017502","repostType":4,"repost":{"id":"1153017502","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639578803,"share":"https://www.laohu8.com/m/news/1153017502?lang=&edition=full","pubTime":"2021-12-15 22:33","market":"us","language":"en","title":"U.S. stock market kicks off lackluster start on Fed decision day,S&P 500 gains 0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153017502","media":"Tiger Newspress","summary":"U.S. stock market kicks off lackluster start on Fed decision day,Nasdaq Composite off less than 0.1%","content":"<p>U.S. stock market kicks off lackluster start on Fed decision day,Nasdaq Composite off less than 0.1%,S&amp;P 500 gains 0.1%; Dow trades flat but hanging around a gain of 0.1%.</p>\n<p>All eyes on Wednesday will be on the Federal Reserve's monetary policy statement and press conference by Federal Reserve Chair Jerome Powell. Many market participants expect these will set the stage for the Fed to speed the withdrawal of its crisis-era stimulus programs, with the firming economic recovery and soaring inflation suggesting the central bank has room for a more hawkish tilt to policy. Last week's Consumer Price Index showed thefastest surge in U.S. consumer prices since 1982on a year-over-year basis in November. And on Tuesday, the U.S. Producer Price Index jumped by the most on record at a 9.6% year-over-year increase for last month.</p>\n<p>Specifically, many investors anticipate the Fed will ramp up the rate of tapering of its asset-purchasing program, which took place at a rate of $120 billion per month in combined Treasuries and agency mortgage-backed securities from the start of the pandemic through November. Last month, the Fed began dialing back these purchases by $15 billion, and announced another $15 billion reduction for December.</p>\n<p>\"We don't think that the Fed is really going to have any surprises for the markets [Wednesday]. They're probably going to announce that they're going to ... accelerate tapering, and that they'll probably finish that by March. But we think that they're going to leave themselves lots flexibility around raising interest rates,\" Tracie McMillion, Wells Fargo Investment Institute head of global asset allocation strategy,told Yahoo Finance Live on Tuesday.She added she expects just one interest rate hike from the Federal Reserve in the second half of next year.</p>\n<p>Other pundits, however, expect an earlier liftoff on interest rates, which maybe be reflected in the Federal Open Market Committee's (FOMC) updated Summary of Economic Projections on Wednesday.</p>\n<p>\"The announcement of faster tapering after today's FOMC meeting is a done deal; we'd be astonished by anything other than a plan to complete asset purchases by the end of March at the latest,\" wrote Ian Shepherdson, chief economist at Pantheon Macroeconomics, in a note on Tuesday. He expects the Fed to stick to its prior plan of purchasing $90 billion in its asset-purchase program this month, before doubling the rate of tapering from its current $15 billion per month starting in January.</p>\n<p>\"That would mean purchases drop to $60 billion in January, $30 billion in February, and zero in March, leaving the door open to a rate hike that month if the inflation outlook has not improved, via a clear and sustained increase in the labor force participation rate,\" he added.</p>\n<p>A number of strategists noted the trading activity in recent sessions and weeks has reflected the market pricing of a more hawkish Fed. Software and other growth names were some of the biggest laggards in the major indexes during Tuesday's session.</p>\n<p>\"When you have an anticipation of higher interest rates, growth stocks or long-duration growth stocks certainly get hit the hardest,\" Art Hogan, national chief market strategist, told Yahoo Finance Live on Tuesday. \"When you do that net present value calculation with a higher interest rate, that implied multiple or ascribed multiple to growth names comes in. So a lot of that's been priced in. When you think about some of those real growth-y names and momentum names and risk assets, they've seen a lot of carnage.\"</p>\n<p>\"What the market is trying to tell us here is that when you set your asset allocation plan for next year, you want to have a barbell approach with growth on one side — you want to have those growth names that are actually valued at a multiple to earnings, not a multiple to revenues or a multiple to cash flows or a multiple to sales,\" he added. \"We anticipate 2022 is going to be very much like 2021, where you really want to have a balance between growth and value.\"</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stock market kicks off lackluster start on Fed decision day,S&P 500 gains 0.1%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stock market kicks off lackluster start on Fed decision day,S&P 500 gains 0.1%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-15 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock market kicks off lackluster start on Fed decision day,Nasdaq Composite off less than 0.1%,S&amp;P 500 gains 0.1%; Dow trades flat but hanging around a gain of 0.1%.</p>\n<p>All eyes on Wednesday will be on the Federal Reserve's monetary policy statement and press conference by Federal Reserve Chair Jerome Powell. Many market participants expect these will set the stage for the Fed to speed the withdrawal of its crisis-era stimulus programs, with the firming economic recovery and soaring inflation suggesting the central bank has room for a more hawkish tilt to policy. Last week's Consumer Price Index showed thefastest surge in U.S. consumer prices since 1982on a year-over-year basis in November. And on Tuesday, the U.S. Producer Price Index jumped by the most on record at a 9.6% year-over-year increase for last month.</p>\n<p>Specifically, many investors anticipate the Fed will ramp up the rate of tapering of its asset-purchasing program, which took place at a rate of $120 billion per month in combined Treasuries and agency mortgage-backed securities from the start of the pandemic through November. Last month, the Fed began dialing back these purchases by $15 billion, and announced another $15 billion reduction for December.</p>\n<p>\"We don't think that the Fed is really going to have any surprises for the markets [Wednesday]. They're probably going to announce that they're going to ... accelerate tapering, and that they'll probably finish that by March. But we think that they're going to leave themselves lots flexibility around raising interest rates,\" Tracie McMillion, Wells Fargo Investment Institute head of global asset allocation strategy,told Yahoo Finance Live on Tuesday.She added she expects just one interest rate hike from the Federal Reserve in the second half of next year.</p>\n<p>Other pundits, however, expect an earlier liftoff on interest rates, which maybe be reflected in the Federal Open Market Committee's (FOMC) updated Summary of Economic Projections on Wednesday.</p>\n<p>\"The announcement of faster tapering after today's FOMC meeting is a done deal; we'd be astonished by anything other than a plan to complete asset purchases by the end of March at the latest,\" wrote Ian Shepherdson, chief economist at Pantheon Macroeconomics, in a note on Tuesday. He expects the Fed to stick to its prior plan of purchasing $90 billion in its asset-purchase program this month, before doubling the rate of tapering from its current $15 billion per month starting in January.</p>\n<p>\"That would mean purchases drop to $60 billion in January, $30 billion in February, and zero in March, leaving the door open to a rate hike that month if the inflation outlook has not improved, via a clear and sustained increase in the labor force participation rate,\" he added.</p>\n<p>A number of strategists noted the trading activity in recent sessions and weeks has reflected the market pricing of a more hawkish Fed. Software and other growth names were some of the biggest laggards in the major indexes during Tuesday's session.</p>\n<p>\"When you have an anticipation of higher interest rates, growth stocks or long-duration growth stocks certainly get hit the hardest,\" Art Hogan, national chief market strategist, told Yahoo Finance Live on Tuesday. \"When you do that net present value calculation with a higher interest rate, that implied multiple or ascribed multiple to growth names comes in. So a lot of that's been priced in. When you think about some of those real growth-y names and momentum names and risk assets, they've seen a lot of carnage.\"</p>\n<p>\"What the market is trying to tell us here is that when you set your asset allocation plan for next year, you want to have a barbell approach with growth on one side — you want to have those growth names that are actually valued at a multiple to earnings, not a multiple to revenues or a multiple to cash flows or a multiple to sales,\" he added. \"We anticipate 2022 is going to be very much like 2021, where you really want to have a balance between growth and value.\"</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153017502","content_text":"U.S. stock market kicks off lackluster start on Fed decision day,Nasdaq Composite off less than 0.1%,S&P 500 gains 0.1%; Dow trades flat but hanging around a gain of 0.1%.\nAll eyes on Wednesday will be on the Federal Reserve's monetary policy statement and press conference by Federal Reserve Chair Jerome Powell. Many market participants expect these will set the stage for the Fed to speed the withdrawal of its crisis-era stimulus programs, with the firming economic recovery and soaring inflation suggesting the central bank has room for a more hawkish tilt to policy. Last week's Consumer Price Index showed thefastest surge in U.S. consumer prices since 1982on a year-over-year basis in November. And on Tuesday, the U.S. Producer Price Index jumped by the most on record at a 9.6% year-over-year increase for last month.\nSpecifically, many investors anticipate the Fed will ramp up the rate of tapering of its asset-purchasing program, which took place at a rate of $120 billion per month in combined Treasuries and agency mortgage-backed securities from the start of the pandemic through November. Last month, the Fed began dialing back these purchases by $15 billion, and announced another $15 billion reduction for December.\n\"We don't think that the Fed is really going to have any surprises for the markets [Wednesday]. They're probably going to announce that they're going to ... accelerate tapering, and that they'll probably finish that by March. But we think that they're going to leave themselves lots flexibility around raising interest rates,\" Tracie McMillion, Wells Fargo Investment Institute head of global asset allocation strategy,told Yahoo Finance Live on Tuesday.She added she expects just one interest rate hike from the Federal Reserve in the second half of next year.\nOther pundits, however, expect an earlier liftoff on interest rates, which maybe be reflected in the Federal Open Market Committee's (FOMC) updated Summary of Economic Projections on Wednesday.\n\"The announcement of faster tapering after today's FOMC meeting is a done deal; we'd be astonished by anything other than a plan to complete asset purchases by the end of March at the latest,\" wrote Ian Shepherdson, chief economist at Pantheon Macroeconomics, in a note on Tuesday. He expects the Fed to stick to its prior plan of purchasing $90 billion in its asset-purchase program this month, before doubling the rate of tapering from its current $15 billion per month starting in January.\n\"That would mean purchases drop to $60 billion in January, $30 billion in February, and zero in March, leaving the door open to a rate hike that month if the inflation outlook has not improved, via a clear and sustained increase in the labor force participation rate,\" he added.\nA number of strategists noted the trading activity in recent sessions and weeks has reflected the market pricing of a more hawkish Fed. Software and other growth names were some of the biggest laggards in the major indexes during Tuesday's session.\n\"When you have an anticipation of higher interest rates, growth stocks or long-duration growth stocks certainly get hit the hardest,\" Art Hogan, national chief market strategist, told Yahoo Finance Live on Tuesday. \"When you do that net present value calculation with a higher interest rate, that implied multiple or ascribed multiple to growth names comes in. So a lot of that's been priced in. When you think about some of those real growth-y names and momentum names and risk assets, they've seen a lot of carnage.\"\n\"What the market is trying to tell us here is that when you set your asset allocation plan for next year, you want to have a barbell approach with growth on one side — you want to have those growth names that are actually valued at a multiple to earnings, not a multiple to revenues or a multiple to cash flows or a multiple to sales,\" he added. \"We anticipate 2022 is going to be very much like 2021, where you really want to have a balance between growth and value.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607182665,"gmtCreate":1639497765903,"gmtModify":1639497766119,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607182665","repostId":"2191955334","repostType":4,"repost":{"id":"2191955334","pubTimestamp":1639494842,"share":"https://www.laohu8.com/m/news/2191955334?lang=&edition=full","pubTime":"2021-12-14 23:14","market":"us","language":"en","title":"If You Like Dividends, You Should Love These 2 Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2191955334","media":"Motley Fool","summary":"Real Estate Investment Trusts are a great way to get dividend income and these two REITs produce plenty.","content":"<p>Finding steady and meaningful income in the current market environment has been difficult for some investors. Stocks are near record highs, interest rates are low, and inflation is rising. It's a tough combination to overcome.</p>\n<p>One traditional path has been through Real Estate Investment Trusts (REITs), which have always been good candidates for income investors. This is because REITs are designed to avoid taxation at the corporate level as long as they limit their business activities and pay out most of their earnings as dividends. The best REITs do this very well.</p>\n<p>Let's look at two interesting REITs that every income investor should try and take time to understand and consider adding to an income portfolio.</p>\n<h2>1. Realty Income raised its dividend 3 times in 2020</h2>\n<p><b>Realty Incom</b>e (NYSE:O) is a real estate investment trust (REIT) that invests in single-tenant real estate. These leases are made to the highest-quality tenants using a triple-net lease model, which means the tenant pays taxes, insurance, and some of the upkeep on the property along with the usual rent. These leases are generally longer-term and include annual rent escalators. Roughly half of Realty Income's tenants are investment-grade entities, and most operate in highly stable industries. Realty Income's tenants include drug stores, dollar stores, and logistics companies.</p>\n<p>During the COVID-19 pandemic, Realty Income was affected much less than most REITs, especially those focusing on more discretionary retailing like the shopping malls. Most of Realty Income's tenant base was considered an essential business, and closures were limited to service tenants like movie theaters, gyms, and education-related operations. Realty Income pays a monthly dividend and is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the classic Dividend Aristocrats, an elite group of <b>S&amp;P 500</b> companies that have increased dividends annually for at least 25 consecutive years. Despite the COVID-19 pandemic in 2020, Realty Income raised its dividend three times. At its current price, Realty Income's dividend yields 4.3%.</p>\n<h2>2. If inflation remains strong, Weyerhaeuser could benefit</h2>\n<p><b>Weyerhaeuser</b> (NYSE:WY) is an interesting dividend story. It pays a normal quarterly dividend and then does a special variable dividend every year, with the inaugural dividend coming in early 2022. As anyone who has built anything over the past year knows, lumber costs were on a tear over the summer as supply chain issues limited availability. Weyerhaeuser is a timber REIT that owns or manages 24.8 million acres of timberland in the United States and Canada. It also manufactures wood products for construction.&nbsp;Residential home construction is a big driver of Weyerhaeuser's business, and there is a major shortage of housing in the United States, which should drive the business going forward.</p>\n<p>Weyerhaeuser has an unusual dividend structure, in which it pays a quarterly base dividend, which is intended to be steady throughout the entire business cycle. In other words, even if demand is low or lumber prices fall, it should be able to cover the quarterly dividend. In addition, Weyerhaeuser pays a variable dividend, which will be based on the prior year's results. Weyerhaeuser will pay its first variable dividend early in 2022. It is too soon to tell how much it will be. However, high lumber prices have boosted Weyerhaeuser's results this year. The company's base dividend of $0.17 per share gives it a yield of 1.7%, though Weyerhaeuser paid a special dividend of $0.50 a share in October as well. Investors who like the housing story and are comfortable with a base yield of 1.7% (which is somewhat low for a typical REIT) might find Weyerhaeuser's somewhat unique dividend model attractive.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If You Like Dividends, You Should Love These 2 Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf You Like Dividends, You Should Love These 2 Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 23:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/14/like-dividends-love-these-stocks-realty-reit/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding steady and meaningful income in the current market environment has been difficult for some investors. Stocks are near record highs, interest rates are low, and inflation is rising. It's a ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/14/like-dividends-love-these-stocks-realty-reit/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"O":"Realty Income Corp","WY":"惠好","BK4080":"零售业房地产投资信托","BK4084":"特种房地产投资信托","REIT":"ALPS Active REIT ETF"},"source_url":"https://www.fool.com/investing/2021/12/14/like-dividends-love-these-stocks-realty-reit/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191955334","content_text":"Finding steady and meaningful income in the current market environment has been difficult for some investors. Stocks are near record highs, interest rates are low, and inflation is rising. It's a tough combination to overcome.\nOne traditional path has been through Real Estate Investment Trusts (REITs), which have always been good candidates for income investors. This is because REITs are designed to avoid taxation at the corporate level as long as they limit their business activities and pay out most of their earnings as dividends. The best REITs do this very well.\nLet's look at two interesting REITs that every income investor should try and take time to understand and consider adding to an income portfolio.\n1. Realty Income raised its dividend 3 times in 2020\nRealty Income (NYSE:O) is a real estate investment trust (REIT) that invests in single-tenant real estate. These leases are made to the highest-quality tenants using a triple-net lease model, which means the tenant pays taxes, insurance, and some of the upkeep on the property along with the usual rent. These leases are generally longer-term and include annual rent escalators. Roughly half of Realty Income's tenants are investment-grade entities, and most operate in highly stable industries. Realty Income's tenants include drug stores, dollar stores, and logistics companies.\nDuring the COVID-19 pandemic, Realty Income was affected much less than most REITs, especially those focusing on more discretionary retailing like the shopping malls. Most of Realty Income's tenant base was considered an essential business, and closures were limited to service tenants like movie theaters, gyms, and education-related operations. Realty Income pays a monthly dividend and is one of the classic Dividend Aristocrats, an elite group of S&P 500 companies that have increased dividends annually for at least 25 consecutive years. Despite the COVID-19 pandemic in 2020, Realty Income raised its dividend three times. At its current price, Realty Income's dividend yields 4.3%.\n2. If inflation remains strong, Weyerhaeuser could benefit\nWeyerhaeuser (NYSE:WY) is an interesting dividend story. It pays a normal quarterly dividend and then does a special variable dividend every year, with the inaugural dividend coming in early 2022. As anyone who has built anything over the past year knows, lumber costs were on a tear over the summer as supply chain issues limited availability. Weyerhaeuser is a timber REIT that owns or manages 24.8 million acres of timberland in the United States and Canada. It also manufactures wood products for construction. Residential home construction is a big driver of Weyerhaeuser's business, and there is a major shortage of housing in the United States, which should drive the business going forward.\nWeyerhaeuser has an unusual dividend structure, in which it pays a quarterly base dividend, which is intended to be steady throughout the entire business cycle. In other words, even if demand is low or lumber prices fall, it should be able to cover the quarterly dividend. In addition, Weyerhaeuser pays a variable dividend, which will be based on the prior year's results. Weyerhaeuser will pay its first variable dividend early in 2022. It is too soon to tell how much it will be. However, high lumber prices have boosted Weyerhaeuser's results this year. The company's base dividend of $0.17 per share gives it a yield of 1.7%, though Weyerhaeuser paid a special dividend of $0.50 a share in October as well. Investors who like the housing story and are comfortable with a base yield of 1.7% (which is somewhat low for a typical REIT) might find Weyerhaeuser's somewhat unique dividend model attractive.","news_type":1},"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604267325,"gmtCreate":1639404994593,"gmtModify":1639405107929,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604267325","repostId":"1161576842","repostType":4,"repost":{"id":"1161576842","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639400492,"share":"https://www.laohu8.com/m/news/1161576842?lang=&edition=full","pubTime":"2021-12-13 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1161576842","media":"Tiger Newspress","summary":"U.S. stock-index futures pointed to muted gains for major indexes ahead of a busy week of central-ba","content":"<p>U.S.&nbsp;stock-index futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.</p>\n<p>At 8:00 a.m. ET, S&amp;P 500 e-minis were up 11.25 points, or 0.24%, Nasdaq 100 e-minis were up 67 points, or 0.41%, and Dow e-minis were up 24 points, or 0.07%.<img src=\"https://static.tigerbbs.com/2db870f3d308c4d0618dd8c4333e65dd\" tg-width=\"1080\" tg-height=\"383\" referrerpolicy=\"no-referrer\">The key inflation reading came ahead of the Federal Reserve’s two-day policy meeting this week where the policymakers are expected to discuss speeding up the end of its bond-buying program.</p>\n<p>Fed Chair Jerome Powell, as well as&nbsp;a parade of Fed speakers, all recently suggested the central bank could end the $120 billion monthly bond purchase program sooner than the current timeline of June 2022.</p>\n<p>“We believe markets can continue to&nbsp;take a higher inflation reading in their stride, though additional volatility remains a risk. With Fed policy staying relatively accommodative, the backdrop for equities is still positive, and we favor winners from global growth,” said Mark Haefele, Chief Investment Officer of UBS Global Wealth Management.</p>\n<p>As of Sunday, the&nbsp;U.S. was approaching&nbsp;800,000 coronavirus-related deaths. The new variant has pushed some government officials to reinstate health restrictions to slow the spread.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/HOG\">Harley-Davidson</a></b>– The motorcycle maker’s stock surged 11.7% in the premarket after it announced that it is merging its “Livewire” electric motorcycle unit with a special purpose acquisition company. Livewire will have an enterprise value of about $1.8 billion and will trade on the New York Stock Exchange under the ticker symbol “LVW.”</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> </b>– <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> rose 1.4% in the premarket while <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> jumped 4.4% after&nbsp;a new Israeli study&nbsp;showed that a booster shot from their Covid-19 vaccine provided strong protection against severe illness from the omicron variant. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>’s pre-market gains were trimmed following news of its deal to acquire Arena Pharmaceuticals.</p>\n<p><b><a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals</a> </b>– The drugmaker&nbsp;agreed to be acquired by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>&nbsp;for $100 per share in cash, or about $6.7 billion. Arena soared 93.1% in premarket trading following news of the transaction.</p>\n<p><b><a href=\"https://laohu8.com/S/PTON\">Peloton Interactive, Inc.</a></b> – The fitness equipment maker rebounded 2.6% in premarket action after falling 7% over the past three sessions. Pelotonreleased an ad&nbsp;featuring actor Chris Noth promoting the value of the company’s equipment, after his character’s death in the “Sex and the City” reboot following a Peloton ride.</p>\n<p><b><a href=\"https://laohu8.com/S/DLTR\">Dollar Tree</a> </b>– The discount retailer’s stock fell 1% in premarket trading after activist investor Mantle Ridge announced its intention to try to replace the entire Dollar Tree board. Dollar Tree called the move “unwarrantedly aggressive” and said it had offered to explore a settlement with Mantle Ridge, which owns 5.7% of Dollar Tree.</p>\n<p><b><a href=\"https://laohu8.com/S/AAPL\">Apple</a> </b>– <a href=\"https://laohu8.com/S/AAPL\">Apple</a> rose 1.1% in the premarket after J.P. Morgan Securities raised its price target for the stock to a Street-high of $210 per share from $180 a share, and reiterated it as a top pick going into 2022.</p>\n<p>Nasdaq-100 additions – Stocks being added to the index as of Monday, December 20, rose in premarket trading following news of their inclusion. The stocks include&nbsp;<b><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a></b>, up 2.7%;<b><a href=\"https://laohu8.com/S/ABNB\">Airbnb, Inc.</a></b> , up 2.1%;<b><a href=\"https://laohu8.com/S/FTNT\">Fortinet</a></b> , up 3.7%;<b><a href=\"https://laohu8.com/S/LCID\">Lucid Group Inc</a></b>, up 5.9%;<b><a href=\"https://laohu8.com/S/ZS\">Zscaler Inc.</a></b>, up 3.4%; and&nbsp;<b><a href=\"https://laohu8.com/S/DDOG\">Datadog</a></b>, up 3.1%.</p>\n<p>Nasdaq-100 subtractions – Stocks being replaced in the Nasdaq-100 include&nbsp;<b><a href=\"https://laohu8.com/S/CDW\">CDW Corp</a></b> , down 1.8% in the premarket;<b><a href=\"https://laohu8.com/S/FOXA\">Fox Corporation Class A</a></b> , down 2.2%;<b><a href=\"https://laohu8.com/S/CERN\">Cerner</a></b> , down 1.8%;<b><a href=\"https://laohu8.com/S/CHKP\">Check Point</a></b> , down 1.1%;<b><a href=\"https://laohu8.com/S/TCOM\">Trip.com Group Limited</a></b> , down 1.2%; and&nbsp;<b><a href=\"https://laohu8.com/S/INCY\">Incyte</a></b>, down 0.6%.</p>\n<p><b><a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive, Inc.</a></b> – The electric vehicle maker’s stock rose 1.9% in the premarket following news that its R1T had been named&nbsp;Motor Trend’s truck of the year, beating out entries from Ford, GM and Hyundai.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S.&nbsp;stock-index futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.</p>\n<p>At 8:00 a.m. ET, S&amp;P 500 e-minis were up 11.25 points, or 0.24%, Nasdaq 100 e-minis were up 67 points, or 0.41%, and Dow e-minis were up 24 points, or 0.07%.<img src=\"https://static.tigerbbs.com/2db870f3d308c4d0618dd8c4333e65dd\" tg-width=\"1080\" tg-height=\"383\" referrerpolicy=\"no-referrer\">The key inflation reading came ahead of the Federal Reserve’s two-day policy meeting this week where the policymakers are expected to discuss speeding up the end of its bond-buying program.</p>\n<p>Fed Chair Jerome Powell, as well as&nbsp;a parade of Fed speakers, all recently suggested the central bank could end the $120 billion monthly bond purchase program sooner than the current timeline of June 2022.</p>\n<p>“We believe markets can continue to&nbsp;take a higher inflation reading in their stride, though additional volatility remains a risk. With Fed policy staying relatively accommodative, the backdrop for equities is still positive, and we favor winners from global growth,” said Mark Haefele, Chief Investment Officer of UBS Global Wealth Management.</p>\n<p>As of Sunday, the&nbsp;U.S. was approaching&nbsp;800,000 coronavirus-related deaths. The new variant has pushed some government officials to reinstate health restrictions to slow the spread.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/HOG\">Harley-Davidson</a></b>– The motorcycle maker’s stock surged 11.7% in the premarket after it announced that it is merging its “Livewire” electric motorcycle unit with a special purpose acquisition company. Livewire will have an enterprise value of about $1.8 billion and will trade on the New York Stock Exchange under the ticker symbol “LVW.”</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> </b>– <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> rose 1.4% in the premarket while <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> jumped 4.4% after&nbsp;a new Israeli study&nbsp;showed that a booster shot from their Covid-19 vaccine provided strong protection against severe illness from the omicron variant. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>’s pre-market gains were trimmed following news of its deal to acquire Arena Pharmaceuticals.</p>\n<p><b><a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals</a> </b>– The drugmaker&nbsp;agreed to be acquired by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>&nbsp;for $100 per share in cash, or about $6.7 billion. Arena soared 93.1% in premarket trading following news of the transaction.</p>\n<p><b><a href=\"https://laohu8.com/S/PTON\">Peloton Interactive, Inc.</a></b> – The fitness equipment maker rebounded 2.6% in premarket action after falling 7% over the past three sessions. Pelotonreleased an ad&nbsp;featuring actor Chris Noth promoting the value of the company’s equipment, after his character’s death in the “Sex and the City” reboot following a Peloton ride.</p>\n<p><b><a href=\"https://laohu8.com/S/DLTR\">Dollar Tree</a> </b>– The discount retailer’s stock fell 1% in premarket trading after activist investor Mantle Ridge announced its intention to try to replace the entire Dollar Tree board. Dollar Tree called the move “unwarrantedly aggressive” and said it had offered to explore a settlement with Mantle Ridge, which owns 5.7% of Dollar Tree.</p>\n<p><b><a href=\"https://laohu8.com/S/AAPL\">Apple</a> </b>– <a href=\"https://laohu8.com/S/AAPL\">Apple</a> rose 1.1% in the premarket after J.P. Morgan Securities raised its price target for the stock to a Street-high of $210 per share from $180 a share, and reiterated it as a top pick going into 2022.</p>\n<p>Nasdaq-100 additions – Stocks being added to the index as of Monday, December 20, rose in premarket trading following news of their inclusion. The stocks include&nbsp;<b><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a></b>, up 2.7%;<b><a href=\"https://laohu8.com/S/ABNB\">Airbnb, Inc.</a></b> , up 2.1%;<b><a href=\"https://laohu8.com/S/FTNT\">Fortinet</a></b> , up 3.7%;<b><a href=\"https://laohu8.com/S/LCID\">Lucid Group Inc</a></b>, up 5.9%;<b><a href=\"https://laohu8.com/S/ZS\">Zscaler Inc.</a></b>, up 3.4%; and&nbsp;<b><a href=\"https://laohu8.com/S/DDOG\">Datadog</a></b>, up 3.1%.</p>\n<p>Nasdaq-100 subtractions – Stocks being replaced in the Nasdaq-100 include&nbsp;<b><a href=\"https://laohu8.com/S/CDW\">CDW Corp</a></b> , down 1.8% in the premarket;<b><a href=\"https://laohu8.com/S/FOXA\">Fox Corporation Class A</a></b> , down 2.2%;<b><a href=\"https://laohu8.com/S/CERN\">Cerner</a></b> , down 1.8%;<b><a href=\"https://laohu8.com/S/CHKP\">Check Point</a></b> , down 1.1%;<b><a href=\"https://laohu8.com/S/TCOM\">Trip.com Group Limited</a></b> , down 1.2%; and&nbsp;<b><a href=\"https://laohu8.com/S/INCY\">Incyte</a></b>, down 0.6%.</p>\n<p><b><a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive, Inc.</a></b> – The electric vehicle maker’s stock rose 1.9% in the premarket following news that its R1T had been named&nbsp;Motor Trend’s truck of the year, beating out entries from Ford, GM and Hyundai.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.",".SPX":"S&P 500 Index","FOXA":"福克斯-A","PTON":"Peloton Interactive, Inc.","BNTX":"BioNTech SE","TCOM":"携程网","HOG":"哈雷戴维森","LCID":"Lucid Group Inc","INCY":"因塞特医疗","CHKP":"Check Point软件科技","ARNA":"阿里那","ABNB":"爱彼迎","DDOG":"Datadog","PFE":"辉瑞",".DJI":"道琼斯","AAPL":"苹果","PANW":"Palo Alto Networks","CDW":"CDW Corporation",".IXIC":"NASDAQ Composite","CERN":"美国塞纳","FTNT":"飞塔信息","ZS":"Zscaler Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161576842","content_text":"U.S. stock-index futures pointed to muted gains for major indexes ahead of a busy week of central-bank decisions in major economies.\nAt 8:00 a.m. ET, S&P 500 e-minis were up 11.25 points, or 0.24%, Nasdaq 100 e-minis were up 67 points, or 0.41%, and Dow e-minis were up 24 points, or 0.07%.The key inflation reading came ahead of the Federal Reserve’s two-day policy meeting this week where the policymakers are expected to discuss speeding up the end of its bond-buying program.\nFed Chair Jerome Powell, as well as a parade of Fed speakers, all recently suggested the central bank could end the $120 billion monthly bond purchase program sooner than the current timeline of June 2022.\n“We believe markets can continue to take a higher inflation reading in their stride, though additional volatility remains a risk. With Fed policy staying relatively accommodative, the backdrop for equities is still positive, and we favor winners from global growth,” said Mark Haefele, Chief Investment Officer of UBS Global Wealth Management.\nAs of Sunday, the U.S. was approaching 800,000 coronavirus-related deaths. The new variant has pushed some government officials to reinstate health restrictions to slow the spread.\nStocks making the biggest moves premarket: \nHarley-Davidson– The motorcycle maker’s stock surged 11.7% in the premarket after it announced that it is merging its “Livewire” electric motorcycle unit with a special purpose acquisition company. Livewire will have an enterprise value of about $1.8 billion and will trade on the New York Stock Exchange under the ticker symbol “LVW.”\nPfizer,BioNTech SE – Pfizer rose 1.4% in the premarket while BioNTech SE jumped 4.4% after a new Israeli study showed that a booster shot from their Covid-19 vaccine provided strong protection against severe illness from the omicron variant. Pfizer’s pre-market gains were trimmed following news of its deal to acquire Arena Pharmaceuticals.\nArena Pharmaceuticals – The drugmaker agreed to be acquired by Pfizer for $100 per share in cash, or about $6.7 billion. Arena soared 93.1% in premarket trading following news of the transaction.\nPeloton Interactive, Inc. – The fitness equipment maker rebounded 2.6% in premarket action after falling 7% over the past three sessions. Pelotonreleased an ad featuring actor Chris Noth promoting the value of the company’s equipment, after his character’s death in the “Sex and the City” reboot following a Peloton ride.\nDollar Tree – The discount retailer’s stock fell 1% in premarket trading after activist investor Mantle Ridge announced its intention to try to replace the entire Dollar Tree board. Dollar Tree called the move “unwarrantedly aggressive” and said it had offered to explore a settlement with Mantle Ridge, which owns 5.7% of Dollar Tree.\nApple – Apple rose 1.1% in the premarket after J.P. Morgan Securities raised its price target for the stock to a Street-high of $210 per share from $180 a share, and reiterated it as a top pick going into 2022.\nNasdaq-100 additions – Stocks being added to the index as of Monday, December 20, rose in premarket trading following news of their inclusion. The stocks include Palo Alto Networks, up 2.7%;Airbnb, Inc. , up 2.1%;Fortinet , up 3.7%;Lucid Group Inc, up 5.9%;Zscaler Inc., up 3.4%; and Datadog, up 3.1%.\nNasdaq-100 subtractions – Stocks being replaced in the Nasdaq-100 include CDW Corp , down 1.8% in the premarket;Fox Corporation Class A , down 2.2%;Cerner , down 1.8%;Check Point , down 1.1%;Trip.com Group Limited , down 1.2%; and Incyte, down 0.6%.\nRivian Automotive, Inc. – The electric vehicle maker’s stock rose 1.9% in the premarket following news that its R1T had been named Motor Trend’s truck of the year, beating out entries from Ford, GM and Hyundai.","news_type":1},"isVote":1,"tweetType":1,"viewCount":271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604943891,"gmtCreate":1639320240474,"gmtModify":1639320240697,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604943891","repostId":"1103250344","repostType":4,"repost":{"id":"1103250344","pubTimestamp":1639280672,"share":"https://www.laohu8.com/m/news/1103250344?lang=&edition=full","pubTime":"2021-12-12 11:44","market":"us","language":"en","title":"US IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1103250344","media":"renaissancecap...","summary":"The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to r","content":"<p>The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to raise $789 million.</p>\n<p>IoT solutions developer<b>Samsara</b>(IOT) plans to raise $753 million at an $11.6 billion market cap. This \"internet-of-things\" company provides a cloud-based platform that connects the assets of businesses with physical operations, enhancing operational efficiency and asset and employee productivity. Fast growing but highly unprofitable, Samsara saw double-digit growth for customers with $100k+ ARR in the 9mo FY22.</p>\n<p>Wine brand<b>Fresh Vine Wine</b>(VINE) plans to raise $21 million at a $116 million market cap. This celebrity-founded company produces low carb, low calorie premium wines. Growing but highly unprofitable, Fresh Vine sells its wines through wholesale, retail, and DTC channels, and is able to conduct wholesale distribution in all 50 states and Puerto Rico.</p>\n<p>Micro-cap satellite developer<b>Sidus Space</b>(SIDU) plans to raise $15 million at an $81 million market cap. This company provides commercial satellite services such as design, manufacture, launch, and data collection. &nbsp;Sidus Space has generated space-related manufacturing revenues to date, but is highly unprofitable with negative gross margin in the 9mo21.</p>\n<p><img src=\"https://static.tigerbbs.com/ead80e54642569e2b7b368c8d50dc265\" tg-width=\"1409\" tg-height=\"457\" referrerpolicy=\"no-referrer\"></p>","source":"lsy1619493174116","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-12 11:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/89474/US-IPO-Week-Ahead-IoT-solutions-wine-and-satellites-in-a-3-IPO-week><strong>renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to raise $789 million.\nIoT solutions developerSamsara(IOT) plans to raise $753 million at an $11.6 ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89474/US-IPO-Week-Ahead-IoT-solutions-wine-and-satellites-in-a-3-IPO-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IOT":"Samsara, Inc.","VINE":"Fresh Vine Wine, Inc",".SPX":"S&P 500 Index","SIDU":"Sidus Space Inc.",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/89474/US-IPO-Week-Ahead-IoT-solutions-wine-and-satellites-in-a-3-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103250344","content_text":"The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to raise $789 million.\nIoT solutions developerSamsara(IOT) plans to raise $753 million at an $11.6 billion market cap. This \"internet-of-things\" company provides a cloud-based platform that connects the assets of businesses with physical operations, enhancing operational efficiency and asset and employee productivity. Fast growing but highly unprofitable, Samsara saw double-digit growth for customers with $100k+ ARR in the 9mo FY22.\nWine brandFresh Vine Wine(VINE) plans to raise $21 million at a $116 million market cap. This celebrity-founded company produces low carb, low calorie premium wines. Growing but highly unprofitable, Fresh Vine sells its wines through wholesale, retail, and DTC channels, and is able to conduct wholesale distribution in all 50 states and Puerto Rico.\nMicro-cap satellite developerSidus Space(SIDU) plans to raise $15 million at an $81 million market cap. This company provides commercial satellite services such as design, manufacture, launch, and data collection.  Sidus Space has generated space-related manufacturing revenues to date, but is highly unprofitable with negative gross margin in the 9mo21.","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605862133,"gmtCreate":1639146046624,"gmtModify":1639146046852,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605862133","repostId":"1115031273","repostType":4,"repost":{"id":"1115031273","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639143317,"share":"https://www.laohu8.com/m/news/1115031273?lang=&edition=full","pubTime":"2021-12-10 21:35","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1115031273","media":"Tiger Newspress","summary":"Stock-market index trade higher after inflation report.\nAt 8:34 a.m. ET, Dow e-minis were up 176 poi","content":"<p>Stock-market index trade higher after inflation report.</p>\n<p>At 8:34 a.m. ET, Dow e-minis were up 176 points, or 0.49%, S&amp;P 500 e-minis were up 30.75 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.</p>\n<p><img src=\"https://static.tigerbbs.com/022d770c8d408fcc5c7a5267e1fa96a1\" tg-width=\"412\" tg-height=\"184\" referrerpolicy=\"no-referrer\"></p>\n<p>Inflation accelerated at its fastest pace since 1982 in November, the Labor Department said Friday, putting pressure on the economic recovery and raising the stakes for the Federal Reserve.</p>\n<p>The consumer price index, which measures the cost of a wide-ranging basket of goods, rose 0.8% for the month, good for a 6.8% pace on a year over year basis and the fastest rate since June 1982.</p>\n<p>Excluding food and energy prices, so-called core CPI was up 0.5% for the month and 4.9% from a year ago, which itself was the sharpest pickup since mid-1991.</p>\n<p>The Dow Jones estimate was for a 6.7% annual gain for headline CPI and 4.9% for core.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Tesla(TSLA)</b>&nbsp;–&nbsp;Tesla Inc&nbsp;Chief Executive Officer Elon Musk has sold another 934,091 shares of the electric vehicle maker worth $963.2 million, U.S. securities filings showed on Thursday.He also exercised stock options to buy 2.17 million shares of Tesla, according to the filings.Musk is \"thinking of\" leaving his jobs and becoming an influencer, the world's richest man tweeted on Thursday.It was not immediately clear if Musk, a prolific user of the social media platform, was being serious about quitting his roles.Tesla shares dropped more&nbsp;than&nbsp;1% in premarket trading.</p>\n<p><b>Oracle(ORCL) </b>– Oracle shares surged 12% in the premarket, after quarterly sales and revenue beat estimates and the business software company announced a $10 billion increase in its share repurchase program.&nbsp;Oracle earned an adjusted $1.21 per share, 10 cents above estimates, with particular strength for its cloud infrastructure business.</p>\n<p><b>Broadcom(AVGO)</b> – The chip maker’s shares rallied nearly 7% in premarket trading after it beat Street forecasts on the top and bottom lines for its latest quarter.&nbsp;Broadcom earned an adjusted $7.81 per share, 7 cents above estimates, and also issued an upbeat forecast on continued high demand from its cloud computing customers.</p>\n<p><b>Chewy(CHWY) </b>– The online pet products retailer’s stock tumbled 10% in the premarket after it reported a wider-than-expected quarterly loss.&nbsp;Sales were in line with Street forecasts, but profit was impacted by higher costs for labor and supply chain issues.</p>\n<p><b>Moderna(MRNA)</b>&nbsp;–&nbsp;Moderna&nbsp;shares&nbsp;plunged&nbsp;10%&nbsp;in premarket trading.Other vaccine stocks also fell.BioNTech&nbsp;fell&nbsp;more&nbsp;than&nbsp;5%,Novavax&nbsp;fell&nbsp;more&nbsp;than&nbsp;3%.</p>\n<p><b>Lululemon(LULU)</b> – The athletic apparel maker reported adjusted quarterly profit of $1.62 per share, 21 cents above estimates, with revenue slightly above forecasts as well.&nbsp;However, Lululemon also warned that new Covid-19 variants could impact demand for “athleisure” clothing if virus concerns lead to temporary store closures and further supply chain issues.&nbsp;The stock slid 1.3% in premarket action.</p>\n<p><b>C3Ai(AI)</b> – The artificial intelligence software company’s stock soared 20% in the premarket after it won a $500 million contract from the U.S. Department of Defense for its suite of AI products.</p>\n<p><b>Costco(COST)</b> – The warehouse retailer earned $2.98 per share for its latest quarter, compared with a consensus estimate of $2.64, with revenue topping Street forecasts as well.&nbsp;The beat came despite higher costs and supply chain issues that Costco said it was able to largely mitigate.&nbsp;Costco rose 1.8% in the premarket.</p>\n<p><b>Beyond Meat(BYND)</b> – Restaurant chain Taco Bell dropped plans to test Beyond Meat’s plant-based version of carne asada,according to a Bloomberg report.&nbsp;Taco Bell is said to have been dissatisfied with samples it received in October, although the companies continue to work together on new products.&nbsp;Beyond Meat slipped 1.6% in premarket trading.</p>\n<p><b>American Outdoor Brands(AOUT)</b> – The outdoor products maker reported adjusted quarterly profit of 58 cents per share, well below the 76 cent consensus estimate, with revenue also falling short of analyst forecasts.&nbsp;The company said sales slowed due to a shift in customer purchase timing into the prior quarter to lessen supply chain concerns.&nbsp;American Outdoor shares plummeted 19% in premarket action.</p>\n<p><b>Vail Resorts(MTN)</b> – The resort operator lost $3.44 per share for its latest quarter, smaller than the loss of $3.62 that analysts had anticipated, thanks to a jump in season pass sales.&nbsp;However, revenue was below estimates.</p>\n<p><b>Peloton(PTON)</b> – The fitness equipment maker’s shares lost 3.6% in the premarket after Credit Suisse downgraded the stock to “neutral” from “outperform”.&nbsp;The firm noted a number of headwinds for Peloton, including a return to out-of-home fitness and a shift in consumer spending.</p>\n<p><b>AMC Entertainment(AMC)</b> – The movie theater operator’s shares slid 1% in premarket trading, after SEC filings showed a sale of 312,500 shares by CEO Adam Aron and a sale of 18,000 shares by CFO Sean Goodman.&nbsp;Aron had indicated in November that he would soon begin selling shares as part of estate planning.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stock-market index trade higher after inflation report.</p>\n<p>At 8:34 a.m. ET, Dow e-minis were up 176 points, or 0.49%, S&amp;P 500 e-minis were up 30.75 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.</p>\n<p><img src=\"https://static.tigerbbs.com/022d770c8d408fcc5c7a5267e1fa96a1\" tg-width=\"412\" tg-height=\"184\" referrerpolicy=\"no-referrer\"></p>\n<p>Inflation accelerated at its fastest pace since 1982 in November, the Labor Department said Friday, putting pressure on the economic recovery and raising the stakes for the Federal Reserve.</p>\n<p>The consumer price index, which measures the cost of a wide-ranging basket of goods, rose 0.8% for the month, good for a 6.8% pace on a year over year basis and the fastest rate since June 1982.</p>\n<p>Excluding food and energy prices, so-called core CPI was up 0.5% for the month and 4.9% from a year ago, which itself was the sharpest pickup since mid-1991.</p>\n<p>The Dow Jones estimate was for a 6.7% annual gain for headline CPI and 4.9% for core.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Tesla(TSLA)</b>&nbsp;–&nbsp;Tesla Inc&nbsp;Chief Executive Officer Elon Musk has sold another 934,091 shares of the electric vehicle maker worth $963.2 million, U.S. securities filings showed on Thursday.He also exercised stock options to buy 2.17 million shares of Tesla, according to the filings.Musk is \"thinking of\" leaving his jobs and becoming an influencer, the world's richest man tweeted on Thursday.It was not immediately clear if Musk, a prolific user of the social media platform, was being serious about quitting his roles.Tesla shares dropped more&nbsp;than&nbsp;1% in premarket trading.</p>\n<p><b>Oracle(ORCL) </b>– Oracle shares surged 12% in the premarket, after quarterly sales and revenue beat estimates and the business software company announced a $10 billion increase in its share repurchase program.&nbsp;Oracle earned an adjusted $1.21 per share, 10 cents above estimates, with particular strength for its cloud infrastructure business.</p>\n<p><b>Broadcom(AVGO)</b> – The chip maker’s shares rallied nearly 7% in premarket trading after it beat Street forecasts on the top and bottom lines for its latest quarter.&nbsp;Broadcom earned an adjusted $7.81 per share, 7 cents above estimates, and also issued an upbeat forecast on continued high demand from its cloud computing customers.</p>\n<p><b>Chewy(CHWY) </b>– The online pet products retailer’s stock tumbled 10% in the premarket after it reported a wider-than-expected quarterly loss.&nbsp;Sales were in line with Street forecasts, but profit was impacted by higher costs for labor and supply chain issues.</p>\n<p><b>Moderna(MRNA)</b>&nbsp;–&nbsp;Moderna&nbsp;shares&nbsp;plunged&nbsp;10%&nbsp;in premarket trading.Other vaccine stocks also fell.BioNTech&nbsp;fell&nbsp;more&nbsp;than&nbsp;5%,Novavax&nbsp;fell&nbsp;more&nbsp;than&nbsp;3%.</p>\n<p><b>Lululemon(LULU)</b> – The athletic apparel maker reported adjusted quarterly profit of $1.62 per share, 21 cents above estimates, with revenue slightly above forecasts as well.&nbsp;However, Lululemon also warned that new Covid-19 variants could impact demand for “athleisure” clothing if virus concerns lead to temporary store closures and further supply chain issues.&nbsp;The stock slid 1.3% in premarket action.</p>\n<p><b>C3Ai(AI)</b> – The artificial intelligence software company’s stock soared 20% in the premarket after it won a $500 million contract from the U.S. Department of Defense for its suite of AI products.</p>\n<p><b>Costco(COST)</b> – The warehouse retailer earned $2.98 per share for its latest quarter, compared with a consensus estimate of $2.64, with revenue topping Street forecasts as well.&nbsp;The beat came despite higher costs and supply chain issues that Costco said it was able to largely mitigate.&nbsp;Costco rose 1.8% in the premarket.</p>\n<p><b>Beyond Meat(BYND)</b> – Restaurant chain Taco Bell dropped plans to test Beyond Meat’s plant-based version of carne asada,according to a Bloomberg report.&nbsp;Taco Bell is said to have been dissatisfied with samples it received in October, although the companies continue to work together on new products.&nbsp;Beyond Meat slipped 1.6% in premarket trading.</p>\n<p><b>American Outdoor Brands(AOUT)</b> – The outdoor products maker reported adjusted quarterly profit of 58 cents per share, well below the 76 cent consensus estimate, with revenue also falling short of analyst forecasts.&nbsp;The company said sales slowed due to a shift in customer purchase timing into the prior quarter to lessen supply chain concerns.&nbsp;American Outdoor shares plummeted 19% in premarket action.</p>\n<p><b>Vail Resorts(MTN)</b> – The resort operator lost $3.44 per share for its latest quarter, smaller than the loss of $3.62 that analysts had anticipated, thanks to a jump in season pass sales.&nbsp;However, revenue was below estimates.</p>\n<p><b>Peloton(PTON)</b> – The fitness equipment maker’s shares lost 3.6% in the premarket after Credit Suisse downgraded the stock to “neutral” from “outperform”.&nbsp;The firm noted a number of headwinds for Peloton, including a return to out-of-home fitness and a shift in consumer spending.</p>\n<p><b>AMC Entertainment(AMC)</b> – The movie theater operator’s shares slid 1% in premarket trading, after SEC filings showed a sale of 312,500 shares by CEO Adam Aron and a sale of 18,000 shares by CFO Sean Goodman.&nbsp;Aron had indicated in November that he would soon begin selling shares as part of estate planning.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AI":"C3.ai, Inc.","CHWY":"Chewy, Inc.","BNTX":"BioNTech SE",".DJI":"道琼斯","MTN":"Vail Resorts Inc","TSLA":"特斯拉","AVGO":"博通",".IXIC":"NASDAQ Composite","ORCL":"甲骨文","MRNA":"Moderna, Inc.","AOUT":"American Outdoor Brands, Inc.","NVAX":"诺瓦瓦克斯医药","COST":"好市多",".SPX":"S&P 500 Index","BYND":"Beyond Meat, Inc.","AMC":"AMC院线","LULU":"lululemon athletica","PTON":"Peloton Interactive, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115031273","content_text":"Stock-market index trade higher after inflation report.\nAt 8:34 a.m. ET, Dow e-minis were up 176 points, or 0.49%, S&P 500 e-minis were up 30.75 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.\n\nInflation accelerated at its fastest pace since 1982 in November, the Labor Department said Friday, putting pressure on the economic recovery and raising the stakes for the Federal Reserve.\nThe consumer price index, which measures the cost of a wide-ranging basket of goods, rose 0.8% for the month, good for a 6.8% pace on a year over year basis and the fastest rate since June 1982.\nExcluding food and energy prices, so-called core CPI was up 0.5% for the month and 4.9% from a year ago, which itself was the sharpest pickup since mid-1991.\nThe Dow Jones estimate was for a 6.7% annual gain for headline CPI and 4.9% for core.\nStocks making the biggest moves premarket:\nTesla(TSLA) – Tesla Inc Chief Executive Officer Elon Musk has sold another 934,091 shares of the electric vehicle maker worth $963.2 million, U.S. securities filings showed on Thursday.He also exercised stock options to buy 2.17 million shares of Tesla, according to the filings.Musk is \"thinking of\" leaving his jobs and becoming an influencer, the world's richest man tweeted on Thursday.It was not immediately clear if Musk, a prolific user of the social media platform, was being serious about quitting his roles.Tesla shares dropped more than 1% in premarket trading.\nOracle(ORCL) – Oracle shares surged 12% in the premarket, after quarterly sales and revenue beat estimates and the business software company announced a $10 billion increase in its share repurchase program. Oracle earned an adjusted $1.21 per share, 10 cents above estimates, with particular strength for its cloud infrastructure business.\nBroadcom(AVGO) – The chip maker’s shares rallied nearly 7% in premarket trading after it beat Street forecasts on the top and bottom lines for its latest quarter. Broadcom earned an adjusted $7.81 per share, 7 cents above estimates, and also issued an upbeat forecast on continued high demand from its cloud computing customers.\nChewy(CHWY) – The online pet products retailer’s stock tumbled 10% in the premarket after it reported a wider-than-expected quarterly loss. Sales were in line with Street forecasts, but profit was impacted by higher costs for labor and supply chain issues.\nModerna(MRNA) – Moderna shares plunged 10% in premarket trading.Other vaccine stocks also fell.BioNTech fell more than 5%,Novavax fell more than 3%.\nLululemon(LULU) – The athletic apparel maker reported adjusted quarterly profit of $1.62 per share, 21 cents above estimates, with revenue slightly above forecasts as well. However, Lululemon also warned that new Covid-19 variants could impact demand for “athleisure” clothing if virus concerns lead to temporary store closures and further supply chain issues. The stock slid 1.3% in premarket action.\nC3Ai(AI) – The artificial intelligence software company’s stock soared 20% in the premarket after it won a $500 million contract from the U.S. Department of Defense for its suite of AI products.\nCostco(COST) – The warehouse retailer earned $2.98 per share for its latest quarter, compared with a consensus estimate of $2.64, with revenue topping Street forecasts as well. The beat came despite higher costs and supply chain issues that Costco said it was able to largely mitigate. Costco rose 1.8% in the premarket.\nBeyond Meat(BYND) – Restaurant chain Taco Bell dropped plans to test Beyond Meat’s plant-based version of carne asada,according to a Bloomberg report. Taco Bell is said to have been dissatisfied with samples it received in October, although the companies continue to work together on new products. Beyond Meat slipped 1.6% in premarket trading.\nAmerican Outdoor Brands(AOUT) – The outdoor products maker reported adjusted quarterly profit of 58 cents per share, well below the 76 cent consensus estimate, with revenue also falling short of analyst forecasts. The company said sales slowed due to a shift in customer purchase timing into the prior quarter to lessen supply chain concerns. American Outdoor shares plummeted 19% in premarket action.\nVail Resorts(MTN) – The resort operator lost $3.44 per share for its latest quarter, smaller than the loss of $3.62 that analysts had anticipated, thanks to a jump in season pass sales. However, revenue was below estimates.\nPeloton(PTON) – The fitness equipment maker’s shares lost 3.6% in the premarket after Credit Suisse downgraded the stock to “neutral” from “outperform”. The firm noted a number of headwinds for Peloton, including a return to out-of-home fitness and a shift in consumer spending.\nAMC Entertainment(AMC) – The movie theater operator’s shares slid 1% in premarket trading, after SEC filings showed a sale of 312,500 shares by CEO Adam Aron and a sale of 18,000 shares by CFO Sean Goodman. Aron had indicated in November that he would soon begin selling shares as part of estate planning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602799475,"gmtCreate":1639063416262,"gmtModify":1639064046205,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602799475","repostId":"2190617302","repostType":4,"repost":{"id":"2190617302","pubTimestamp":1639063118,"share":"https://www.laohu8.com/m/news/2190617302?lang=&edition=full","pubTime":"2021-12-09 23:18","market":"us","language":"en","title":"2 Short-Squeeze Candidates That Could Go Parabolic Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2190617302","media":"Motley Fool","summary":"Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.","content":"<p>Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called \"meme stocks\" generated jaw-dropping gains for investors earlier this year due to this phenomenon.</p>\n<p>The mechanics of a short squeeze are fairly straightforward. Short-sellers, or investors betting against an equity, are essentially forced to cover their position in response to an uptick in investors buying the stock. The net result, more often than not, is a brief, parabolic-like move higher in the stock in question.</p>\n<p>Last month, short-sellers seemingly took advantage of the widespread weakness across the biopharma space. As a result, scores of biopharma equities sport sizable short positions as a percentage of the outstanding shares. The Alzheimer's&nbsp; specialist <b>Cortexyme</b> (NASDAQ:CRTX) and the commercial-stage biotech <b>Heron Therapeutics</b> (NASDAQ:HRTX) were two of the most heavily shorted pharma stocks at last count. These two drugmakers, however, could prove to be terrible stocks to bet against. Here's why.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6841093892c649c73d00f9f0f9f2663\" tg-width=\"700\" tg-height=\"533\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Cortexyme: Alzheimer's drugs are too risky to short</h2>\n<p>Cortexyme, a small-molecule drug developer, became a huge target for short-sellers after its experimental Alzheimer's disease treatment atuzaginstat flopped in a late-stage trial toward the end of October. In fact, the biotech's shares were <i>the</i> most heavily shorted equity among biopharmas at last count, a little over two weeks ago. Short-sellers are clearly betting that atuzaginstat is basically dead on arrival. That rather dire take might not be the case, however.</p>\n<p>During a recent conference call, Cortexyme management said that the drug does appear to show a worthwhile clinical benefit for Alzheimer's patients who also tested positive for the gum-disease bacteria Porphyromonas gingivalis. While this analysis is far from definitive, it may help the company identify the correct patient population to evaluate atuzaginstat in, via another late-stage trial. Cortexyme intends to do just that. Almost immediately after the drug disappointed in this all-comer study, management announced plans to target a more-focused group of patients in another pivotal study.</p>\n<p>Why is Cortexyme an outstanding short-squeeze candidate? Even as a drug exclusively for Alzheimer's disease patients with an active P. gingivalis infection, it should still generate mega-blockbuster sales (greater than $5 billion). That's a massive revenue stream for a company with a $420 million market cap at present. Cortexyme plans to provide an update to investors on this upcoming clinical trial in the first quarter of 2022. This update could very well spark a short squeeze in the biotech's stock.</p>\n<h2>Heron Therapeutics: Down but not out</h2>\n<p>Heron Therapeutics has been a top short-seller target for well over a year now. As a result, the biotech's stock is currently <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most heavily shorted within its immediate peer group. Bears have bet against this small-cap pharma stock for two clear reasons. First, Heron's chemotherapy-induced nausea and vomiting franchise has underwhelmed from a commercial standpoint.</p>\n<p>Second, the biotech's highly anticipated acute pain medication Zynrelef didn't get the type of broad label from the Food and Drug Administration (FDA) that would have allowed it to become a major growth driver right off the bat.&nbsp;Heron is working with the FDA to expand Zynrelef's label, but this process will take a while to work through.</p>\n<p>The good news is that Zynrelef still holds the potential to rake in upward of $500 million in sales by the middle of the decade. That's a nice chunk of change for a biotech with a sub-$1 billion market cap.</p>\n<p>Why might Heron be gearing up for a noteworthy short squeeze? It is expected to announce important commercial and regulatory updates for Zynrelef before the end of February 2022. If the drug's commercial launch continues to show promise and its label-expansion plans remain on track, the stock should reverse course. The biotech's shares, after all, are currently trading at under 3 times 2023 sales, which is a dirt cheap valuation for a commercial-stage biotech.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Short-Squeeze Candidates That Could Go Parabolic Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Short-Squeeze Candidates That Could Go Parabolic Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 23:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/09/2-short-squeeze-stock-candidates-that-could-go-par/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called \"meme stocks\" generated jaw-dropping gains for investors earlier this year due to this phenomenon.\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/09/2-short-squeeze-stock-candidates-that-could-go-par/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","HRTX":"Heron Therapeutics Inc."},"source_url":"https://www.fool.com/investing/2021/12/09/2-short-squeeze-stock-candidates-that-could-go-par/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190617302","content_text":"Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called \"meme stocks\" generated jaw-dropping gains for investors earlier this year due to this phenomenon.\nThe mechanics of a short squeeze are fairly straightforward. Short-sellers, or investors betting against an equity, are essentially forced to cover their position in response to an uptick in investors buying the stock. The net result, more often than not, is a brief, parabolic-like move higher in the stock in question.\nLast month, short-sellers seemingly took advantage of the widespread weakness across the biopharma space. As a result, scores of biopharma equities sport sizable short positions as a percentage of the outstanding shares. The Alzheimer's  specialist Cortexyme (NASDAQ:CRTX) and the commercial-stage biotech Heron Therapeutics (NASDAQ:HRTX) were two of the most heavily shorted pharma stocks at last count. These two drugmakers, however, could prove to be terrible stocks to bet against. Here's why.\nImage source: Getty Images.\nCortexyme: Alzheimer's drugs are too risky to short\nCortexyme, a small-molecule drug developer, became a huge target for short-sellers after its experimental Alzheimer's disease treatment atuzaginstat flopped in a late-stage trial toward the end of October. In fact, the biotech's shares were the most heavily shorted equity among biopharmas at last count, a little over two weeks ago. Short-sellers are clearly betting that atuzaginstat is basically dead on arrival. That rather dire take might not be the case, however.\nDuring a recent conference call, Cortexyme management said that the drug does appear to show a worthwhile clinical benefit for Alzheimer's patients who also tested positive for the gum-disease bacteria Porphyromonas gingivalis. While this analysis is far from definitive, it may help the company identify the correct patient population to evaluate atuzaginstat in, via another late-stage trial. Cortexyme intends to do just that. Almost immediately after the drug disappointed in this all-comer study, management announced plans to target a more-focused group of patients in another pivotal study.\nWhy is Cortexyme an outstanding short-squeeze candidate? Even as a drug exclusively for Alzheimer's disease patients with an active P. gingivalis infection, it should still generate mega-blockbuster sales (greater than $5 billion). That's a massive revenue stream for a company with a $420 million market cap at present. Cortexyme plans to provide an update to investors on this upcoming clinical trial in the first quarter of 2022. This update could very well spark a short squeeze in the biotech's stock.\nHeron Therapeutics: Down but not out\nHeron Therapeutics has been a top short-seller target for well over a year now. As a result, the biotech's stock is currently one of the most heavily shorted within its immediate peer group. Bears have bet against this small-cap pharma stock for two clear reasons. First, Heron's chemotherapy-induced nausea and vomiting franchise has underwhelmed from a commercial standpoint.\nSecond, the biotech's highly anticipated acute pain medication Zynrelef didn't get the type of broad label from the Food and Drug Administration (FDA) that would have allowed it to become a major growth driver right off the bat. Heron is working with the FDA to expand Zynrelef's label, but this process will take a while to work through.\nThe good news is that Zynrelef still holds the potential to rake in upward of $500 million in sales by the middle of the decade. That's a nice chunk of change for a biotech with a sub-$1 billion market cap.\nWhy might Heron be gearing up for a noteworthy short squeeze? It is expected to announce important commercial and regulatory updates for Zynrelef before the end of February 2022. If the drug's commercial launch continues to show promise and its label-expansion plans remain on track, the stock should reverse course. The biotech's shares, after all, are currently trading at under 3 times 2023 sales, which is a dirt cheap valuation for a commercial-stage biotech.","news_type":1},"isVote":1,"tweetType":1,"viewCount":275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":873833333,"gmtCreate":1636906777344,"gmtModify":1636906777463,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/873833333","repostId":"1103944030","repostType":4,"repost":{"id":"1103944030","pubTimestamp":1636857439,"share":"https://www.laohu8.com/m/news/1103944030?lang=&edition=full","pubTime":"2021-11-14 10:37","market":"us","language":"en","title":"These are the next three mega-cap tech stocks you’ll be hearing more about","url":"https://stock-news.laohu8.com/highlight/detail?id=1103944030","media":"MarketWatch","summary":"AMD is among companies poised to eclipse $200 billion in market value\nAMD Chief Executive Lisa Su is","content":"<p>AMD is among companies poised to eclipse $200 billion in market value</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8977785546ccb691b11117bea0aa1480\" tg-width=\"1320\" tg-height=\"742\" referrerpolicy=\"no-referrer\"><span>AMD Chief Executive Lisa Su is seen in 2017. AFP via Getty Images</span></p>\n<p>As technology stocks have led the market for the better part of a dozen years, there are now 15 companies in the sector that have risen to mega-cap status — those valued at $200 billion or more.</p>\n<p>Five are valued at more than $1 trillion, including electric-vehicle maker Tesla,which I consider a tech company.</p>\n<p>Bets have been placed on which companies will rise to a trillion next, with Meta Platforms&nbsp;— aka Facebook — at the top of most lists and&nbsp;Nvidia,sitting on top of mine as a call I made 14 months ago.</p>\n<p>Perhaps harder than rising from north of half a trillion to a trillion is rising from less than&nbsp;$200 billion&nbsp;to break the threshold into mega-cap status.</p>\n<p>However, a few companies look destined for this outcome precisely, and I believe three have an incredibly compelling case to get there within the next 12 to 18 months — if not sooner.</p>\n<p><b>1. ServiceNow:</b>&nbsp;ServiceNow&nbsp;has been on an incredible run for more than a decade. From 2010 to 2020, revenues grew at a 59.2% average annual rate, while its stock rose at 44% a year. The company finished the 2020 calendar year at about $4.5 billion in revenue, and its trailing 12 months have surged close to $5.5 billion.</p>\n<p>The company now has more than 1,266 customers with a million or more dollars in recurring revenue, and is seeing this number grow at a substantial rate, including 25% in its most recent quarter.</p>\n<p>Beyond the numbers, the company’s technology, which enables companies to automate and implement digital workflows, continues to prove robust and best of breed. The most recent release of its Rome platform, three additional acquisitions to expand its portfolio and a deepened partnership with Microsoft&nbsp;are just a few recent highlights that provide the company a pathway to growth that should accelerate based on trends including app modernization, hybrid work, workflow automation, and even enterprise ESG initiatives.</p>\n<p>It’s hard to see ServiceNow not providing the robust growth that will take its market cap above $200 billion.&nbsp;The company’s market value is about $138 billion as of Monday.</p>\n<p><b>2. Qualcomm:</b>Qualcomm’s&nbsp;strong earnings report released last week — earnings per share jumped 76% year over year and revenue rose 43% — helped drive the stock to over $160 from the low $120s in mid-October.</p>\n<p>Consequently, that took the company’s market cap from about $145 billion to over $180 billion in just a matter of days. It serves as a timely reminder of how quickly a tech company in the right markets can produce momentum.</p>\n<p>Qualcomm, while best known as a chip provider for mobile handsets, is rapidly becoming a much bigger force in many categories, including the internet of things (IoT), automotive and wireless RFFE. With IoT and wireless RFFE surpassing a billion dollars a quarter in revenue, and automotive reaching nearly a billion in annual revenue with a $10 billion design pipeline, the company is becoming increasingly diversified. Thirty-eight percent of revenue in its QCT semiconductor business is now unrelated to handsets.</p>\n<p>Perhaps these adjacent business successes alone could catapult the company’s market value to over $200 billion, but what Qualcomm also has going for it is an undisputable global market leadership in 5G, which will continue to accelerate its handset business, as well as all of its adjacencies and massive licensing business.</p>\n<p><b>3. AMD:</b>&nbsp;I’ve been critical at times of Advanced Micro Devices,and sometimes you have to lean into calls you get wrong. While Intel&nbsp;under new CEO Pat Gelsinger shows more ambition and clear direction, AMD under Lisa Su has been on an absolute tear.</p>\n<p>In August, Mercury Research reported that AMD’s 22.5% x86 market share was its best in 14 years. With 4.2% year-over-year market share growth in its second quarter and another 54% overall revenue growth in the third quarter, the company’s market share gains look likely to continue.</p>\n<p>While I do think Intel is quickly patching its gaps and going to be a much more robust competitor, I believe the overall demand for CPUs (central processing units), GPUs (graphics processing units) and FPGAs (field-programmable gate arrays) will drive a larger total addressable market, and AMD’s going to grow revenues even if market share gains level off.</p>\n<p>Speaking of FPGA’s, the impending Xilinx deal, which I believe will gain regulatory approval, hasn’t been accounted for by many investors.</p>\n<p>AMD’s market value rose to over $180 billion Monday after the stock surged more than 10%. The company on Monday announced a range of news, including the fact that Meta will use its Epyc processors in its data center computers.</p>\n<p>After those three, I would add Micron Technology&nbsp;as an honorable mention. The company sits at closer to $85 billion in market cap. Still, as our thirst for compute continues to grow, the need for memory technology will scale dramatically, making Micron a significant beneficiary along with the likes of Samsung, which already sits well inside mega-cap territory.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the next three mega-cap tech stocks you’ll be hearing more about</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the next three mega-cap tech stocks you’ll be hearing more about\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-14 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/these-are-the-next-three-mega-cap-tech-stocks-youll-be-hearing-more-about-11636392083?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMD is among companies poised to eclipse $200 billion in market value\nAMD Chief Executive Lisa Su is seen in 2017. AFP via Getty Images\nAs technology stocks have led the market for the better part of ...</p>\n\n<a href=\"https://www.marketwatch.com/story/these-are-the-next-three-mega-cap-tech-stocks-youll-be-hearing-more-about-11636392083?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NOW":"ServiceNow","QCOM":"高通","NVDA":"英伟达","AMD":"美国超微公司"},"source_url":"https://www.marketwatch.com/story/these-are-the-next-three-mega-cap-tech-stocks-youll-be-hearing-more-about-11636392083?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103944030","content_text":"AMD is among companies poised to eclipse $200 billion in market value\nAMD Chief Executive Lisa Su is seen in 2017. AFP via Getty Images\nAs technology stocks have led the market for the better part of a dozen years, there are now 15 companies in the sector that have risen to mega-cap status — those valued at $200 billion or more.\nFive are valued at more than $1 trillion, including electric-vehicle maker Tesla,which I consider a tech company.\nBets have been placed on which companies will rise to a trillion next, with Meta Platforms — aka Facebook — at the top of most lists and Nvidia,sitting on top of mine as a call I made 14 months ago.\nPerhaps harder than rising from north of half a trillion to a trillion is rising from less than $200 billion to break the threshold into mega-cap status.\nHowever, a few companies look destined for this outcome precisely, and I believe three have an incredibly compelling case to get there within the next 12 to 18 months — if not sooner.\n1. ServiceNow: ServiceNow has been on an incredible run for more than a decade. From 2010 to 2020, revenues grew at a 59.2% average annual rate, while its stock rose at 44% a year. The company finished the 2020 calendar year at about $4.5 billion in revenue, and its trailing 12 months have surged close to $5.5 billion.\nThe company now has more than 1,266 customers with a million or more dollars in recurring revenue, and is seeing this number grow at a substantial rate, including 25% in its most recent quarter.\nBeyond the numbers, the company’s technology, which enables companies to automate and implement digital workflows, continues to prove robust and best of breed. The most recent release of its Rome platform, three additional acquisitions to expand its portfolio and a deepened partnership with Microsoft are just a few recent highlights that provide the company a pathway to growth that should accelerate based on trends including app modernization, hybrid work, workflow automation, and even enterprise ESG initiatives.\nIt’s hard to see ServiceNow not providing the robust growth that will take its market cap above $200 billion. The company’s market value is about $138 billion as of Monday.\n2. Qualcomm:Qualcomm’s strong earnings report released last week — earnings per share jumped 76% year over year and revenue rose 43% — helped drive the stock to over $160 from the low $120s in mid-October.\nConsequently, that took the company’s market cap from about $145 billion to over $180 billion in just a matter of days. It serves as a timely reminder of how quickly a tech company in the right markets can produce momentum.\nQualcomm, while best known as a chip provider for mobile handsets, is rapidly becoming a much bigger force in many categories, including the internet of things (IoT), automotive and wireless RFFE. With IoT and wireless RFFE surpassing a billion dollars a quarter in revenue, and automotive reaching nearly a billion in annual revenue with a $10 billion design pipeline, the company is becoming increasingly diversified. Thirty-eight percent of revenue in its QCT semiconductor business is now unrelated to handsets.\nPerhaps these adjacent business successes alone could catapult the company’s market value to over $200 billion, but what Qualcomm also has going for it is an undisputable global market leadership in 5G, which will continue to accelerate its handset business, as well as all of its adjacencies and massive licensing business.\n3. AMD: I’ve been critical at times of Advanced Micro Devices,and sometimes you have to lean into calls you get wrong. While Intel under new CEO Pat Gelsinger shows more ambition and clear direction, AMD under Lisa Su has been on an absolute tear.\nIn August, Mercury Research reported that AMD’s 22.5% x86 market share was its best in 14 years. With 4.2% year-over-year market share growth in its second quarter and another 54% overall revenue growth in the third quarter, the company’s market share gains look likely to continue.\nWhile I do think Intel is quickly patching its gaps and going to be a much more robust competitor, I believe the overall demand for CPUs (central processing units), GPUs (graphics processing units) and FPGAs (field-programmable gate arrays) will drive a larger total addressable market, and AMD’s going to grow revenues even if market share gains level off.\nSpeaking of FPGA’s, the impending Xilinx deal, which I believe will gain regulatory approval, hasn’t been accounted for by many investors.\nAMD’s market value rose to over $180 billion Monday after the stock surged more than 10%. The company on Monday announced a range of news, including the fact that Meta will use its Epyc processors in its data center computers.\nAfter those three, I would add Micron Technology as an honorable mention. The company sits at closer to $85 billion in market cap. Still, as our thirst for compute continues to grow, the need for memory technology will scale dramatically, making Micron a significant beneficiary along with the likes of Samsung, which already sits well inside mega-cap territory.","news_type":1},"isVote":1,"tweetType":1,"viewCount":57,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698850170,"gmtCreate":1640346574159,"gmtModify":1640346574440,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698850170","repostId":"2193127176","repostType":4,"repost":{"id":"2193127176","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640345481,"share":"https://www.laohu8.com/m/news/2193127176?lang=&edition=full","pubTime":"2021-12-24 19:31","market":"us","language":"en","title":"Japan health panel approves Merck's oral COVID-19 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2193127176","media":"Reuters","summary":"TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COV","content":"<p>TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck &amp; Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.</p>\n<p>The panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.</p>\n<p>Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.</p>\n<p>In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill&nbsp;developed by Pfizer Inc. And Japan's Shionogi &amp; Co is expected to soon file for approval of its own treatment&nbsp;supplying another 1 million doses by early next year.</p>\n<p>U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.</p>\n<p>Countries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.</p>\n<p>Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan health panel approves Merck's oral COVID-19 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan health panel approves Merck's oral COVID-19 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck &amp; Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.</p>\n<p>The panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.</p>\n<p>Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.</p>\n<p>In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill&nbsp;developed by Pfizer Inc. And Japan's Shionogi &amp; Co is expected to soon file for approval of its own treatment&nbsp;supplying another 1 million doses by early next year.</p>\n<p>U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.</p>\n<p>Countries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.</p>\n<p>Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","MRK":"默沙东","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4516":"特朗普概念","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193127176","content_text":"TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck & Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.\nThe panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.\nJapan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.\nIn addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill developed by Pfizer Inc. And Japan's Shionogi & Co is expected to soon file for approval of its own treatment supplying another 1 million doses by early next year.\nU.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.\nCountries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.\nJapan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":901,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843093651,"gmtCreate":1635780694779,"gmtModify":1635780694914,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/843093651","repostId":"2179250221","repostType":4,"repost":{"id":"2179250221","pubTimestamp":1635721559,"share":"https://www.laohu8.com/m/news/2179250221?lang=&edition=full","pubTime":"2021-11-01 07:05","market":"us","language":"en","title":"Federal Reserve decision, October jobs report: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2179250221","media":"Yahoo Finance","summary":"The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set th","content":"<p><img src=\"https://static.tigerbbs.com/790c3fdfdc38fa2b5b3a13d89fb1959a\" tg-width=\"1878\" tg-height=\"2940\" width=\"100%\" height=\"auto\"></p>\n<p>The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also await more data on the U.S. economic recovery with the Labor Department's monthly jobs report later this week.</p>\n<p>The Federal Open Market Committee's (FOMC) November meeting will take place from Tuesday to Wednesday, with the policy statement and press conference from the meeting serving as the central bank's penultimate opportunity this year to announce formal plans to begin rolling back its crisis-era quantitative easing program. For the past year-and-a-half, the central bank has been purchasing $120 billion per month in agency mortgage-backed securities and Treasuries, as <a href=\"https://laohu8.com/S/AONE.U\">one</a> major tool to support the economy during the pandemic.</p>\n<p>In late September, the FOMC's latest monetary policy statement and press conference from Federal Reserve Chair Jerome <a href=\"https://laohu8.com/S/POWL\">Powell</a> suggested the central bank was apt to announce the start of tapering before year-end, and continue the tapering process until \"around the middle of next year.\"</p>\n<p>\"The upcoming FOMC meeting will be important for three reasons: 1) the announcement of tapering; 2) guidance around what tapering means for the path of hikes; and 3) nuanced changes in views around inflation risks given recent data,\" wrote <a href=\"https://laohu8.com/S/BAC\">Bank of America</a> economist Michelle Meyer in a note.</p>\n<p>\"The statement that announces the new pace of asset purchases will be followed by a note regarding flexibility stating that asset purchases are not on a pre-set course and will depend on the outlook for the labor market and inflation as well as an assessment of the efficacy of asset purchases,\" she predicted.</p>\n<p>She noted that Powell may also use the press conference to reiterate that the end of tapering would not necessarily indicate the start of rate hikes, and that both policy actions are distinct. In previous public remarks, Powell has already made a similar point in previous public remarks, saying, \"the timing and pace of the coming reduction in asset purchases will not be intended to carry a direct signal regarding the timing of interest rate liftoff.\"</p>\n<p>Given the market has been anticipating the start to tapering for months now, speculation around when the Fed will make a move on interest rates has become a point of particular interest to investors. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> and economists have mulled whether the Fed may need to act more quickly than previously telegraphed on adjusting interest rates to stave off inflation, which has proven more long-lasting than some had suggested.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f0f0ae63a784eef5578397df02340483\" tg-width=\"4932\" tg-height=\"3288\" referrerpolicy=\"no-referrer\"><span>WASHINGTON, DC - SEPTEMBER 24: Federal Reserve Board Chairman Jerome Powell testifies during a Senate Banking Committee hearing on Capitol Hill on September 24, 2020 in Washington, DC. Powell and U.S. Treasury Secretary Steve Mnuchin are testifying about the CARES Act and the economic effects of the coronavirus pandemic. (Photo by Drew Angerer/Getty Images)Drew Angerer via Getty Images</span></p>\n<p>In September, core personal consumption expenditures — the Fed's preferred gauge of underlying inflation — rose 3.6% over last year for a fourth consecutive month, coming in at the fastest clip since 1991. And earlier this month, Powell acknowledged in public remarks that the supply chain constraints and shortages that spurred the latest rise in prices are \"likely to last longer than previously expected, likely well into next year.\"</p>\n<p>While the central bank will not release an updated Summary of Economic Projections with their policy statement on Wednesday, the latest projections from the September meeting suggested the committee was split on rate hikes for 2022, with nine members seeing no rate hikes by the end of next year while the other nine members saw at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> hike.</p>\n<p>\"I think the Fed has pretty well determined to start the taper pretty quickly. We expect them to announce it next week and then start it soon thereafter, so that's pretty well carved in stone,\" Kathy Jones, <a href=\"https://laohu8.com/S/SCHW\">Charles Schwab</a> chief fixed income strategist, told Yahoo Finance Live last week. \"I think the big debate now is how quickly the Fed moves toward actually raising rates. The expectation in the market has really shifted to expecting as many as two rate hikes in 2022 and 2023 ... that’s a pretty aggressive pace of tightening.\"</p>\n<h2>October jobs report</h2>\n<p>One of this week's most closely watched pieces of economic data will be the October jobs report, which is due for release on Friday from the Labor Department.</p>\n<p>Economists are looking to see a pick-up in the pace of hiring for October after a disappointing print in September, when just 194,000 non-farm payrolls returned versus the half million expected. Over the past two months, payroll gains averaged at just 280,000. The unemployment rate is expected to take another small step toward pre-pandemic levels in October as well, with the jobless rate anticipated to dip to 4.7% from 4.8% the prior month.</p>\n<p>Still, the labor market has still fallen short its pre-pandemic conditions on a number of fronts. The unemployment rate has yet to return to its 50-year low of 3.5% from February 2020. And as of September, the civilian labor force was still down by about 3.1 million individuals from pre-virus levels.</p>\n<p>One factor weighing on the labor market in August and September was the Delta variant, which may have deterred some workers from seeking employment in person for risk of infection. And an ongoing element dragging on the labor market's recovery has been a mismatch of supply and demand, with employers struggling to fill a near-record number of job openings while voluntary quits jumped to a historically high level.</p>\n<p>\"Next week’s October payrolls report will shed light on whether supply eased on diminishing constraints or if the labor market continues to face headwinds for now,\" wrote Rubeela Farooqi, chief U.S. economist for High Frequency Economics, in a note last week.</p>\n<p>But some data from the past couple weeks has reflected favorably on conditions in the labor market in October. Weekly new unemployment claims broke below 300,000 for the first time since the start of the pandemic during the survey week for the October jobs report, or the week that includes the 12th of the month. And in the Conference Board's October Consumer Confidence Index, just 10.6% of consumers said jobs were \"hard to get,\" down from 13.0% in September. That brought the Conference Board's closely watched labor market differential, or percentage of consumers saying jobs are \"hard to get\" subtracted from the percentage saying jobs \"are plentiful,\" to 45, or its highest level since 2000.</p>\n<h2>Economic calendar</h2>\n<ul>\n <li><p><b>Monday: </b><a href=\"https://laohu8.com/S/MRKT\">Markit</a> U.S. Manufacturing PMI, Oct. final (59.3 expected, 59.2 in September); Constructing spending, month-over-month, September (0.4% expected, 0.0% in August); ISM Manufacturing Index, Oct. (60.5 expected, 61.1 in September)</p></li>\n <li><p><b>Tuesday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Wednesday: </b>MBA Mortgage Applications, week ended Oct. 29 (0.3% during prior week); ADP Employment Change, Oct. (400,000 expected, 568,000 in September); ISM Services Index, October (62.0 expected, 61.9 in September); Factory Orders, September (-0.1% expected, 1.2% in August); Durable goods orders, September final (-0.4% in prior print; Durable goods orders excluding transportation, September final (0.4% in prior print); Non-defense capital goods orders excluding aircraft, September final (0.8% in prior print); Markit U.S. Services PMI, October final (58.2 expected, 58.2 in prior print); Markit U.S. Composite PMI, October final (57.3 in prior print); Federal Open Market Committee monetary policy decision</p></li>\n <li><p><b>Thursday: </b>Challenger job cuts, year-over-year, October (-84.9% in September); Initial jobless claims, week ended Oct. 30 (275,000 expected, 281,000 during prior week); Continuing claims, week ended Oct. 23 (2.147 million expected, 2.243 million during prior week); Non-farm productivity, Q3 preliminary (-3.2% expected, 2.1% in <a href=\"https://laohu8.com/S/QTWO\">Q2</a>); <a href=\"https://laohu8.com/S/UNT\">Unit</a> Labor Costs, Q3 preliminary (6.9% expected, 1.3% in Q2); Trade balance, September (-$80.1 billion expected, -$73.3 billion in August)</p></li>\n <li><p><b>Friday: </b>Change in non-farm payrolls, October (450,000 expected, 194,000 in September); Unemployment rate, October (4.7% expected, 4.8% in September); Average hourly earnings, month-over-month, October (4.7% expected, 4.8% in September); Average hourly earnings, year-over-year, October (4.9% expected, 4.6% in September); Labor Force Participation Rate, October (61.8% expected, 61.6% in September); Consumer Credit, September ($16.200 billion expected, $14.379 million in August)</p></li>\n</ul>\n<h2>Earnings calendar</h2>\n<ul>\n <li><p><b>Monday: </b><a href=\"https://laohu8.com/S/CLX\">Clorox</a> (CLX), <a href=\"https://laohu8.com/S/CAR\">Avis Budget</a> Group (<a href=\"https://laohu8.com/S/00699\">CAR</a>), ZoomInfo Technologies (ZI), <a href=\"https://laohu8.com/S/CHGG\">Chegg Inc</a>. (CHGG), <a href=\"https://laohu8.com/S/FANG\">Diamondback Energy</a> (FANG), The <a href=\"https://laohu8.com/S/SPG\">Simon Property</a> Group (SPG) after market close</p></li>\n <li><p><b>Tuesday: </b><a href=\"https://laohu8.com/S/UA.C\">Under Armour</a> (UAA), <a href=\"https://laohu8.com/S/EL\">Estee Lauder</a> (EL), <a href=\"https://laohu8.com/S/RL\">Ralph Lauren</a> (RL), Apollo Global Management (APO), Corsair Gaming (CRSR), <a href=\"https://laohu8.com/S/BLMN\">Bloomin' Brands</a> (BLMN), <a href=\"https://laohu8.com/S/COP\">ConocoPhillips</a> (COP), <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE), <a href=\"https://laohu8.com/S/GRPN\">Groupon</a> (GPN), <a href=\"https://laohu8.com/S/MPC\">Marathon</a> Petroleum (MPC) before market open; <a href=\"https://laohu8.com/S/MDLZ\">Mondelez</a> (MDLZ), T-Mobile (TMUS), <a href=\"https://laohu8.com/S/AKAM\">Akamai</a> (AKAM), <a href=\"https://laohu8.com/S/ATVI\">Activision Blizzard</a> (ATVI), Lyft (LYFT), <a href=\"https://laohu8.com/S/MTCH\">Match</a> Group (MTCH), <a href=\"https://laohu8.com/S/DVN\">Devon</a> Energy (DVN), <a href=\"https://laohu8.com/S/CHK\">Chesapeake</a> Energy (CHK), Coursera (COUR), <a href=\"https://laohu8.com/S/Z\">Zillow</a> Group (ZG), <a href=\"https://laohu8.com/S/AMGN\">Amgen</a> (AMGN) after market close</p></li>\n <li><p><b>Wednesday: </b><a href=\"https://laohu8.com/S/HUM\">Humana</a> (HUM), <a href=\"https://laohu8.com/S/DISCA\">Discovery</a> Inc. (DISCA), The <a href=\"https://laohu8.com/S/NYT\">New York Times</a> (NYT), <a href=\"https://laohu8.com/S/NCLH\">Norwegian Cruise Line</a> Holdings (NCLH), <a href=\"https://laohu8.com/S/MAR\">Marriott</a> International (MAR), <a href=\"https://laohu8.com/S/CVS\">CVS Health</a> Corp. (CVS), <a href=\"https://laohu8.com/S/SBGI\">Sinclair Broadcast Group</a> (SBGI) before market open; <a href=\"https://laohu8.com/S/BKNG\">Booking Holdings</a> (BKNG), <a href=\"https://laohu8.com/S/QRVO\">Qorvo</a> (QRVO), The <a href=\"https://laohu8.com/S/ALL\">Allstate</a> Corp. (ALL), <a href=\"https://laohu8.com/S/MGM\">MGM Resorts International</a> (MGM), $Take-<a href=\"https://laohu8.com/S/TWOA.U\">Two</a> Interactive Software(TTWO)$ (TTWO), <a href=\"https://laohu8.com/S/EA\">Electronic Arts</a> (EA), Vimeo (VMEO), <a href=\"https://laohu8.com/S/ETSY\">Etsy</a> (ETSY), <a href=\"https://laohu8.com/S/GDDY\">GoDaddy</a> (GDDY), <a href=\"https://laohu8.com/S/MRO\">Marathon</a> Oil Corp. (MRO), Roku (ROKU), <a href=\"https://laohu8.com/S/QCOM\">Qualcomm</a> (QCOM) after market close</p></li>\n <li><p><b>Thursday: </b><a href=\"https://laohu8.com/S/CI\">Cigna</a> (CI), <a href=\"https://laohu8.com/S/W\">Wayfair</a> (W), ViacomCBS (VIAC), Nikola (NKLA), <a href=\"https://laohu8.com/S/DEX.AU\">Duke</a> Energy (DUK), <a href=\"https://laohu8.com/S/CTXS\">Citrix</a> Systems (CTXS), <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> (REGN), <a href=\"https://laohu8.com/S/HBI\">Hanesbrands</a> (HBI), Moderna (MRNA), <a href=\"https://laohu8.com/S/PLNT\">Planet Fitness</a> (PLNT), Vulcan Material (VMC), <a href=\"https://laohu8.com/S/K\">Kellogg</a> (K), <a href=\"https://laohu8.com/S/SQ\">Square</a> (SQ), Cloudflare (NET), <a href=\"https://laohu8.com/S/OXY\">Occidental</a> Petroleum (OXY), <a href=\"https://laohu8.com/S/UBER\">Uber</a> Technologies (UBER), <a href=\"https://laohu8.com/S/AFG\">American</a> International Group (AIG), <a href=\"https://laohu8.com/S/SHAK\">Shake Shack</a> (SHAK), iHeartMedia (IHRT), <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NVAX), IAC Interactive Corp. (IAC), Peloton (PTON), Dropbox (DBX), DataDog (DDOG), Pinterest (PINS), <a href=\"https://laohu8.com/S/SWKS\">Skyworks Solutions</a> (SWKS), <a href=\"https://laohu8.com/S/EXPE\">Expedia</a> (EXPE), Rocket Cos. (RKT), <a href=\"https://laohu8.com/S/LYV\">Live Nation Entertainment</a> (LYV), Airbnb (ABNB)</p></li>\n <li><p><b>Friday: </b><a href=\"https://laohu8.com/S/WYNN\">Wynn</a> Resorts (WYNN), Dish Networks (DISH), Dominion Energy (D), DraftKings (DKNG), <a href=\"https://laohu8.com/S/GT\">Goodyear</a> Tire and Rubber (GT), <a href=\"https://laohu8.com/S/CNK\">Cinemark</a> Holdings (CNK) before market open</p></li>\n</ul>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Federal Reserve decision, October jobs report: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFederal Reserve decision, October jobs report: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-01 07:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also ...</p>\n\n<a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"APO":"阿波罗全球管理","UBER":"优步","ATVI":"动视暴雪","CRSR":"Corsair Gaming, Inc.",".DJI":"道琼斯",".SPX":"S&P 500 Index","PFE":"辉瑞","COP":"康菲石油","CLX":"高乐氏",".IXIC":"NASDAQ Composite","BLMN":"Bloomin' Brands","EL":"雅诗兰黛","RL":"拉夫劳伦"},"source_url":"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2179250221","content_text":"The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also await more data on the U.S. economic recovery with the Labor Department's monthly jobs report later this week.\nThe Federal Open Market Committee's (FOMC) November meeting will take place from Tuesday to Wednesday, with the policy statement and press conference from the meeting serving as the central bank's penultimate opportunity this year to announce formal plans to begin rolling back its crisis-era quantitative easing program. For the past year-and-a-half, the central bank has been purchasing $120 billion per month in agency mortgage-backed securities and Treasuries, as one major tool to support the economy during the pandemic.\nIn late September, the FOMC's latest monetary policy statement and press conference from Federal Reserve Chair Jerome Powell suggested the central bank was apt to announce the start of tapering before year-end, and continue the tapering process until \"around the middle of next year.\"\n\"The upcoming FOMC meeting will be important for three reasons: 1) the announcement of tapering; 2) guidance around what tapering means for the path of hikes; and 3) nuanced changes in views around inflation risks given recent data,\" wrote Bank of America economist Michelle Meyer in a note.\n\"The statement that announces the new pace of asset purchases will be followed by a note regarding flexibility stating that asset purchases are not on a pre-set course and will depend on the outlook for the labor market and inflation as well as an assessment of the efficacy of asset purchases,\" she predicted.\nShe noted that Powell may also use the press conference to reiterate that the end of tapering would not necessarily indicate the start of rate hikes, and that both policy actions are distinct. In previous public remarks, Powell has already made a similar point in previous public remarks, saying, \"the timing and pace of the coming reduction in asset purchases will not be intended to carry a direct signal regarding the timing of interest rate liftoff.\"\nGiven the market has been anticipating the start to tapering for months now, speculation around when the Fed will make a move on interest rates has become a point of particular interest to investors. Investors and economists have mulled whether the Fed may need to act more quickly than previously telegraphed on adjusting interest rates to stave off inflation, which has proven more long-lasting than some had suggested.\nWASHINGTON, DC - SEPTEMBER 24: Federal Reserve Board Chairman Jerome Powell testifies during a Senate Banking Committee hearing on Capitol Hill on September 24, 2020 in Washington, DC. Powell and U.S. Treasury Secretary Steve Mnuchin are testifying about the CARES Act and the economic effects of the coronavirus pandemic. (Photo by Drew Angerer/Getty Images)Drew Angerer via Getty Images\nIn September, core personal consumption expenditures — the Fed's preferred gauge of underlying inflation — rose 3.6% over last year for a fourth consecutive month, coming in at the fastest clip since 1991. And earlier this month, Powell acknowledged in public remarks that the supply chain constraints and shortages that spurred the latest rise in prices are \"likely to last longer than previously expected, likely well into next year.\"\nWhile the central bank will not release an updated Summary of Economic Projections with their policy statement on Wednesday, the latest projections from the September meeting suggested the committee was split on rate hikes for 2022, with nine members seeing no rate hikes by the end of next year while the other nine members saw at least one hike.\n\"I think the Fed has pretty well determined to start the taper pretty quickly. We expect them to announce it next week and then start it soon thereafter, so that's pretty well carved in stone,\" Kathy Jones, Charles Schwab chief fixed income strategist, told Yahoo Finance Live last week. \"I think the big debate now is how quickly the Fed moves toward actually raising rates. The expectation in the market has really shifted to expecting as many as two rate hikes in 2022 and 2023 ... that’s a pretty aggressive pace of tightening.\"\nOctober jobs report\nOne of this week's most closely watched pieces of economic data will be the October jobs report, which is due for release on Friday from the Labor Department.\nEconomists are looking to see a pick-up in the pace of hiring for October after a disappointing print in September, when just 194,000 non-farm payrolls returned versus the half million expected. Over the past two months, payroll gains averaged at just 280,000. The unemployment rate is expected to take another small step toward pre-pandemic levels in October as well, with the jobless rate anticipated to dip to 4.7% from 4.8% the prior month.\nStill, the labor market has still fallen short its pre-pandemic conditions on a number of fronts. The unemployment rate has yet to return to its 50-year low of 3.5% from February 2020. And as of September, the civilian labor force was still down by about 3.1 million individuals from pre-virus levels.\nOne factor weighing on the labor market in August and September was the Delta variant, which may have deterred some workers from seeking employment in person for risk of infection. And an ongoing element dragging on the labor market's recovery has been a mismatch of supply and demand, with employers struggling to fill a near-record number of job openings while voluntary quits jumped to a historically high level.\n\"Next week’s October payrolls report will shed light on whether supply eased on diminishing constraints or if the labor market continues to face headwinds for now,\" wrote Rubeela Farooqi, chief U.S. economist for High Frequency Economics, in a note last week.\nBut some data from the past couple weeks has reflected favorably on conditions in the labor market in October. Weekly new unemployment claims broke below 300,000 for the first time since the start of the pandemic during the survey week for the October jobs report, or the week that includes the 12th of the month. And in the Conference Board's October Consumer Confidence Index, just 10.6% of consumers said jobs were \"hard to get,\" down from 13.0% in September. That brought the Conference Board's closely watched labor market differential, or percentage of consumers saying jobs are \"hard to get\" subtracted from the percentage saying jobs \"are plentiful,\" to 45, or its highest level since 2000.\nEconomic calendar\n\nMonday: Markit U.S. Manufacturing PMI, Oct. final (59.3 expected, 59.2 in September); Constructing spending, month-over-month, September (0.4% expected, 0.0% in August); ISM Manufacturing Index, Oct. (60.5 expected, 61.1 in September)\nTuesday: No notable reports scheduled for release\nWednesday: MBA Mortgage Applications, week ended Oct. 29 (0.3% during prior week); ADP Employment Change, Oct. (400,000 expected, 568,000 in September); ISM Services Index, October (62.0 expected, 61.9 in September); Factory Orders, September (-0.1% expected, 1.2% in August); Durable goods orders, September final (-0.4% in prior print; Durable goods orders excluding transportation, September final (0.4% in prior print); Non-defense capital goods orders excluding aircraft, September final (0.8% in prior print); Markit U.S. Services PMI, October final (58.2 expected, 58.2 in prior print); Markit U.S. Composite PMI, October final (57.3 in prior print); Federal Open Market Committee monetary policy decision\nThursday: Challenger job cuts, year-over-year, October (-84.9% in September); Initial jobless claims, week ended Oct. 30 (275,000 expected, 281,000 during prior week); Continuing claims, week ended Oct. 23 (2.147 million expected, 2.243 million during prior week); Non-farm productivity, Q3 preliminary (-3.2% expected, 2.1% in Q2); Unit Labor Costs, Q3 preliminary (6.9% expected, 1.3% in Q2); Trade balance, September (-$80.1 billion expected, -$73.3 billion in August)\nFriday: Change in non-farm payrolls, October (450,000 expected, 194,000 in September); Unemployment rate, October (4.7% expected, 4.8% in September); Average hourly earnings, month-over-month, October (4.7% expected, 4.8% in September); Average hourly earnings, year-over-year, October (4.9% expected, 4.6% in September); Labor Force Participation Rate, October (61.8% expected, 61.6% in September); Consumer Credit, September ($16.200 billion expected, $14.379 million in August)\n\nEarnings calendar\n\nMonday: Clorox (CLX), Avis Budget Group (CAR), ZoomInfo Technologies (ZI), Chegg Inc. (CHGG), Diamondback Energy (FANG), The Simon Property Group (SPG) after market close\nTuesday: Under Armour (UAA), Estee Lauder (EL), Ralph Lauren (RL), Apollo Global Management (APO), Corsair Gaming (CRSR), Bloomin' Brands (BLMN), ConocoPhillips (COP), Pfizer (PFE), Groupon (GPN), Marathon Petroleum (MPC) before market open; Mondelez (MDLZ), T-Mobile (TMUS), Akamai (AKAM), Activision Blizzard (ATVI), Lyft (LYFT), Match Group (MTCH), Devon Energy (DVN), Chesapeake Energy (CHK), Coursera (COUR), Zillow Group (ZG), Amgen (AMGN) after market close\nWednesday: Humana (HUM), Discovery Inc. (DISCA), The New York Times (NYT), Norwegian Cruise Line Holdings (NCLH), Marriott International (MAR), CVS Health Corp. (CVS), Sinclair Broadcast Group (SBGI) before market open; Booking Holdings (BKNG), Qorvo (QRVO), The Allstate Corp. (ALL), MGM Resorts International (MGM), $Take-Two Interactive Software(TTWO)$ (TTWO), Electronic Arts (EA), Vimeo (VMEO), Etsy (ETSY), GoDaddy (GDDY), Marathon Oil Corp. (MRO), Roku (ROKU), Qualcomm (QCOM) after market close\nThursday: Cigna (CI), Wayfair (W), ViacomCBS (VIAC), Nikola (NKLA), Duke Energy (DUK), Citrix Systems (CTXS), Regeneron Pharmaceuticals (REGN), Hanesbrands (HBI), Moderna (MRNA), Planet Fitness (PLNT), Vulcan Material (VMC), Kellogg (K), Square (SQ), Cloudflare (NET), Occidental Petroleum (OXY), Uber Technologies (UBER), American International Group (AIG), Shake Shack (SHAK), iHeartMedia (IHRT), Novavax (NVAX), IAC Interactive Corp. (IAC), Peloton (PTON), Dropbox (DBX), DataDog (DDOG), Pinterest (PINS), Skyworks Solutions (SWKS), Expedia (EXPE), Rocket Cos. (RKT), Live Nation Entertainment (LYV), Airbnb (ABNB)\nFriday: Wynn Resorts (WYNN), Dish Networks (DISH), Dominion Energy (D), DraftKings (DKNG), Goodyear Tire and Rubber (GT), Cinemark Holdings (CNK) before market open","news_type":1},"isVote":1,"tweetType":1,"viewCount":89,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853429364,"gmtCreate":1634829955063,"gmtModify":1634830120435,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/853429364","repostId":"1152715784","repostType":4,"repost":{"id":"1152715784","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634829692,"share":"https://www.laohu8.com/m/news/1152715784?lang=&edition=full","pubTime":"2021-10-21 23:21","market":"us","language":"en","title":"Portillo's stock soared more than 40% after it opened at $26.00 above $20 IPO price","url":"https://stock-news.laohu8.com/highlight/detail?id=1152715784","media":"Tiger Newspress","summary":"Portillo's stock soared more than 40% after it opened at $26.00, or 30% above $20 IPO price.The comp","content":"<p>Portillo's stock soared&nbsp;more&nbsp;than&nbsp;40%&nbsp;after&nbsp;it&nbsp;opened at $26.00, or 30% above $20 IPO price.<img src=\"https://static.tigerbbs.com/2687d25199804ec9c0af74b0e976cefb\" tg-width=\"769\" tg-height=\"370\" width=\"100%\" height=\"auto\">The&nbsp;company&nbsp;is&nbsp;known for its Chicago-style hot dogs, planned to raise $375 million with a market value of $1.3 billion. It&nbsp;was&nbsp;acquired by Berkshire Partners in 2014,which&nbsp;owns and operates a fast food chain with 67 restaurants in the Chicago metropolitan area. While the company saw a slight drop in footfall in the third quarter of 2021, it will open 600 chains in the U.S. in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Portillo's stock soared more than 40% after it opened at $26.00 above $20 IPO price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPortillo's stock soared more than 40% after it opened at $26.00 above $20 IPO price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-21 23:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Portillo's stock soared&nbsp;more&nbsp;than&nbsp;40%&nbsp;after&nbsp;it&nbsp;opened at $26.00, or 30% above $20 IPO price.<img src=\"https://static.tigerbbs.com/2687d25199804ec9c0af74b0e976cefb\" tg-width=\"769\" tg-height=\"370\" width=\"100%\" height=\"auto\">The&nbsp;company&nbsp;is&nbsp;known for its Chicago-style hot dogs, planned to raise $375 million with a market value of $1.3 billion. It&nbsp;was&nbsp;acquired by Berkshire Partners in 2014,which&nbsp;owns and operates a fast food chain with 67 restaurants in the Chicago metropolitan area. While the company saw a slight drop in footfall in the third quarter of 2021, it will open 600 chains in the U.S. in the future.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PTLO":"Portillo’s Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152715784","content_text":"Portillo's stock soared more than 40% after it opened at $26.00, or 30% above $20 IPO price.The company is known for its Chicago-style hot dogs, planned to raise $375 million with a market value of $1.3 billion. It was acquired by Berkshire Partners in 2014,which owns and operates a fast food chain with 67 restaurants in the Chicago metropolitan area. While the company saw a slight drop in footfall in the third quarter of 2021, it will open 600 chains in the U.S. in the future.","news_type":1},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600056781,"gmtCreate":1638018132825,"gmtModify":1638018132931,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/600056781","repostId":"2186344334","repostType":4,"repost":{"id":"2186344334","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637967996,"share":"https://www.laohu8.com/m/news/2186344334?lang=&edition=full","pubTime":"2021-11-27 07:06","market":"us","language":"en","title":"Dow plunges 905 points in Black Friday selloff, books worst day in over a year as WHO declares new COVID 'variant of concern'","url":"https://stock-news.laohu8.com/highlight/detail?id=2186344334","media":"Dow Jones","summary":"Dow notches worst day for blue chips since Oct. 28, 2020, FactSet data show\nU.S. stock benchmarks su","content":"<p>Dow notches worst day for blue chips since Oct. 28, 2020, FactSet data show</p>\n<p>U.S. stock benchmarks suffered withering losses on Friday as stock and commodity markets plunged, after scientists detected a new COVID variant in South Africa that could be to blame for a recent sharp surge in cases, especially in Europe.</p>\n<p>U.S. markets were closed for Thanksgiving on Thursday and ended at 1 p.m. Eastern Time on Friday, three hours earlier than usual, and bond market trading ends at 2 p.m., an hour earlier than is typical.</p>\n<p>How are stock-index futures trading?</p>\n<p>On Wednesday, the Dow industrials fell 9.42 points to finish nearly flat at 35,804.38. The S&amp;P 500 slipped 0.2% to close at 4,701.46, just 0.1% below its Nov. 18 record close of 4,704.54, according to Dow Jones Market Data. The Nasdaq Composite Index rose 0.4% to 15,84.23.</p>\n<p>What's driving the market?</p>\n<p>It was an ugly day for stock investors during a thinly traded Black Friday session, which was susceptible to big swings on alarming news from public health officials who were assessing a new variant of the coronavirus that causes COVID-19.</p>\n<p>Late in the session, the World Health Organization's technical advisory group assigned the B. 1.1.529 variant of the virus the Greek letter omicron and declared it a \"variant of concern,\" as it did with the delta variant.</p>\n<p>Fear of a new variant overshadowed the usual focus on U.S. Black Friday shopping day, which puts the focus on retailers as consumers shop for bargains.</p>\n<p>Particularly notable about the variant is the \"large number of mutations, some of which are concerning,\" the WHO group said in a statement. The mutations could make omicron more resistant to the current batch of vaccines.</p>\n<p>The discovery of the new COVID strain was announced on Friday by South Africa's health minister Joe Phaahla. He said scientists were concerned because of its high number of mutations and the dramatic surge in infections the country had seen over the past four or five days.</p>\n<p>\"The pandemic and COVID variants remain <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest risks to markets, and are likely to continue to inject volatility over the next year(s),\" wrote Keith Lerner, co-chief investment officer and chief market strategist at Truist Advisory Services, in a Friday note. \"It's hard to say at this point how lasting or impactful this latest variant will be for markets,\" the analyst wrote.</p>\n<p>The omicron strain has been detected in Botswana and in Hong Kong in travelers who had visited South Africa.</p>\n<p>\"The one bull in the China shop that could truly derail the global recovery has always been a new strain of Covid-19 that swept the world and caused the reimposition of mass social retractions,\" said Jeffrey Halley, senior market analyst, at OANDA, in a note. \"All we know so far is the B. 1.1.529 is heavily mutated but markets are taking no chances.\"</p>\n<p>\"Just when you thought Covid was being controlled in a holiday shortened week,\" said Sam Stovall, chief investment strategist at CFRA Research, in emailed comments.</p>\n<p>Trading around the Thanksgiving holiday is often associated with lower trading volumes as traders typically wait until Monday to return to work. There was no U.S. economic data on the calendar for Friday.</p>\n<p>After new cases stabilized at 200 a day, South Africa reported more than 1,200 on Wednesday and 2,465 on Thursday.</p>\n<p>The U.K. government is banning flights from South Africa along with five other African nations, effective Friday.</p>\n<p>\"Predictably, energy, travel related and financials are the leading decliners and treasuries are rallying,\" wrote Jay Hatfield, CEO and portfolio manager at Infrastructure Capital Management, in emailed comments on Friday.</p>\n<p>\"It makes sense to have a market significant correction given the high level of uncertainty,\" the money manager wrote.</p>\n<p>\"At this stage very little is known,\" Deutsche Bank strategists, led by Jim Reid, told clients in a note. \"Mutations are often less severe so we shouldn't jump to conclusions but there is clearly a lot of concern about this one. Also South Africa is one of the world leaders in sequencing so we are more likely to see this sort of news originate from there than many countries. Suffice to say at this stage no one in markets will have any idea which way this will go.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow plunges 905 points in Black Friday selloff, books worst day in over a year as WHO declares new COVID 'variant of concern'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow plunges 905 points in Black Friday selloff, books worst day in over a year as WHO declares new COVID 'variant of concern'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-27 07:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dow notches worst day for blue chips since Oct. 28, 2020, FactSet data show</p>\n<p>U.S. stock benchmarks suffered withering losses on Friday as stock and commodity markets plunged, after scientists detected a new COVID variant in South Africa that could be to blame for a recent sharp surge in cases, especially in Europe.</p>\n<p>U.S. markets were closed for Thanksgiving on Thursday and ended at 1 p.m. Eastern Time on Friday, three hours earlier than usual, and bond market trading ends at 2 p.m., an hour earlier than is typical.</p>\n<p>How are stock-index futures trading?</p>\n<p>On Wednesday, the Dow industrials fell 9.42 points to finish nearly flat at 35,804.38. The S&amp;P 500 slipped 0.2% to close at 4,701.46, just 0.1% below its Nov. 18 record close of 4,704.54, according to Dow Jones Market Data. The Nasdaq Composite Index rose 0.4% to 15,84.23.</p>\n<p>What's driving the market?</p>\n<p>It was an ugly day for stock investors during a thinly traded Black Friday session, which was susceptible to big swings on alarming news from public health officials who were assessing a new variant of the coronavirus that causes COVID-19.</p>\n<p>Late in the session, the World Health Organization's technical advisory group assigned the B. 1.1.529 variant of the virus the Greek letter omicron and declared it a \"variant of concern,\" as it did with the delta variant.</p>\n<p>Fear of a new variant overshadowed the usual focus on U.S. Black Friday shopping day, which puts the focus on retailers as consumers shop for bargains.</p>\n<p>Particularly notable about the variant is the \"large number of mutations, some of which are concerning,\" the WHO group said in a statement. The mutations could make omicron more resistant to the current batch of vaccines.</p>\n<p>The discovery of the new COVID strain was announced on Friday by South Africa's health minister Joe Phaahla. He said scientists were concerned because of its high number of mutations and the dramatic surge in infections the country had seen over the past four or five days.</p>\n<p>\"The pandemic and COVID variants remain <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest risks to markets, and are likely to continue to inject volatility over the next year(s),\" wrote Keith Lerner, co-chief investment officer and chief market strategist at Truist Advisory Services, in a Friday note. \"It's hard to say at this point how lasting or impactful this latest variant will be for markets,\" the analyst wrote.</p>\n<p>The omicron strain has been detected in Botswana and in Hong Kong in travelers who had visited South Africa.</p>\n<p>\"The one bull in the China shop that could truly derail the global recovery has always been a new strain of Covid-19 that swept the world and caused the reimposition of mass social retractions,\" said Jeffrey Halley, senior market analyst, at OANDA, in a note. \"All we know so far is the B. 1.1.529 is heavily mutated but markets are taking no chances.\"</p>\n<p>\"Just when you thought Covid was being controlled in a holiday shortened week,\" said Sam Stovall, chief investment strategist at CFRA Research, in emailed comments.</p>\n<p>Trading around the Thanksgiving holiday is often associated with lower trading volumes as traders typically wait until Monday to return to work. There was no U.S. economic data on the calendar for Friday.</p>\n<p>After new cases stabilized at 200 a day, South Africa reported more than 1,200 on Wednesday and 2,465 on Thursday.</p>\n<p>The U.K. government is banning flights from South Africa along with five other African nations, effective Friday.</p>\n<p>\"Predictably, energy, travel related and financials are the leading decliners and treasuries are rallying,\" wrote Jay Hatfield, CEO and portfolio manager at Infrastructure Capital Management, in emailed comments on Friday.</p>\n<p>\"It makes sense to have a market significant correction given the high level of uncertainty,\" the money manager wrote.</p>\n<p>\"At this stage very little is known,\" Deutsche Bank strategists, led by Jim Reid, told clients in a note. \"Mutations are often less severe so we shouldn't jump to conclusions but there is clearly a lot of concern about this one. Also South Africa is one of the world leaders in sequencing so we are more likely to see this sort of news originate from there than many countries. Suffice to say at this stage no one in markets will have any idea which way this will go.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4023":"应用软件","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BK4525":"远程办公概念","BK4190":"消闲用品","ZM":"Zoom","BK4554":"元宇宙及AR概念","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BK4505":"高瓴资本持仓","PTON":"Peloton Interactive, Inc.","BK4528":"SaaS概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186344334","content_text":"Dow notches worst day for blue chips since Oct. 28, 2020, FactSet data show\nU.S. stock benchmarks suffered withering losses on Friday as stock and commodity markets plunged, after scientists detected a new COVID variant in South Africa that could be to blame for a recent sharp surge in cases, especially in Europe.\nU.S. markets were closed for Thanksgiving on Thursday and ended at 1 p.m. Eastern Time on Friday, three hours earlier than usual, and bond market trading ends at 2 p.m., an hour earlier than is typical.\nHow are stock-index futures trading?\nOn Wednesday, the Dow industrials fell 9.42 points to finish nearly flat at 35,804.38. The S&P 500 slipped 0.2% to close at 4,701.46, just 0.1% below its Nov. 18 record close of 4,704.54, according to Dow Jones Market Data. The Nasdaq Composite Index rose 0.4% to 15,84.23.\nWhat's driving the market?\nIt was an ugly day for stock investors during a thinly traded Black Friday session, which was susceptible to big swings on alarming news from public health officials who were assessing a new variant of the coronavirus that causes COVID-19.\nLate in the session, the World Health Organization's technical advisory group assigned the B. 1.1.529 variant of the virus the Greek letter omicron and declared it a \"variant of concern,\" as it did with the delta variant.\nFear of a new variant overshadowed the usual focus on U.S. Black Friday shopping day, which puts the focus on retailers as consumers shop for bargains.\nParticularly notable about the variant is the \"large number of mutations, some of which are concerning,\" the WHO group said in a statement. The mutations could make omicron more resistant to the current batch of vaccines.\nThe discovery of the new COVID strain was announced on Friday by South Africa's health minister Joe Phaahla. He said scientists were concerned because of its high number of mutations and the dramatic surge in infections the country had seen over the past four or five days.\n\"The pandemic and COVID variants remain one of the biggest risks to markets, and are likely to continue to inject volatility over the next year(s),\" wrote Keith Lerner, co-chief investment officer and chief market strategist at Truist Advisory Services, in a Friday note. \"It's hard to say at this point how lasting or impactful this latest variant will be for markets,\" the analyst wrote.\nThe omicron strain has been detected in Botswana and in Hong Kong in travelers who had visited South Africa.\n\"The one bull in the China shop that could truly derail the global recovery has always been a new strain of Covid-19 that swept the world and caused the reimposition of mass social retractions,\" said Jeffrey Halley, senior market analyst, at OANDA, in a note. \"All we know so far is the B. 1.1.529 is heavily mutated but markets are taking no chances.\"\n\"Just when you thought Covid was being controlled in a holiday shortened week,\" said Sam Stovall, chief investment strategist at CFRA Research, in emailed comments.\nTrading around the Thanksgiving holiday is often associated with lower trading volumes as traders typically wait until Monday to return to work. There was no U.S. economic data on the calendar for Friday.\nAfter new cases stabilized at 200 a day, South Africa reported more than 1,200 on Wednesday and 2,465 on Thursday.\nThe U.K. government is banning flights from South Africa along with five other African nations, effective Friday.\n\"Predictably, energy, travel related and financials are the leading decliners and treasuries are rallying,\" wrote Jay Hatfield, CEO and portfolio manager at Infrastructure Capital Management, in emailed comments on Friday.\n\"It makes sense to have a market significant correction given the high level of uncertainty,\" the money manager wrote.\n\"At this stage very little is known,\" Deutsche Bank strategists, led by Jim Reid, told clients in a note. \"Mutations are often less severe so we shouldn't jump to conclusions but there is clearly a lot of concern about this one. Also South Africa is one of the world leaders in sequencing so we are more likely to see this sort of news originate from there than many countries. Suffice to say at this stage no one in markets will have any idea which way this will go.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877933211,"gmtCreate":1637855742640,"gmtModify":1637855742784,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877933211","repostId":"1122037796","repostType":4,"repost":{"id":"1122037796","pubTimestamp":1637849010,"share":"https://www.laohu8.com/m/news/1122037796?lang=&edition=full","pubTime":"2021-11-25 22:03","market":"us","language":"en","title":"7 stocks with the most Thanksgiving exposure, according to Bank of America","url":"https://stock-news.laohu8.com/highlight/detail?id=1122037796","media":"finance.yahoo","summary":"Thanksgiving feasts will likely draw larger crowds than last year and incur higher costs.\nA recent B","content":"<p>Thanksgiving feasts will likely draw larger crowds than last year and&nbsp;incur higher costs.</p>\n<p>A recent Bank of America note detailed which companies have the most exposure to the top holiday dishes amid supply chain bottlenecks, inflation, lingering COVID concerns, low inventories, and evolving consumer behaviors.</p>\n<p>Those companies are Campbell's Soup Company (CPB), General Mills (GIS), The Kraft Heinz Company (KHC), Conagra Brands (CAG), Hormel Foods Corporation (HRL), McCormick &amp; Company (MKC), and The Duckhorn Portfolio, Inc. (NAPA).</p>\n<p>\"We looked at companies’ exposure to the top Thanksgiving dishes: turkey, stuffing, dinner rolls, gravy, green bean casserole, potatoes, mac &amp; cheese dessert and wine,\" the analysts stated. \"Overall CPB, GIS, KHC, CAG, MKC, HRL and NAPA are the most exposed. KHC and NAPA are our favorite stocks in this group.\"</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/39aa902f366c0bd07e076520c33cdf52\" tg-width=\"705\" tg-height=\"409\" width=\"100%\" height=\"auto\"><span>Key companies exposed to Thanksgiving meal trends. (Source: BofA)Thanksgiving 'center of the plate' items see more pricing power</span></p>\n<p>People appear to be gathering around the table again, the analysts stated, as data from social media conversations found mentions of \"vaccines\" on the rise while mentions of \"FaceTime,\" \"social distancing,\" and \"canceled\" declined. (\"Friendsgiving\" and \"day drinking\" also saw increases.)</p>\n<p>And whether consumers opt for turkey or ham, mashed potatoes or marshmallow-topped sweet potatoes, traditional orplant-based options, they're likely to pay more with inflation hitting food prices.</p>\n<p>The&nbsp;American Farm Bureau Thanksgiving cost index&nbsp;projects a 14% year-over-year increase for 2021, led by a 24% increase in turkey prices.</p>\n<p>“When you look at more of the center of the plate sort of food items, typically, there has not historically been a lot of pricing power,” Bryan Spillane, a senior food and beverage analyst at BofA Global Research, told Yahoo Finance Live (video above). “But what's unusual this year is that there has been. Food companies, in particular, began raising prices the middle of the year, and there's virtually been no elasticity.”</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8e60ff60917eb4db45a68c41bd19a337\" tg-width=\"705\" tg-height=\"529\" width=\"100%\" height=\"auto\"><span>Frozen turkeys in Philadelphia, Wednesday, Nov. 17, 2021. (AP Photo/Matt Rourke)</span></p>\n<p>That said, Spillane added, consumer behavior is expected to change at some point.</p>\n<p>“Something that we're really watching as we move into next year is: At what point does the consumer begin to push back and do we begin to see some trading down or other behavior that demonstrates that consumers are feeling that pinch?” Spillane said.</p>\n<p>Investor appetite for food and beverage companies</p>\n<p>The top company with the most upside or downside potential is Campbell's, which BofA gave an \"underperform\" rating.</p>\n<p>“Campbell's struggling from a few issues,” Spillane said. “One is they are experiencing a material amount of inflation. They have a product portfolio that's a little bit more skewed… to kind of middle and low-income households. So, that's, maybe, an area where there may be some sensitivity around passing those prices through.”</p>\n<p>The iconic soup company also has a lot of direct and indirect exposure to labor shortages and higher labor costs, Spillane added.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be1718627f49a5fcc29f52e9e322313f\" tg-width=\"705\" tg-height=\"470\" width=\"100%\" height=\"auto\"><span>Cans of Campbell's Soup are displayed in a supermarket in New York City, U.S. February 15, 2017. REUTERS/Brendan McDermid</span></p>\n<p>BofA also gave seasoning-maker McCormick &amp; Company an \"underperform\" rating, with an $84 price target.</p>\n<p>McCormick is “still trading at a premium valuation,” Spillane said, adding that while it has benefitted from people having cooked at home more in the last 18 months, “at some point, as things moderate, you're going to see less of that cooking at home behavior. And that's going to create an overhang for McCormick.”</p>\n<p>On the flip side, “Hershey [HSY] is well-positioned,” Spillane said, especially when it comes to the inflationary environment.</p>\n<p>“The combination of a category that's still growing very strongly where there's still a lot of product innovation and where there's been demonstrated pricing power, we think that Hershey is set up really well to be able to maybe even more than protect margins, maybe potentially grow margins as we cycle through some of this inflation,” he explained.</p>\n<p>BofA also awarded Stove Top stuffing-maker Kraft Heinz a buy rating with a $46 price objective.</p>\n<p>“We believe this is justified based our view that KHC is well positioned to capture growth associated with changing consumer demand patterns related to recessions and pantry stocking offset by higher than average debt levels,” the analysts wrote.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 stocks with the most Thanksgiving exposure, according to Bank of America</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 stocks with the most Thanksgiving exposure, according to Bank of America\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 22:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/7-stocks-thanksgiving-exposure-bank-of-america-134505457.html><strong>finance.yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thanksgiving feasts will likely draw larger crowds than last year and incur higher costs.\nA recent Bank of America note detailed which companies have the most exposure to the top holiday dishes amid ...</p>\n\n<a href=\"https://finance.yahoo.com/news/7-stocks-thanksgiving-exposure-bank-of-america-134505457.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAG":"康尼格拉","MKC":"味好美","GIS":"通用磨坊","HRL":"荷美尔","CPB":"金宝汤","KHC":"卡夫亨氏","NAPA":"The Duckhorn Portfolio, Inc."},"source_url":"https://finance.yahoo.com/news/7-stocks-thanksgiving-exposure-bank-of-america-134505457.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122037796","content_text":"Thanksgiving feasts will likely draw larger crowds than last year and incur higher costs.\nA recent Bank of America note detailed which companies have the most exposure to the top holiday dishes amid supply chain bottlenecks, inflation, lingering COVID concerns, low inventories, and evolving consumer behaviors.\nThose companies are Campbell's Soup Company (CPB), General Mills (GIS), The Kraft Heinz Company (KHC), Conagra Brands (CAG), Hormel Foods Corporation (HRL), McCormick & Company (MKC), and The Duckhorn Portfolio, Inc. (NAPA).\n\"We looked at companies’ exposure to the top Thanksgiving dishes: turkey, stuffing, dinner rolls, gravy, green bean casserole, potatoes, mac & cheese dessert and wine,\" the analysts stated. \"Overall CPB, GIS, KHC, CAG, MKC, HRL and NAPA are the most exposed. KHC and NAPA are our favorite stocks in this group.\"\nKey companies exposed to Thanksgiving meal trends. (Source: BofA)Thanksgiving 'center of the plate' items see more pricing power\nPeople appear to be gathering around the table again, the analysts stated, as data from social media conversations found mentions of \"vaccines\" on the rise while mentions of \"FaceTime,\" \"social distancing,\" and \"canceled\" declined. (\"Friendsgiving\" and \"day drinking\" also saw increases.)\nAnd whether consumers opt for turkey or ham, mashed potatoes or marshmallow-topped sweet potatoes, traditional orplant-based options, they're likely to pay more with inflation hitting food prices.\nThe American Farm Bureau Thanksgiving cost index projects a 14% year-over-year increase for 2021, led by a 24% increase in turkey prices.\n“When you look at more of the center of the plate sort of food items, typically, there has not historically been a lot of pricing power,” Bryan Spillane, a senior food and beverage analyst at BofA Global Research, told Yahoo Finance Live (video above). “But what's unusual this year is that there has been. Food companies, in particular, began raising prices the middle of the year, and there's virtually been no elasticity.”\nFrozen turkeys in Philadelphia, Wednesday, Nov. 17, 2021. (AP Photo/Matt Rourke)\nThat said, Spillane added, consumer behavior is expected to change at some point.\n“Something that we're really watching as we move into next year is: At what point does the consumer begin to push back and do we begin to see some trading down or other behavior that demonstrates that consumers are feeling that pinch?” Spillane said.\nInvestor appetite for food and beverage companies\nThe top company with the most upside or downside potential is Campbell's, which BofA gave an \"underperform\" rating.\n“Campbell's struggling from a few issues,” Spillane said. “One is they are experiencing a material amount of inflation. They have a product portfolio that's a little bit more skewed… to kind of middle and low-income households. So, that's, maybe, an area where there may be some sensitivity around passing those prices through.”\nThe iconic soup company also has a lot of direct and indirect exposure to labor shortages and higher labor costs, Spillane added.\nCans of Campbell's Soup are displayed in a supermarket in New York City, U.S. February 15, 2017. REUTERS/Brendan McDermid\nBofA also gave seasoning-maker McCormick & Company an \"underperform\" rating, with an $84 price target.\nMcCormick is “still trading at a premium valuation,” Spillane said, adding that while it has benefitted from people having cooked at home more in the last 18 months, “at some point, as things moderate, you're going to see less of that cooking at home behavior. And that's going to create an overhang for McCormick.”\nOn the flip side, “Hershey [HSY] is well-positioned,” Spillane said, especially when it comes to the inflationary environment.\n“The combination of a category that's still growing very strongly where there's still a lot of product innovation and where there's been demonstrated pricing power, we think that Hershey is set up really well to be able to maybe even more than protect margins, maybe potentially grow margins as we cycle through some of this inflation,” he explained.\nBofA also awarded Stove Top stuffing-maker Kraft Heinz a buy rating with a $46 price objective.\n“We believe this is justified based our view that KHC is well positioned to capture growth associated with changing consumer demand patterns related to recessions and pantry stocking offset by higher than average debt levels,” the analysts wrote.","news_type":1},"isVote":1,"tweetType":1,"viewCount":6,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854827009,"gmtCreate":1635434656948,"gmtModify":1635434657256,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/854827009","repostId":"1167749810","repostType":4,"repost":{"id":"1167749810","pubTimestamp":1635434496,"share":"https://www.laohu8.com/m/news/1167749810?lang=&edition=full","pubTime":"2021-10-28 23:21","market":"us","language":"en","title":"‘Sticky’ Inflation May Drive Gold to New Peak, Agnico CEO Says","url":"https://stock-news.laohu8.com/highlight/detail?id=1167749810","media":"Bloomberg","summary":"Gold may hit a fresh record high in the next 12 months as investors seek haven from a buildup of inf","content":"<p>Gold may hit a fresh record high in the next 12 months as investors seek haven from a buildup of inflationary pressures.</p>\n<p>That’s the view of Agnico-Eagle Mines Ltd. Chief Executive Officer Sean Boyd, who expects bullion to surpass the current record of $2,075.47 an ounce reached in August last year.</p>\n<p>“Inflation is not transitory,” Boyd said in a phone interview, noting that costs pressures are “more sticky” than three months ago. “We’ll see higher inflation as we move down the road, which is generally a very favorable environment for gold.”</p>\n<p>Bullion’s traditional role as a haven asset in times of economic turmoils has faltered this year as the global economy gradually rebounds from Covid-19’s nadir. Massive pandemic-era stimulus and reopening economies have also led to rising inflation, while power shortages accelerated a surge in energy prices on top of a broad commodities rally. This sparked concerns that higher prices may stay much longer and hurt a nascent recovery, boosting gold’s appeal as an inflation hedge.</p>\n<p>One difference this time around is that large corporations are talking about passing through increased costs to consumers, which will ultimately lead to higher labor costs, according to Boyd, whose comments came after the Canadian gold miner posted third-quarter earnings on Wednesday.</p>\n<p>Cost pressures, largely stemming from rising commodities prices and global supply chain woes, have accelerated for Agnico since the second quarter, the Toronto-based gold miner said in its earnings statement.</p>\n<p>‘Merger of Equals’</p>\n<p>Spot gold is headed for its third straight weekly advance as bond yields slid amid concerns over the global recovery. The precious metal was up 0.3% at $1,801.49 an ounce as of 10:20 a.m. in New York.</p>\n<p>“The current gold price is good for the industry, and the industry remains fairly discipline in terms of capital allocation,” Boyd said, adding that any opportunity from reaching new highs “is more in the high-quality gold stocks than it is in gold.”</p>\n<p>Boyd also said Agnico’s “merger of equals” with Kirkland Lake Gold Ltd., announced in late September, will continue to focus on exploration as the gold industry consolidates during the next couple years.</p>\n<p>“The best way to participate in that consolidation is to focus on regional opportunities -- not just to get bigger, but to focus on in areas we’re currently operating where we can realize significant synergies,” Boyd said. “The merger with Kirkland does that. We always look for opportunities in the regions we operate in.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>‘Sticky’ Inflation May Drive Gold to New Peak, Agnico CEO Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n‘Sticky’ Inflation May Drive Gold to New Peak, Agnico CEO Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sticky-inflation-may-drive-gold-144549784.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gold may hit a fresh record high in the next 12 months as investors seek haven from a buildup of inflationary pressures.\nThat’s the view of Agnico-Eagle Mines Ltd. Chief Executive Officer Sean Boyd, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sticky-inflation-may-drive-gold-144549784.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/sticky-inflation-may-drive-gold-144549784.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167749810","content_text":"Gold may hit a fresh record high in the next 12 months as investors seek haven from a buildup of inflationary pressures.\nThat’s the view of Agnico-Eagle Mines Ltd. Chief Executive Officer Sean Boyd, who expects bullion to surpass the current record of $2,075.47 an ounce reached in August last year.\n“Inflation is not transitory,” Boyd said in a phone interview, noting that costs pressures are “more sticky” than three months ago. “We’ll see higher inflation as we move down the road, which is generally a very favorable environment for gold.”\nBullion’s traditional role as a haven asset in times of economic turmoils has faltered this year as the global economy gradually rebounds from Covid-19’s nadir. Massive pandemic-era stimulus and reopening economies have also led to rising inflation, while power shortages accelerated a surge in energy prices on top of a broad commodities rally. This sparked concerns that higher prices may stay much longer and hurt a nascent recovery, boosting gold’s appeal as an inflation hedge.\nOne difference this time around is that large corporations are talking about passing through increased costs to consumers, which will ultimately lead to higher labor costs, according to Boyd, whose comments came after the Canadian gold miner posted third-quarter earnings on Wednesday.\nCost pressures, largely stemming from rising commodities prices and global supply chain woes, have accelerated for Agnico since the second quarter, the Toronto-based gold miner said in its earnings statement.\n‘Merger of Equals’\nSpot gold is headed for its third straight weekly advance as bond yields slid amid concerns over the global recovery. The precious metal was up 0.3% at $1,801.49 an ounce as of 10:20 a.m. in New York.\n“The current gold price is good for the industry, and the industry remains fairly discipline in terms of capital allocation,” Boyd said, adding that any opportunity from reaching new highs “is more in the high-quality gold stocks than it is in gold.”\nBoyd also said Agnico’s “merger of equals” with Kirkland Lake Gold Ltd., announced in late September, will continue to focus on exploration as the gold industry consolidates during the next couple years.\n“The best way to participate in that consolidation is to focus on regional opportunities -- not just to get bigger, but to focus on in areas we’re currently operating where we can realize significant synergies,” Boyd said. “The merger with Kirkland does that. We always look for opportunities in the regions we operate in.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":858528679,"gmtCreate":1635086711570,"gmtModify":1635086711925,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/858528679","repostId":"1174514229","repostType":4,"repost":{"id":"1174514229","pubTimestamp":1635035471,"share":"https://www.laohu8.com/m/news/1174514229?lang=&edition=full","pubTime":"2021-10-24 08:31","market":"us","language":"en","title":"US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1174514229","media":"Renaissance Capital","summary":"The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.","content":"<p>The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.</p>\n<p>Semiconductor foundry&nbsp;<b>GlobalFoundries</b>(GFS) plans to raise $2.4 billion at a $24.6 billion market cap. Backed by Abu Dhabi’s Mubadala, US-based GlobalFoundries is one of the world’s leading specialty semiconductor foundries. Unprofitable with lumpy growth, the company states that it is the only scaled pure-play foundry with a global footprint that is not based in China.</p>\n<p>Enterprise cloud data management platform&nbsp;<b>Informatica</b>(INFA) plans to raise $885 million at an $8.7 billion market cap. This company provides data integration services on its AI-powered platform to over 5,700 customers through both licenses and subscriptions. Although it will be highly leveraged post-IPO, Informatica is a recognized leader in the global data management market and saw strong subscription ARR growth in the 1H21.</p>\n<p>Energy storage provider&nbsp;<b>Fluence Energy</b>(FLNC) plans to raise $698 million at a $3.8 billion market cap. Formed by Siemens and AES, this company sells energy storage products and services to utilities, independent power producers, project developers, and commercial and industrial customers. Fast growing but unprofitable, Fluence Energy deployed 942 MW of storage products as of 6/30/21.</p>\n<p>Revenue cycle management platform&nbsp;<b>Ensemble Health Partners</b>(ENSB) plans to raise $605 million at a $3.6 billion market cap. This platform provides revenue cycle management solutions to the healthcare industry. Profitable with accelerating growth in the 1H21, Ensemble Health has over $20 billion in annual client net patient revenue under management.</p>\n<p>Hiring solutions provider&nbsp;<b>HireRight Holdings</b>(HRT) plans to raise $500 million at a $1.8 billion market cap. This company provides background checks, verification, identification, monitoring, and drug and health screening services to over 40,000 customers. HireRight was profitable on an EBIT basis in the 1H21, though cash flow swung negative.</p>\n<p>Online education marketplace&nbsp;<b>Udemy</b>(UDMY) plans to raise $406 million at a $4.3 billion market cap. This education platform provides over 183,000 courses in 75 languages to over 44 million customers in over 180 countries. Growing but unprofitable, Udemy has registered more than 73 million users since its inception.</p>\n<p>Chinese drug in-licensor&nbsp;<b>LianBio</b>(LIAN) plans to raise $325 million at a $1.8 billion market cap. Focused on China and other Asian markets, this biopharmaceutical company develops and commercializes drugs for a variety of indications. LianBio’s pipeline currently consists of nine product candidates across five different therapeutics areas.</p>\n<p><b>Rent the Runway</b>(RENT) plans to raise $293 million at a $1.4 billion market cap. This apparel rental company originally focused on a-la-carte rentals of dresses for events, but has gradually transitioned to mostly generating revenue from monthly subscription boxes. While the company has seen active subscribers and revenue rebound in the last two quarters, it is unprofitable and leveraged post-IPO.</p>\n<p>Aesthetic medical device maker&nbsp;<b>Candela Medical</b>(CDLA) plans to raise $250 million at a $1.7 billion market cap. Selling products directly in 18 countries and indirectly in 66 countries, this company develops medical devices for elective aesthetic procedures. Despite being hard hit by the pandemic, Candela Medical saw strong growth and turned profitable in the 1H21.</p>\n<p>Fire pit brand&nbsp;<b>Solo Brands</b>(DTC) plans to raise $200 million at a $1.5 billion market cap. Solo Brands sells fire pits, camp stoves, and other outdoor gear through its DTC platform. Fast growing and profitable, this outdoor e-commerce has an installed base of more than 2.3 million customers.</p>\n<p>Body contouring provider&nbsp;<b>AirSculpt Technologies</b>(AIRS) plans to raise $160 million at an $886 million market cap. This company provides minimally-invasive body contouring procedures through 16 centers across 13 states in the US. AirSculpt Technologies is profitable with solid growth, and has seen an increase in same-center case volume as a result of lessening effects of COVID-19.</p>\n<p>Technology firm&nbsp;<b>Arteris</b>(AIP) plans to raise $75 million at a $555 million market cap. This technology company develops and licenses interconnect intellectual property that manages the on-chip communications in System-on-Chip semiconductor devices. Arteris is unprofitable but saw growth accelerate in the 1H21.</p>\n<p><img src=\"https://static.tigerbbs.com/99c3b0173e59f4e69ff484c12bd137e7\" tg-width=\"1270\" tg-height=\"704\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/64e34b3c49a856e99ba64a2d57410844\" tg-width=\"1272\" tg-height=\"582\" referrerpolicy=\"no-referrer\"></p>\n<p>Street research is expected for six companies, and lock-up periods will be expiring for up to 12 companies.</p>\n<p><b>IPO Market Snapshot</b></p>\n<p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 10/22/21, the Renaissance IPO Index was up 8.2% year-to-date, while the S&amp;P 500 was up 21.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Moderna (MRNA). The Renaissance International IPO Index was down 15.8% year-to-date, while the ACWX was up 9.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.</p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: Semiconductors, energy storage, designer apparel, and more in a 12 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-24 08:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/87676/US-IPO-Week-Ahead-Semiconductors-energy-storage-designer-apparel-and-more-i><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.\nSemiconductor foundry GlobalFoundries(GFS) plans to raise $2.4 billion at a $24.6 billion market ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/87676/US-IPO-Week-Ahead-Semiconductors-energy-storage-designer-apparel-and-more-i\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UDMY":"Udemy, Inc.","RENT":"Rent the Runway, Inc.","INFA":"Informatica Inc.",".SPX":"S&P 500 Index",".DJI":"道琼斯","LIAN":"联拓生物","FLNC":"Fluence Energy, Inc.",".IXIC":"NASDAQ Composite","AIP":"Arteris, Inc.","GFS":"GLOBALFOUNDRIES Inc.","AIRS":"Airsculpt Technologies","HRT":"HireRight Holdings Corp.","DTC":"Solo Brands, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/87676/US-IPO-Week-Ahead-Semiconductors-energy-storage-designer-apparel-and-more-i","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174514229","content_text":"The IPO market continues to stay busy with 12 IPOs schedule to raise $6.8 billion in the week ahead.\nSemiconductor foundry GlobalFoundries(GFS) plans to raise $2.4 billion at a $24.6 billion market cap. Backed by Abu Dhabi’s Mubadala, US-based GlobalFoundries is one of the world’s leading specialty semiconductor foundries. Unprofitable with lumpy growth, the company states that it is the only scaled pure-play foundry with a global footprint that is not based in China.\nEnterprise cloud data management platform Informatica(INFA) plans to raise $885 million at an $8.7 billion market cap. This company provides data integration services on its AI-powered platform to over 5,700 customers through both licenses and subscriptions. Although it will be highly leveraged post-IPO, Informatica is a recognized leader in the global data management market and saw strong subscription ARR growth in the 1H21.\nEnergy storage provider Fluence Energy(FLNC) plans to raise $698 million at a $3.8 billion market cap. Formed by Siemens and AES, this company sells energy storage products and services to utilities, independent power producers, project developers, and commercial and industrial customers. Fast growing but unprofitable, Fluence Energy deployed 942 MW of storage products as of 6/30/21.\nRevenue cycle management platform Ensemble Health Partners(ENSB) plans to raise $605 million at a $3.6 billion market cap. This platform provides revenue cycle management solutions to the healthcare industry. Profitable with accelerating growth in the 1H21, Ensemble Health has over $20 billion in annual client net patient revenue under management.\nHiring solutions provider HireRight Holdings(HRT) plans to raise $500 million at a $1.8 billion market cap. This company provides background checks, verification, identification, monitoring, and drug and health screening services to over 40,000 customers. HireRight was profitable on an EBIT basis in the 1H21, though cash flow swung negative.\nOnline education marketplace Udemy(UDMY) plans to raise $406 million at a $4.3 billion market cap. This education platform provides over 183,000 courses in 75 languages to over 44 million customers in over 180 countries. Growing but unprofitable, Udemy has registered more than 73 million users since its inception.\nChinese drug in-licensor LianBio(LIAN) plans to raise $325 million at a $1.8 billion market cap. Focused on China and other Asian markets, this biopharmaceutical company develops and commercializes drugs for a variety of indications. LianBio’s pipeline currently consists of nine product candidates across five different therapeutics areas.\nRent the Runway(RENT) plans to raise $293 million at a $1.4 billion market cap. This apparel rental company originally focused on a-la-carte rentals of dresses for events, but has gradually transitioned to mostly generating revenue from monthly subscription boxes. While the company has seen active subscribers and revenue rebound in the last two quarters, it is unprofitable and leveraged post-IPO.\nAesthetic medical device maker Candela Medical(CDLA) plans to raise $250 million at a $1.7 billion market cap. Selling products directly in 18 countries and indirectly in 66 countries, this company develops medical devices for elective aesthetic procedures. Despite being hard hit by the pandemic, Candela Medical saw strong growth and turned profitable in the 1H21.\nFire pit brand Solo Brands(DTC) plans to raise $200 million at a $1.5 billion market cap. Solo Brands sells fire pits, camp stoves, and other outdoor gear through its DTC platform. Fast growing and profitable, this outdoor e-commerce has an installed base of more than 2.3 million customers.\nBody contouring provider AirSculpt Technologies(AIRS) plans to raise $160 million at an $886 million market cap. This company provides minimally-invasive body contouring procedures through 16 centers across 13 states in the US. AirSculpt Technologies is profitable with solid growth, and has seen an increase in same-center case volume as a result of lessening effects of COVID-19.\nTechnology firm Arteris(AIP) plans to raise $75 million at a $555 million market cap. This technology company develops and licenses interconnect intellectual property that manages the on-chip communications in System-on-Chip semiconductor devices. Arteris is unprofitable but saw growth accelerate in the 1H21.\n\nStreet research is expected for six companies, and lock-up periods will be expiring for up to 12 companies.\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 10/22/21, the Renaissance IPO Index was up 8.2% year-to-date, while the S&P 500 was up 21.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Moderna (MRNA). The Renaissance International IPO Index was down 15.8% year-to-date, while the ACWX was up 9.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865418134,"gmtCreate":1633010475985,"gmtModify":1633010476272,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/865418134","repostId":"2171953891","repostType":4,"repost":{"id":"2171953891","pubTimestamp":1633010371,"share":"https://www.laohu8.com/m/news/2171953891?lang=&edition=full","pubTime":"2021-09-30 21:59","market":"us","language":"en","title":"What You Need to Know About IBM's $19 Billion Spinoff","url":"https://stock-news.laohu8.com/highlight/detail?id=2171953891","media":"Motley Fool","summary":"Some details have emerged about IBM's plan to spin off a major business unit.","content":"<p>The biggest move made by <b>International Business Machines</b> (NYSE:<a href=\"https://laohu8.com/S/IBM\">IBM</a>) since CEO Arvind Krishna took the helm last year was the planned spinoff of the managed infrastructure services unit. The new company will be called Kyndryl, and it will be led by former IBM CFO Martin Schroeter.</p>\n<p>Details have been scarce on the spinoff since it was announced in late 2020. On Tuesday, Kyndryl filed its Form 10 registration statement with the SEC that filled in some of the blanks. Here's what IBM investors need to know.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/57354134ba16364bb4ec10c31c3066cb\" tg-width=\"700\" tg-height=\"406\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. IBM shareholders will become Kyndryl shareholders</h2>\n<p>The plan has always been for IBM to distribute shares of Kyndryl to its shareholders in a tax-free transaction. We now know more about what that transaction will look like. IBM shareholders will receive at least 80.1% of Kyndryl's common stock when the spinoff is complete, with IBM retaining the remaining stake.</p>\n<p>IBM plans to exchange its stake in Kyndryl for IBM debt over the following 12-month period. After a year, IBM won't hold any financial interest in Kyndryl if all goes according to plan. For IBM shareholders, no action is required to receive shares of Kyndryl.</p>\n<h2>2. Kyndryl will be a $19 billion behemoth in a massive industry</h2>\n<p>Kyndryl is already a major player in the realm of designing, building, managing, and modernizing mission-critical technology systems. The company has 4,000 customers in more than 100 countries, and it generated $19.4 billion of revenue in 2020.</p>\n<p>Kyndryl estimates that its current addressable market is $415 billion. That market is expected to grow by 7% annually, reaching $510 billion in 2024. Kyndryl's biggest growth opportunities over the next few years will be public cloud managed services, data services, security services, intelligent automation services, and managed services for edge environments.</p>\n<h2>3. Kyndryl is free cash flow positive if you make some adjustments</h2>\n<p>Measuring the profitability of a business that's still part of a larger parent company can be difficult. On an unadjusted basis, Kyndryl produced a pre-tax loss of $1.8 billion and a free cash flow loss of $0.3 billion in 2020.</p>\n<p>These numbers don't necessarily reflect how Kyndryl will perform once it's officially a stand-alone company. Among other things, Kyndryl's financials include allocations for marketing and global sales coverage design that aren't consistent with how the company will look once the spinoff is complete. If you back out the relevant items, Kyndryl produced positive free cash flow of roughly $0.7 billion.</p>\n<h2>4. IBM will be smaller but have higher margins</h2>\n<p>IBM is giving up around $19 billion of annual revenue by spinning off Kyndryl, but it's not giving up all that much free cash flow. IBM reported revenue of $73.6 billion and free cash flow of $10.8 billion in 2020. Excluding Kyndryl, revenue would have been $57.5 billion and free cash flow would have been around $10 billion.</p>\n<p>IBM will provide more details of its financial position and outlook for the post-separation period during a virtual investor briefing on Oct. 4.</p>\n<h2>5. IBM will be focused on the hybrid cloud</h2>\n<p>While Kyndryl has a large market opportunity, managed infrastructure services is a labor-intensive business. Kyndryl will have around 90,000 employees, so revenue per employee will be just over $200,000. That's lower than <b>Walmart</b>, for comparison.</p>\n<p>What remains of IBM will be less focused on low-margin services and more focused on high-margin software. More than half of IBM's revenue currently comes from services. When the spinoff is done, the majority of IBM's revenue will be tied to cloud software and solutions.</p>\n<p>Hybrid cloud computing and artificial intelligence will be at the center of everything IBM does. IBM is betting that its large enterprise clients will opt for an infrastructure that mixes on-premises hardware and public cloud platforms, instead of simply going all-in on <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the major cloud platforms.</p>\n<p>By removing $19 billion of slow-growing and low-margin revenue, IBM should have an easier time reporting consistent revenue and earnings growth in the years ahead. The company's on-again off-again flirtation with growth has rubbed investors the wrong way, and the stock has been stuck for years. This spinoff may be just what IBM needs to change the narrative.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What You Need to Know About IBM's $19 Billion Spinoff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat You Need to Know About IBM's $19 Billion Spinoff\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-30 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/30/ibm-kyndryl-spin-off/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biggest move made by International Business Machines (NYSE:IBM) since CEO Arvind Krishna took the helm last year was the planned spinoff of the managed infrastructure services unit. The new ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/30/ibm-kyndryl-spin-off/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IBM":"IBM"},"source_url":"https://www.fool.com/investing/2021/09/30/ibm-kyndryl-spin-off/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2171953891","content_text":"The biggest move made by International Business Machines (NYSE:IBM) since CEO Arvind Krishna took the helm last year was the planned spinoff of the managed infrastructure services unit. The new company will be called Kyndryl, and it will be led by former IBM CFO Martin Schroeter.\nDetails have been scarce on the spinoff since it was announced in late 2020. On Tuesday, Kyndryl filed its Form 10 registration statement with the SEC that filled in some of the blanks. Here's what IBM investors need to know.\nImage source: Getty Images.\n1. IBM shareholders will become Kyndryl shareholders\nThe plan has always been for IBM to distribute shares of Kyndryl to its shareholders in a tax-free transaction. We now know more about what that transaction will look like. IBM shareholders will receive at least 80.1% of Kyndryl's common stock when the spinoff is complete, with IBM retaining the remaining stake.\nIBM plans to exchange its stake in Kyndryl for IBM debt over the following 12-month period. After a year, IBM won't hold any financial interest in Kyndryl if all goes according to plan. For IBM shareholders, no action is required to receive shares of Kyndryl.\n2. Kyndryl will be a $19 billion behemoth in a massive industry\nKyndryl is already a major player in the realm of designing, building, managing, and modernizing mission-critical technology systems. The company has 4,000 customers in more than 100 countries, and it generated $19.4 billion of revenue in 2020.\nKyndryl estimates that its current addressable market is $415 billion. That market is expected to grow by 7% annually, reaching $510 billion in 2024. Kyndryl's biggest growth opportunities over the next few years will be public cloud managed services, data services, security services, intelligent automation services, and managed services for edge environments.\n3. Kyndryl is free cash flow positive if you make some adjustments\nMeasuring the profitability of a business that's still part of a larger parent company can be difficult. On an unadjusted basis, Kyndryl produced a pre-tax loss of $1.8 billion and a free cash flow loss of $0.3 billion in 2020.\nThese numbers don't necessarily reflect how Kyndryl will perform once it's officially a stand-alone company. Among other things, Kyndryl's financials include allocations for marketing and global sales coverage design that aren't consistent with how the company will look once the spinoff is complete. If you back out the relevant items, Kyndryl produced positive free cash flow of roughly $0.7 billion.\n4. IBM will be smaller but have higher margins\nIBM is giving up around $19 billion of annual revenue by spinning off Kyndryl, but it's not giving up all that much free cash flow. IBM reported revenue of $73.6 billion and free cash flow of $10.8 billion in 2020. Excluding Kyndryl, revenue would have been $57.5 billion and free cash flow would have been around $10 billion.\nIBM will provide more details of its financial position and outlook for the post-separation period during a virtual investor briefing on Oct. 4.\n5. IBM will be focused on the hybrid cloud\nWhile Kyndryl has a large market opportunity, managed infrastructure services is a labor-intensive business. Kyndryl will have around 90,000 employees, so revenue per employee will be just over $200,000. That's lower than Walmart, for comparison.\nWhat remains of IBM will be less focused on low-margin services and more focused on high-margin software. More than half of IBM's revenue currently comes from services. When the spinoff is done, the majority of IBM's revenue will be tied to cloud software and solutions.\nHybrid cloud computing and artificial intelligence will be at the center of everything IBM does. IBM is betting that its large enterprise clients will opt for an infrastructure that mixes on-premises hardware and public cloud platforms, instead of simply going all-in on one of the major cloud platforms.\nBy removing $19 billion of slow-growing and low-margin revenue, IBM should have an easier time reporting consistent revenue and earnings growth in the years ahead. The company's on-again off-again flirtation with growth has rubbed investors the wrong way, and the stock has been stuck for years. This spinoff may be just what IBM needs to change the narrative.","news_type":1},"isVote":1,"tweetType":1,"viewCount":144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696382108,"gmtCreate":1640618475036,"gmtModify":1640618475276,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696382108","repostId":"1103486686","repostType":4,"repost":{"id":"1103486686","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640616531,"share":"https://www.laohu8.com/m/news/1103486686?lang=&edition=full","pubTime":"2021-12-27 22:48","market":"us","language":"en","title":"Novavax shares dropped 8% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1103486686","media":"Tiger Newspress","summary":"Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.","content":"<p>Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.</p>\n<p><img src=\"https://static.tigerbbs.com/d6627c5ec391aa02c9ec15dfc36c8f87\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares dropped 8% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares dropped 8% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-27 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.</p>\n<p><img src=\"https://static.tigerbbs.com/d6627c5ec391aa02c9ec15dfc36c8f87\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103486686","content_text":"Novavax shares dropped 8% in morning trading.The stock fell 3.3% in the previous trading day.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690230103,"gmtCreate":1639668050409,"gmtModify":1639668050659,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Loke","listText":"Loke","text":"Loke","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/690230103","repostId":"1108384523","repostType":4,"repost":{"id":"1108384523","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639667369,"share":"https://www.laohu8.com/m/news/1108384523?lang=&edition=full","pubTime":"2021-12-16 23:09","market":"us","language":"en","title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","media":"Tiger Newspress","summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108384523","content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","news_type":1},"isVote":1,"tweetType":1,"viewCount":184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":828806392,"gmtCreate":1633877854561,"gmtModify":1633877854703,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/828806392","repostId":"2174920514","repostType":4,"repost":{"id":"2174920514","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1633764600,"share":"https://www.laohu8.com/m/news/2174920514?lang=&edition=full","pubTime":"2021-10-09 15:30","market":"us","language":"en","title":"Is the stock market open on Columbus Day? Yes! But the bond market isn't--Here's why","url":"https://stock-news.laohu8.com/highlight/detail?id=2174920514","media":"Dow Jones","summary":"It's also Indigenous Peoples Day.\nIt's almost a perennial question on Wall Street. With Columbus Day","content":"<p>It's also Indigenous Peoples Day.</p>\n<p>It's almost a perennial question on Wall Street. With Columbus Day a federal holiday on Monday, investors are curious if the stock market will be opened.</p>\n<p>Here is the short answer: yes. But it isn't that simple.</p>\n<p>The bond market isn't. Bond traders are off as recommended by the Securities Industry and Financial Markets Association, known as Sifma.</p>\n<p>Columbus Day and Veterans Day are the two federal holidays when fixed-income markets are closed due to the federal holiday.</p>\n<p>As per usual, the Intercontinental Exchange<a href=\"https://laohu8.com/S/ICE\">$(ICE)$</a>-owned New York Stock Exchange and the Nasdaq Inc. <a href=\"https://laohu8.com/S/NDAQ\">$(NDAQ)$</a> will both be open regular hours. So, the Dow Jones Industrial Average , the S&amp;P 500 index and the Nasdaq Composite Index , to note the three main U.S. bourses, can figure out whether the weaker-than-expected jobs report released on Friday was bullish or bearish in the near term.</p>\n<p>Meanwhile, benchmark bonds can take a breather after the 10-year Treasury note yield, 30-year Treasury bond and 2-year Treasury note touched their highest yields in months (since March of 2020 in the case of the shorter-date debt).</p>\n<p>Now back to Columbus Day and the curious case of mixed up market closures.</p>\n<p>Here's perhaps why it is closed and equities trade on.</p>\n<p>Begun back in 1792 and declared a federal day off in 1937 by President Franklin D. Roosevelt, Columbus Day marks a state and federal holiday. Federal offices, including the U.S. Treasury Department, are closed. That means, Treasurys--a chunk of typical trading activity on regular days and a key benchmark--are also forced to take a holiday.</p>\n<p>Columbus Day isn't without its controversy as a holiday intended to celebrate Christopher Columbus for sailing the ocean blue in 1492. Firstly, not all states celebrate the Italian explorer's occasion on the same day. Tennessee tends to celebrate the holiday on Friday. Some states don't acknowledge the day at all, with Alaska, Vermont, Hawaii and South Dakota choosing not to observe it.</p>\n<p>Some regions choose to celebrate Indigenous Peoples Day, which honors Native Americans and challenges the concept that Columbus was the first to discover America. The holiday has been gaining support, as an alternative to Columbus Day.</p>\n<p>So, the next time that someone asks if the market is open on Columbus Day, you can tell them that it is complicated.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is the stock market open on Columbus Day? Yes! But the bond market isn't--Here's why</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs the stock market open on Columbus Day? Yes! But the bond market isn't--Here's why\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-10-09 15:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It's also Indigenous Peoples Day.</p>\n<p>It's almost a perennial question on Wall Street. With Columbus Day a federal holiday on Monday, investors are curious if the stock market will be opened.</p>\n<p>Here is the short answer: yes. But it isn't that simple.</p>\n<p>The bond market isn't. Bond traders are off as recommended by the Securities Industry and Financial Markets Association, known as Sifma.</p>\n<p>Columbus Day and Veterans Day are the two federal holidays when fixed-income markets are closed due to the federal holiday.</p>\n<p>As per usual, the Intercontinental Exchange<a href=\"https://laohu8.com/S/ICE\">$(ICE)$</a>-owned New York Stock Exchange and the Nasdaq Inc. <a href=\"https://laohu8.com/S/NDAQ\">$(NDAQ)$</a> will both be open regular hours. So, the Dow Jones Industrial Average , the S&amp;P 500 index and the Nasdaq Composite Index , to note the three main U.S. bourses, can figure out whether the weaker-than-expected jobs report released on Friday was bullish or bearish in the near term.</p>\n<p>Meanwhile, benchmark bonds can take a breather after the 10-year Treasury note yield, 30-year Treasury bond and 2-year Treasury note touched their highest yields in months (since March of 2020 in the case of the shorter-date debt).</p>\n<p>Now back to Columbus Day and the curious case of mixed up market closures.</p>\n<p>Here's perhaps why it is closed and equities trade on.</p>\n<p>Begun back in 1792 and declared a federal day off in 1937 by President Franklin D. Roosevelt, Columbus Day marks a state and federal holiday. Federal offices, including the U.S. Treasury Department, are closed. That means, Treasurys--a chunk of typical trading activity on regular days and a key benchmark--are also forced to take a holiday.</p>\n<p>Columbus Day isn't without its controversy as a holiday intended to celebrate Christopher Columbus for sailing the ocean blue in 1492. Firstly, not all states celebrate the Italian explorer's occasion on the same day. Tennessee tends to celebrate the holiday on Friday. Some states don't acknowledge the day at all, with Alaska, Vermont, Hawaii and South Dakota choosing not to observe it.</p>\n<p>Some regions choose to celebrate Indigenous Peoples Day, which honors Native Americans and challenges the concept that Columbus was the first to discover America. The holiday has been gaining support, as an alternative to Columbus Day.</p>\n<p>So, the next time that someone asks if the market is open on Columbus Day, you can tell them that it is complicated.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ICE":"洲际交易所",".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","NDAQ":"纳斯达克OMX交易所"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2174920514","content_text":"It's also Indigenous Peoples Day.\nIt's almost a perennial question on Wall Street. With Columbus Day a federal holiday on Monday, investors are curious if the stock market will be opened.\nHere is the short answer: yes. But it isn't that simple.\nThe bond market isn't. Bond traders are off as recommended by the Securities Industry and Financial Markets Association, known as Sifma.\nColumbus Day and Veterans Day are the two federal holidays when fixed-income markets are closed due to the federal holiday.\nAs per usual, the Intercontinental Exchange$(ICE)$-owned New York Stock Exchange and the Nasdaq Inc. $(NDAQ)$ will both be open regular hours. So, the Dow Jones Industrial Average , the S&P 500 index and the Nasdaq Composite Index , to note the three main U.S. bourses, can figure out whether the weaker-than-expected jobs report released on Friday was bullish or bearish in the near term.\nMeanwhile, benchmark bonds can take a breather after the 10-year Treasury note yield, 30-year Treasury bond and 2-year Treasury note touched their highest yields in months (since March of 2020 in the case of the shorter-date debt).\nNow back to Columbus Day and the curious case of mixed up market closures.\nHere's perhaps why it is closed and equities trade on.\nBegun back in 1792 and declared a federal day off in 1937 by President Franklin D. Roosevelt, Columbus Day marks a state and federal holiday. Federal offices, including the U.S. Treasury Department, are closed. That means, Treasurys--a chunk of typical trading activity on regular days and a key benchmark--are also forced to take a holiday.\nColumbus Day isn't without its controversy as a holiday intended to celebrate Christopher Columbus for sailing the ocean blue in 1492. Firstly, not all states celebrate the Italian explorer's occasion on the same day. Tennessee tends to celebrate the holiday on Friday. Some states don't acknowledge the day at all, with Alaska, Vermont, Hawaii and South Dakota choosing not to observe it.\nSome regions choose to celebrate Indigenous Peoples Day, which honors Native Americans and challenges the concept that Columbus was the first to discover America. The holiday has been gaining support, as an alternative to Columbus Day.\nSo, the next time that someone asks if the market is open on Columbus Day, you can tell them that it is complicated.","news_type":1},"isVote":1,"tweetType":1,"viewCount":86,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868976489,"gmtCreate":1632584080541,"gmtModify":1632654971541,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/868976489","repostId":"1149730497","repostType":4,"repost":{"id":"1149730497","pubTimestamp":1632538837,"share":"https://www.laohu8.com/m/news/1149730497?lang=&edition=full","pubTime":"2021-09-25 11:00","market":"us","language":"en","title":"7 Best Stocks To Buy for Investors Building a ‘Brands’ Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=1149730497","media":"investorplace","summary":"'Brands' are big and these seven stocks each bring investors a stake in recognized quality products ","content":"<p>'Brands' are big and these seven stocks each bring investors a stake in recognized quality products and services</p>\n<p>I saw a recent article from<i>Quartz at Work</i>about Reebok, other brand reboots, and what<b>Authentic Brands</b>plans to doto revitalize the once-dominant sneaker company. While the rise and fall of Reebok is a fascinating story, the article got me thinking about stocks to buy for the “Brands” portfolio.</p>\n<p>After all, Authentic Brands itself hasfiled to go public. My fellow<i>InvestorPlace</i>contributor Dana Blankenhorn calls it the most fascinating IPO of the year.</p>\n<p>“Authentic’s S-1has more pictures than<b>Pinterest</b>(NYSE:<b><u>PINS</u></b>), but tells little about the business. The numbers are for 2020, before a host of recent deals. It only identifies direct licensing revenue, $488 million of it in that year. But $211 million of that money, 43%, wound up as net income. This is said to justify a $10 billion enterprise valuation,” Dana wrote on Sep. 20.</p>\n<p>I agree with my colleague. It’s definitely up there. Heck, by the time I’ve written this, the company’s stock might be eligible for my newest portfolio.</p>\n<p>But, for now,<i>Finviz.com</i>tells me there are34 public companieswith the word “Brands” as part of their corporate name. So, I’ll recommend the seven best stocks to buy from the bunch.</p>\n<ul>\n <li><b>Restaurant Brands International</b>(NYSE:<b><u>QSR)</u></b></li>\n <li><b>Constellation Brands</b>(NYSE:<b><u>STZ)</u></b></li>\n <li><b>Fortune Brands Home &amp; Security</b>(NYSE:<b><u>FBHS</u></b>)</li>\n <li><b>Newell Brands</b>(NASDAQ:<b><u>NWL</u></b>)</li>\n <li><b>Acuity Brands</b>(NYSE:<b><u>AYI</u></b>)</li>\n <li><b>Cornerstone Building Brands</b>(NYSE:<b><u>CNR</u></b>)</li>\n <li><b>BellRing Brands</b>(NYSE:<b><u>BRBR</u></b>)</li>\n</ul>\n<p>Stocks to Buy: Restaurant Brands International (QSR)</p>\n<p>I begrudgingly put Restaurant Brands International, the owner of Tim Hortons, Burger King and Popeye’s, on my list of stocks to buy.</p>\n<p>Burger King acquired Tim Hortons in 2014 to form RBI. Ever since, I’ve had a hard time accepting the merger, given Burger King’s CEO made each Tim Horton’s head office employee justify their jobs in15-minute interviews.</p>\n<p>To date, I’d say I was right to be concerned about the poor treatment of employees. Over the past five years through Sept. 22, QSR stock has a total return of 9.0%, less than the Canadian market on the whole and nearly half the return of the entire U.S. market.</p>\n<p>In August, Tim Hortons China, a joint-venture between RBI and Hong Kong private equity firm<b>Cartesian Capital</b>, agreed to merge with<b>Silver Crest Acquisition Corp.</b>(NASDAQ:<b><u>SLCR</u></b>) in a transaction that valued the Chinese segment of Tim Hortons at$1.7 billion.</p>\n<p>As long as<b>3G Capital</b>continues to own almost 30% of RBI stock, I’ll remain cautious in my praise.</p>\n<p>However, with$1.35 billionin trailing 12-month (TTM) free cash flow (FCF) and a 7.0% FCF yield, now could be an opportune time to pick up some shares.</p>\n<p>Constellation Brands (STZ)<img src=\"https://static.tigerbbs.com/51af367100d1d75a5ca277a1a9675c31\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: ShinoStock / Shutterstock.com</p>\n<p>A telltale sign Constellation Brands has become a big deal in corporate America is therecent announcementthat it would move 400 of its employees from its offices in Canandaigua, New York, to downtown Rochester.</p>\n<p>“The company investment is estimated at $50 million, while Landers [Peter Landers, majority investor in group that owns the downtown property] says the owners/developers’ will spend close to $35 million on historic restoration, stripping paint from the barrel ceilings and brick walls, and building a 120-space parking structure,” The<i>Democrat &amp; Chronicle</i>reported.</p>\n<p>While Constellation is known for Corona and Modelo beer, Svedka vodka, and Woodbridge wine, amongst others, it isthe company’s investmentin<b>Canopy Growth</b>(NASDAQ:<b><u>CGC</u></b>) that gets most of the attention.</p>\n<p>That’s because it’s taking forever to see the benefits of its multi-billion-dollar investment in the Canadian cannabis company. Since it acquired9.9% in October 2017, STZ stock has gone sideways over nearly 48 months.</p>\n<p>As a glass-half-full kind of person, I see the potential upside of its Canopy investment as a big reason to buy at current prices.</p>\n<p>Constellation has a TTM FCF of$2.0 billion, good for an FCF yield of 4.9%. When you consider the value yet to be extracted by its investment, STZ’s valuation is more than reasonable.</p>\n<p>Stocks to Buy: Fortune Brands Home &amp; Security (FBHS)<img src=\"https://static.tigerbbs.com/c43d12689a9a34fc77425af4b7ac66d2\" tg-width=\"300\" tg-height=\"165\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: Shutterstock</p>\n<p>Fortune Brands Home &amp; Security wasspun offfrom<b>Fortune Brands Inc</b>, part of the then-holding company’s plan to deliver additional value for its shareholders almost a decade ago.</p>\n<p>At the same time, it sold its Acushnet business for $1.225 billion and renamed Fortune Brands as<b>Beam Inc.</b>, the holding company’s spirits business. Beam was subsequently sold to<b>Suntory Holdings</b>in 2014 for $16 billion, including the assumption of debt.</p>\n<p>Fortune shareholders got one share of FBHS for each share in the parent. FBHS stock has generated a total return of 22.4% over the past decade, 548 basis points higher than the entire U.S. market.</p>\n<p>The company hasthree operating segments: Plumbing, Outdoors &amp; Security, and Cabinets. Its brands include Moen faucets, Larson doors, Master Lock locks, MasterBrand cabinets, and many more.</p>\n<p>Together, they have TTM sales of $7.02 billion, $1.03 billion in operating income, $650 million in FCF, and an FCF yield of 5.0%.</p>\n<p>It’s a great business to own for the long haul.</p>\n<p>Newell Brands (NWL)<img src=\"https://static.tigerbbs.com/b002bc9b30d4f4cc62b40222b912a1b0\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: Casimiro PT / Shutterstock.com</p>\n<p>Newell CEO Ravi Saligram was recently named one ofAtlanta’s best CEOsby the<i>Atlanta Business Chronicle.</i>Saligram joined Newell as CEO inOctober 2019. Before that, he was CEO of<b>Ritchie Bros. Auctioneers</b>(NYSE:<b><u>RBA</u></b>) from July 2014 to July 2019 and OfficeMax from November 2010 to November 2013. In addition, he oversaw the merger between OfficeMax and Office Depot.</p>\n<p>He’s been an executive for many years working in several different industries. Since joining Newell, NWL stock has gained 32% over nearly 24 months. That compares to 50% for the<b>S&amp;P 500 index</b>over the same period.</p>\n<p>Over the years, Newell Brands became quite bloated, with too many businesses generating too few profits. Newell might have underperformed so far in Saligram’s tenure, but he’s doing his best to set the company up for sustainable growth.</p>\n<p>“Along our journey, we will add capabilities to build competitive advantage. For example, we are building on our eCommerce capabilities and Digital First mindset (over 21% of our global sales are sold online) to become truly omni channel,” Saligram told the<i>Atlanta Business Chronicle.</i></p>\n<p>“We are creating consistent and compelling brand experiences for consumers no matter where they shop, how they shop or when they shop be it buy online, deliver to home, buy online pick up at the store, buy online pick up at curbside or shop at a store.”</p>\n<p>In 2019, Newell had an FCF of$780 million. In the TTM, it was $1.1 billion, a 41% increase. I would expect this FCF growth to continue.</p>\n<p>The performance in the next 24 months ought to be much better than the last 24.</p>\n<p>Stocks to Buy: Acuity Brands (AYI)<img src=\"https://static.tigerbbs.com/d0fc99bca07cdb144fe2c7208776aed8\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: JHVEPhoto / Shutterstock.com</p>\n<p>It’s great to see the provider of commercial and residential lighting solutions doing well in the markets after a long stretch of less-than-stellar Acuity Brands shareholder returns.</p>\n<p>For example, if you invested $10,000 in AYI stock in September 2020, today, you would have approximately $17,294. However, if you invested the same $10,000 in its stock three years ago, you’d have $10,609.</p>\n<p>While the company got lost in the woods for a time, it’s been able to find its way back, thanks in part to its hiring of CEO Neil Ashe inJanuary 2020. Ashe has held some high-powered jobs, including being in charge of<b>Walmart’s</b>(NYSE:<b><u>WMT</u></b>) eCommerce &amp; Technology unit from 2012 through 2016.</p>\n<p>Ashe replaced Vernon Nagel, who served as Acuity’s CEO for 16 years. Nagel moved into theexecutive chairman role. They ought to make an excellent pairing.</p>\n<p>In the company’s Q3 2021 results, Acuity had a 16% increase in sales to$899.7 million, with a 56% increase in earnings to $2.37 a share. In 2021, it expects growth to continue.</p>\n<p>InJanuary 2019, I suggested that Acuity needed a new CEO who could bring a fresh perspective. Less than a year later, it did just that. Kudos to Nagel for recognizing it was time to move aside.</p>\n<p>Cornerstone Building Brands (CNR)<img src=\"https://static.tigerbbs.com/60a34aa2f9805656c3d30d8bf03763eb\" tg-width=\"300\" tg-height=\"227\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: ©iStock.com/Sashick</p>\n<p>Of all the names on this list, Cornerstone Building Brands is the only one I didn’t recognize.</p>\n<p>The North Carolina-based provider of commercial, residential, and repair &amp; remodel building products is the largest manufacturer of exterior building products in North America.</p>\n<p>Although the Cornerstone name only came into existence inNovember 2018after the merger between NCI Building Systems and Ply Gem Parent LLC, the two companies have a history of more than 75 years.</p>\n<p>Since the merger’s completion, CNR stock has experienced its fair share of highs and lows, falling to less than $3 in the March 2020 correction, then recovering to almost $20 in June before settling back into the mid-teens in late September.</p>\n<p>A prominent owner of Cornerstone stock is<b>BlueTower Asset Management</b>, a Texas-based portfolio manager. The company’s Global Value Strategy owns17 stocks, CNR being the largest weighting at 18.6% of the portfolio.</p>\n<p>Here’s what BlueTower had to say about Cornerstone in itsQ2 2021 shareholder letter:</p>\n<p>“As the company realizes acquisition synergies, the housing boom continues, and Cornerstone pays down debt, the company’s value will become apparent to investors and share price will rise to meet its true fundamental value,” BlueTower portfolio manager Andrew Oskoui wrote.</p>\n<p>“Investors who were previously repelled by the high debt levels will invest at lower leverage levels. The share price has already tripled from the average price our long-term investors in the strategy composite paid, but we still believe the company has a high expected forward rate of return.”</p>\n<p>What’s not to like?</p>\n<p>Stocks to Buy: BellRing Brands (BRBR)<img src=\"https://static.tigerbbs.com/00df020d2a1a57e564587b5d95e0c571\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: rblfmr / Shutterstock.com</p>\n<p>If you’ve ever eaten a PowerBar, you’ve heard of and supported BellRing Brands.</p>\n<p>In October 2019,<b>Post Holdings</b>(NYSE:<b><u>POST</u></b>) spun off its former active nutrition business — PowerBar, Premier Protein, and Dymatize brands — selling 39.43 million shares at $14 per share. It raised approximately$516.4 millionfrom the IPO. It used the proceeds to pay down some debt owed to the parent and buy shares of the operating company, BellRing Brands LLC.</p>\n<p>After the IPO, Post owned 71% of BRBR stock. In August 2021, Post announced thatit plans to distributemost of this stake to shareholders. The move’s expected to include a special cash dividend for Post shareholders.</p>\n<p>At the same time, it announced the distribution; it also announced Q3 2021 results. Sales in the quarter jumped 68% over last year to $342.6 million, while its operating profit increased by 68% to $51.5 million.</p>\n<p>BellRing’s TTM FCF is$214.3 million. Based on a market cap of $1.3 billion, it has an FCF yield of 16.5%, well into value territory.</p>\n<p>If I’m a Post shareholder, I’d be hanging on to my BellRing shares for the long haul.</p>\n<p><i>On the date of publication, Will Ashworthdid not have (either directly or indirectly) any positions in the securities mentioned in this article.The opinions expressed in this article are those of the writer, subject to the</i>InvestorPlace.comPublishing Guidelines<i>.</i></p>\n<p><i>Will Ashworth has written about investments full-time since 2008. Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities.</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Best Stocks To Buy for Investors Building a ‘Brands’ Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Best Stocks To Buy for Investors Building a ‘Brands’ Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-25 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/7-best-stocks-to-buy-for-investors-building-a-brands-portfolio/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>'Brands' are big and these seven stocks each bring investors a stake in recognized quality products and services\nI saw a recent article fromQuartz at Workabout Reebok, other brand reboots, and ...</p>\n\n<a href=\"https://investorplace.com/2021/09/7-best-stocks-to-buy-for-investors-building-a-brands-portfolio/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISBC":"投资者银行"},"source_url":"https://investorplace.com/2021/09/7-best-stocks-to-buy-for-investors-building-a-brands-portfolio/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149730497","content_text":"'Brands' are big and these seven stocks each bring investors a stake in recognized quality products and services\nI saw a recent article fromQuartz at Workabout Reebok, other brand reboots, and whatAuthentic Brandsplans to doto revitalize the once-dominant sneaker company. While the rise and fall of Reebok is a fascinating story, the article got me thinking about stocks to buy for the “Brands” portfolio.\nAfter all, Authentic Brands itself hasfiled to go public. My fellowInvestorPlacecontributor Dana Blankenhorn calls it the most fascinating IPO of the year.\n“Authentic’s S-1has more pictures thanPinterest(NYSE:PINS), but tells little about the business. The numbers are for 2020, before a host of recent deals. It only identifies direct licensing revenue, $488 million of it in that year. But $211 million of that money, 43%, wound up as net income. This is said to justify a $10 billion enterprise valuation,” Dana wrote on Sep. 20.\nI agree with my colleague. It’s definitely up there. Heck, by the time I’ve written this, the company’s stock might be eligible for my newest portfolio.\nBut, for now,Finviz.comtells me there are34 public companieswith the word “Brands” as part of their corporate name. So, I’ll recommend the seven best stocks to buy from the bunch.\n\nRestaurant Brands International(NYSE:QSR)\nConstellation Brands(NYSE:STZ)\nFortune Brands Home & Security(NYSE:FBHS)\nNewell Brands(NASDAQ:NWL)\nAcuity Brands(NYSE:AYI)\nCornerstone Building Brands(NYSE:CNR)\nBellRing Brands(NYSE:BRBR)\n\nStocks to Buy: Restaurant Brands International (QSR)\nI begrudgingly put Restaurant Brands International, the owner of Tim Hortons, Burger King and Popeye’s, on my list of stocks to buy.\nBurger King acquired Tim Hortons in 2014 to form RBI. Ever since, I’ve had a hard time accepting the merger, given Burger King’s CEO made each Tim Horton’s head office employee justify their jobs in15-minute interviews.\nTo date, I’d say I was right to be concerned about the poor treatment of employees. Over the past five years through Sept. 22, QSR stock has a total return of 9.0%, less than the Canadian market on the whole and nearly half the return of the entire U.S. market.\nIn August, Tim Hortons China, a joint-venture between RBI and Hong Kong private equity firmCartesian Capital, agreed to merge withSilver Crest Acquisition Corp.(NASDAQ:SLCR) in a transaction that valued the Chinese segment of Tim Hortons at$1.7 billion.\nAs long as3G Capitalcontinues to own almost 30% of RBI stock, I’ll remain cautious in my praise.\nHowever, with$1.35 billionin trailing 12-month (TTM) free cash flow (FCF) and a 7.0% FCF yield, now could be an opportune time to pick up some shares.\nConstellation Brands (STZ)Source: ShinoStock / Shutterstock.com\nA telltale sign Constellation Brands has become a big deal in corporate America is therecent announcementthat it would move 400 of its employees from its offices in Canandaigua, New York, to downtown Rochester.\n“The company investment is estimated at $50 million, while Landers [Peter Landers, majority investor in group that owns the downtown property] says the owners/developers’ will spend close to $35 million on historic restoration, stripping paint from the barrel ceilings and brick walls, and building a 120-space parking structure,” TheDemocrat & Chroniclereported.\nWhile Constellation is known for Corona and Modelo beer, Svedka vodka, and Woodbridge wine, amongst others, it isthe company’s investmentinCanopy Growth(NASDAQ:CGC) that gets most of the attention.\nThat’s because it’s taking forever to see the benefits of its multi-billion-dollar investment in the Canadian cannabis company. Since it acquired9.9% in October 2017, STZ stock has gone sideways over nearly 48 months.\nAs a glass-half-full kind of person, I see the potential upside of its Canopy investment as a big reason to buy at current prices.\nConstellation has a TTM FCF of$2.0 billion, good for an FCF yield of 4.9%. When you consider the value yet to be extracted by its investment, STZ’s valuation is more than reasonable.\nStocks to Buy: Fortune Brands Home & Security (FBHS)Source: Shutterstock\nFortune Brands Home & Security wasspun offfromFortune Brands Inc, part of the then-holding company’s plan to deliver additional value for its shareholders almost a decade ago.\nAt the same time, it sold its Acushnet business for $1.225 billion and renamed Fortune Brands asBeam Inc., the holding company’s spirits business. Beam was subsequently sold toSuntory Holdingsin 2014 for $16 billion, including the assumption of debt.\nFortune shareholders got one share of FBHS for each share in the parent. FBHS stock has generated a total return of 22.4% over the past decade, 548 basis points higher than the entire U.S. market.\nThe company hasthree operating segments: Plumbing, Outdoors & Security, and Cabinets. Its brands include Moen faucets, Larson doors, Master Lock locks, MasterBrand cabinets, and many more.\nTogether, they have TTM sales of $7.02 billion, $1.03 billion in operating income, $650 million in FCF, and an FCF yield of 5.0%.\nIt’s a great business to own for the long haul.\nNewell Brands (NWL)Source: Casimiro PT / Shutterstock.com\nNewell CEO Ravi Saligram was recently named one ofAtlanta’s best CEOsby theAtlanta Business Chronicle.Saligram joined Newell as CEO inOctober 2019. Before that, he was CEO ofRitchie Bros. Auctioneers(NYSE:RBA) from July 2014 to July 2019 and OfficeMax from November 2010 to November 2013. In addition, he oversaw the merger between OfficeMax and Office Depot.\nHe’s been an executive for many years working in several different industries. Since joining Newell, NWL stock has gained 32% over nearly 24 months. That compares to 50% for theS&P 500 indexover the same period.\nOver the years, Newell Brands became quite bloated, with too many businesses generating too few profits. Newell might have underperformed so far in Saligram’s tenure, but he’s doing his best to set the company up for sustainable growth.\n“Along our journey, we will add capabilities to build competitive advantage. For example, we are building on our eCommerce capabilities and Digital First mindset (over 21% of our global sales are sold online) to become truly omni channel,” Saligram told theAtlanta Business Chronicle.\n“We are creating consistent and compelling brand experiences for consumers no matter where they shop, how they shop or when they shop be it buy online, deliver to home, buy online pick up at the store, buy online pick up at curbside or shop at a store.”\nIn 2019, Newell had an FCF of$780 million. In the TTM, it was $1.1 billion, a 41% increase. I would expect this FCF growth to continue.\nThe performance in the next 24 months ought to be much better than the last 24.\nStocks to Buy: Acuity Brands (AYI)Source: JHVEPhoto / Shutterstock.com\nIt’s great to see the provider of commercial and residential lighting solutions doing well in the markets after a long stretch of less-than-stellar Acuity Brands shareholder returns.\nFor example, if you invested $10,000 in AYI stock in September 2020, today, you would have approximately $17,294. However, if you invested the same $10,000 in its stock three years ago, you’d have $10,609.\nWhile the company got lost in the woods for a time, it’s been able to find its way back, thanks in part to its hiring of CEO Neil Ashe inJanuary 2020. Ashe has held some high-powered jobs, including being in charge ofWalmart’s(NYSE:WMT) eCommerce & Technology unit from 2012 through 2016.\nAshe replaced Vernon Nagel, who served as Acuity’s CEO for 16 years. Nagel moved into theexecutive chairman role. They ought to make an excellent pairing.\nIn the company’s Q3 2021 results, Acuity had a 16% increase in sales to$899.7 million, with a 56% increase in earnings to $2.37 a share. In 2021, it expects growth to continue.\nInJanuary 2019, I suggested that Acuity needed a new CEO who could bring a fresh perspective. Less than a year later, it did just that. Kudos to Nagel for recognizing it was time to move aside.\nCornerstone Building Brands (CNR)Source: ©iStock.com/Sashick\nOf all the names on this list, Cornerstone Building Brands is the only one I didn’t recognize.\nThe North Carolina-based provider of commercial, residential, and repair & remodel building products is the largest manufacturer of exterior building products in North America.\nAlthough the Cornerstone name only came into existence inNovember 2018after the merger between NCI Building Systems and Ply Gem Parent LLC, the two companies have a history of more than 75 years.\nSince the merger’s completion, CNR stock has experienced its fair share of highs and lows, falling to less than $3 in the March 2020 correction, then recovering to almost $20 in June before settling back into the mid-teens in late September.\nA prominent owner of Cornerstone stock isBlueTower Asset Management, a Texas-based portfolio manager. The company’s Global Value Strategy owns17 stocks, CNR being the largest weighting at 18.6% of the portfolio.\nHere’s what BlueTower had to say about Cornerstone in itsQ2 2021 shareholder letter:\n“As the company realizes acquisition synergies, the housing boom continues, and Cornerstone pays down debt, the company’s value will become apparent to investors and share price will rise to meet its true fundamental value,” BlueTower portfolio manager Andrew Oskoui wrote.\n“Investors who were previously repelled by the high debt levels will invest at lower leverage levels. The share price has already tripled from the average price our long-term investors in the strategy composite paid, but we still believe the company has a high expected forward rate of return.”\nWhat’s not to like?\nStocks to Buy: BellRing Brands (BRBR)Source: rblfmr / Shutterstock.com\nIf you’ve ever eaten a PowerBar, you’ve heard of and supported BellRing Brands.\nIn October 2019,Post Holdings(NYSE:POST) spun off its former active nutrition business — PowerBar, Premier Protein, and Dymatize brands — selling 39.43 million shares at $14 per share. It raised approximately$516.4 millionfrom the IPO. It used the proceeds to pay down some debt owed to the parent and buy shares of the operating company, BellRing Brands LLC.\nAfter the IPO, Post owned 71% of BRBR stock. In August 2021, Post announced thatit plans to distributemost of this stake to shareholders. The move’s expected to include a special cash dividend for Post shareholders.\nAt the same time, it announced the distribution; it also announced Q3 2021 results. Sales in the quarter jumped 68% over last year to $342.6 million, while its operating profit increased by 68% to $51.5 million.\nBellRing’s TTM FCF is$214.3 million. Based on a market cap of $1.3 billion, it has an FCF yield of 16.5%, well into value territory.\nIf I’m a Post shareholder, I’d be hanging on to my BellRing shares for the long haul.\nOn the date of publication, Will Ashworthdid not have (either directly or indirectly) any positions in the securities mentioned in this article.The opinions expressed in this article are those of the writer, subject to theInvestorPlace.comPublishing Guidelines.\nWill Ashworth has written about investments full-time since 2008. Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities.","news_type":1},"isVote":1,"tweetType":1,"viewCount":31,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698937949,"gmtCreate":1640273647428,"gmtModify":1640273647655,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698937949","repostId":"1192623075","repostType":4,"repost":{"id":"1192623075","pubTimestamp":1640269891,"share":"https://www.laohu8.com/m/news/1192623075?lang=&edition=full","pubTime":"2021-12-23 22:31","market":"us","language":"en","title":"U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=1192623075","media":"SeattleTimes","summary":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea","content":"<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p>\n<p>The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p>\n<p>As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p>\n<p>The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p>\n<p>Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p>\n<p>The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p>\n<p>The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p>\n<p>Some experts question whether there will be much of a role for the Merck drug in the U.S.</p>\n<p>“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p>\n<p>For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p>\n<p>The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p>\n<p>Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p>\n<p>The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p>\n<p>Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p>","source":"lsy1640271591192","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. adds Merck pill as 2nd easy-to-use drug against COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 22:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/><strong>SeattleTimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug ...</p>\n\n<a href=\"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192623075","content_text":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.\nAs a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.\nThe Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.\nKnown as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.\nThe restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.\nThe Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.\nSome experts question whether there will be much of a role for the Merck drug in the U.S.\n“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”\nFor now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.\nThe FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.\nFederal officials have agreed to purchase enough of the drug to treat 3.1 million people.\nThe U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.\nMerck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607482798,"gmtCreate":1639579232175,"gmtModify":1639579232441,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607482798","repostId":"1153017502","repostType":4,"repost":{"id":"1153017502","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639578803,"share":"https://www.laohu8.com/m/news/1153017502?lang=&edition=full","pubTime":"2021-12-15 22:33","market":"us","language":"en","title":"U.S. stock market kicks off lackluster start on Fed decision day,S&P 500 gains 0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153017502","media":"Tiger Newspress","summary":"U.S. stock market kicks off lackluster start on Fed decision day,Nasdaq Composite off less than 0.1%","content":"<p>U.S. stock market kicks off lackluster start on Fed decision day,Nasdaq Composite off less than 0.1%,S&amp;P 500 gains 0.1%; Dow trades flat but hanging around a gain of 0.1%.</p>\n<p>All eyes on Wednesday will be on the Federal Reserve's monetary policy statement and press conference by Federal Reserve Chair Jerome Powell. Many market participants expect these will set the stage for the Fed to speed the withdrawal of its crisis-era stimulus programs, with the firming economic recovery and soaring inflation suggesting the central bank has room for a more hawkish tilt to policy. Last week's Consumer Price Index showed thefastest surge in U.S. consumer prices since 1982on a year-over-year basis in November. And on Tuesday, the U.S. Producer Price Index jumped by the most on record at a 9.6% year-over-year increase for last month.</p>\n<p>Specifically, many investors anticipate the Fed will ramp up the rate of tapering of its asset-purchasing program, which took place at a rate of $120 billion per month in combined Treasuries and agency mortgage-backed securities from the start of the pandemic through November. Last month, the Fed began dialing back these purchases by $15 billion, and announced another $15 billion reduction for December.</p>\n<p>\"We don't think that the Fed is really going to have any surprises for the markets [Wednesday]. They're probably going to announce that they're going to ... accelerate tapering, and that they'll probably finish that by March. But we think that they're going to leave themselves lots flexibility around raising interest rates,\" Tracie McMillion, Wells Fargo Investment Institute head of global asset allocation strategy,told Yahoo Finance Live on Tuesday.She added she expects just one interest rate hike from the Federal Reserve in the second half of next year.</p>\n<p>Other pundits, however, expect an earlier liftoff on interest rates, which maybe be reflected in the Federal Open Market Committee's (FOMC) updated Summary of Economic Projections on Wednesday.</p>\n<p>\"The announcement of faster tapering after today's FOMC meeting is a done deal; we'd be astonished by anything other than a plan to complete asset purchases by the end of March at the latest,\" wrote Ian Shepherdson, chief economist at Pantheon Macroeconomics, in a note on Tuesday. He expects the Fed to stick to its prior plan of purchasing $90 billion in its asset-purchase program this month, before doubling the rate of tapering from its current $15 billion per month starting in January.</p>\n<p>\"That would mean purchases drop to $60 billion in January, $30 billion in February, and zero in March, leaving the door open to a rate hike that month if the inflation outlook has not improved, via a clear and sustained increase in the labor force participation rate,\" he added.</p>\n<p>A number of strategists noted the trading activity in recent sessions and weeks has reflected the market pricing of a more hawkish Fed. Software and other growth names were some of the biggest laggards in the major indexes during Tuesday's session.</p>\n<p>\"When you have an anticipation of higher interest rates, growth stocks or long-duration growth stocks certainly get hit the hardest,\" Art Hogan, national chief market strategist, told Yahoo Finance Live on Tuesday. \"When you do that net present value calculation with a higher interest rate, that implied multiple or ascribed multiple to growth names comes in. So a lot of that's been priced in. When you think about some of those real growth-y names and momentum names and risk assets, they've seen a lot of carnage.\"</p>\n<p>\"What the market is trying to tell us here is that when you set your asset allocation plan for next year, you want to have a barbell approach with growth on one side — you want to have those growth names that are actually valued at a multiple to earnings, not a multiple to revenues or a multiple to cash flows or a multiple to sales,\" he added. \"We anticipate 2022 is going to be very much like 2021, where you really want to have a balance between growth and value.\"</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stock market kicks off lackluster start on Fed decision day,S&P 500 gains 0.1%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stock market kicks off lackluster start on Fed decision day,S&P 500 gains 0.1%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-15 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock market kicks off lackluster start on Fed decision day,Nasdaq Composite off less than 0.1%,S&amp;P 500 gains 0.1%; Dow trades flat but hanging around a gain of 0.1%.</p>\n<p>All eyes on Wednesday will be on the Federal Reserve's monetary policy statement and press conference by Federal Reserve Chair Jerome Powell. Many market participants expect these will set the stage for the Fed to speed the withdrawal of its crisis-era stimulus programs, with the firming economic recovery and soaring inflation suggesting the central bank has room for a more hawkish tilt to policy. Last week's Consumer Price Index showed thefastest surge in U.S. consumer prices since 1982on a year-over-year basis in November. And on Tuesday, the U.S. Producer Price Index jumped by the most on record at a 9.6% year-over-year increase for last month.</p>\n<p>Specifically, many investors anticipate the Fed will ramp up the rate of tapering of its asset-purchasing program, which took place at a rate of $120 billion per month in combined Treasuries and agency mortgage-backed securities from the start of the pandemic through November. Last month, the Fed began dialing back these purchases by $15 billion, and announced another $15 billion reduction for December.</p>\n<p>\"We don't think that the Fed is really going to have any surprises for the markets [Wednesday]. They're probably going to announce that they're going to ... accelerate tapering, and that they'll probably finish that by March. But we think that they're going to leave themselves lots flexibility around raising interest rates,\" Tracie McMillion, Wells Fargo Investment Institute head of global asset allocation strategy,told Yahoo Finance Live on Tuesday.She added she expects just one interest rate hike from the Federal Reserve in the second half of next year.</p>\n<p>Other pundits, however, expect an earlier liftoff on interest rates, which maybe be reflected in the Federal Open Market Committee's (FOMC) updated Summary of Economic Projections on Wednesday.</p>\n<p>\"The announcement of faster tapering after today's FOMC meeting is a done deal; we'd be astonished by anything other than a plan to complete asset purchases by the end of March at the latest,\" wrote Ian Shepherdson, chief economist at Pantheon Macroeconomics, in a note on Tuesday. He expects the Fed to stick to its prior plan of purchasing $90 billion in its asset-purchase program this month, before doubling the rate of tapering from its current $15 billion per month starting in January.</p>\n<p>\"That would mean purchases drop to $60 billion in January, $30 billion in February, and zero in March, leaving the door open to a rate hike that month if the inflation outlook has not improved, via a clear and sustained increase in the labor force participation rate,\" he added.</p>\n<p>A number of strategists noted the trading activity in recent sessions and weeks has reflected the market pricing of a more hawkish Fed. Software and other growth names were some of the biggest laggards in the major indexes during Tuesday's session.</p>\n<p>\"When you have an anticipation of higher interest rates, growth stocks or long-duration growth stocks certainly get hit the hardest,\" Art Hogan, national chief market strategist, told Yahoo Finance Live on Tuesday. \"When you do that net present value calculation with a higher interest rate, that implied multiple or ascribed multiple to growth names comes in. So a lot of that's been priced in. When you think about some of those real growth-y names and momentum names and risk assets, they've seen a lot of carnage.\"</p>\n<p>\"What the market is trying to tell us here is that when you set your asset allocation plan for next year, you want to have a barbell approach with growth on one side — you want to have those growth names that are actually valued at a multiple to earnings, not a multiple to revenues or a multiple to cash flows or a multiple to sales,\" he added. \"We anticipate 2022 is going to be very much like 2021, where you really want to have a balance between growth and value.\"</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153017502","content_text":"U.S. stock market kicks off lackluster start on Fed decision day,Nasdaq Composite off less than 0.1%,S&P 500 gains 0.1%; Dow trades flat but hanging around a gain of 0.1%.\nAll eyes on Wednesday will be on the Federal Reserve's monetary policy statement and press conference by Federal Reserve Chair Jerome Powell. Many market participants expect these will set the stage for the Fed to speed the withdrawal of its crisis-era stimulus programs, with the firming economic recovery and soaring inflation suggesting the central bank has room for a more hawkish tilt to policy. Last week's Consumer Price Index showed thefastest surge in U.S. consumer prices since 1982on a year-over-year basis in November. And on Tuesday, the U.S. Producer Price Index jumped by the most on record at a 9.6% year-over-year increase for last month.\nSpecifically, many investors anticipate the Fed will ramp up the rate of tapering of its asset-purchasing program, which took place at a rate of $120 billion per month in combined Treasuries and agency mortgage-backed securities from the start of the pandemic through November. Last month, the Fed began dialing back these purchases by $15 billion, and announced another $15 billion reduction for December.\n\"We don't think that the Fed is really going to have any surprises for the markets [Wednesday]. They're probably going to announce that they're going to ... accelerate tapering, and that they'll probably finish that by March. But we think that they're going to leave themselves lots flexibility around raising interest rates,\" Tracie McMillion, Wells Fargo Investment Institute head of global asset allocation strategy,told Yahoo Finance Live on Tuesday.She added she expects just one interest rate hike from the Federal Reserve in the second half of next year.\nOther pundits, however, expect an earlier liftoff on interest rates, which maybe be reflected in the Federal Open Market Committee's (FOMC) updated Summary of Economic Projections on Wednesday.\n\"The announcement of faster tapering after today's FOMC meeting is a done deal; we'd be astonished by anything other than a plan to complete asset purchases by the end of March at the latest,\" wrote Ian Shepherdson, chief economist at Pantheon Macroeconomics, in a note on Tuesday. He expects the Fed to stick to its prior plan of purchasing $90 billion in its asset-purchase program this month, before doubling the rate of tapering from its current $15 billion per month starting in January.\n\"That would mean purchases drop to $60 billion in January, $30 billion in February, and zero in March, leaving the door open to a rate hike that month if the inflation outlook has not improved, via a clear and sustained increase in the labor force participation rate,\" he added.\nA number of strategists noted the trading activity in recent sessions and weeks has reflected the market pricing of a more hawkish Fed. Software and other growth names were some of the biggest laggards in the major indexes during Tuesday's session.\n\"When you have an anticipation of higher interest rates, growth stocks or long-duration growth stocks certainly get hit the hardest,\" Art Hogan, national chief market strategist, told Yahoo Finance Live on Tuesday. \"When you do that net present value calculation with a higher interest rate, that implied multiple or ascribed multiple to growth names comes in. So a lot of that's been priced in. When you think about some of those real growth-y names and momentum names and risk assets, they've seen a lot of carnage.\"\n\"What the market is trying to tell us here is that when you set your asset allocation plan for next year, you want to have a barbell approach with growth on one side — you want to have those growth names that are actually valued at a multiple to earnings, not a multiple to revenues or a multiple to cash flows or a multiple to sales,\" he added. \"We anticipate 2022 is going to be very much like 2021, where you really want to have a balance between growth and value.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602799475,"gmtCreate":1639063416262,"gmtModify":1639064046205,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602799475","repostId":"2190617302","repostType":4,"repost":{"id":"2190617302","pubTimestamp":1639063118,"share":"https://www.laohu8.com/m/news/2190617302?lang=&edition=full","pubTime":"2021-12-09 23:18","market":"us","language":"en","title":"2 Short-Squeeze Candidates That Could Go Parabolic Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2190617302","media":"Motley Fool","summary":"Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.","content":"<p>Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called \"meme stocks\" generated jaw-dropping gains for investors earlier this year due to this phenomenon.</p>\n<p>The mechanics of a short squeeze are fairly straightforward. Short-sellers, or investors betting against an equity, are essentially forced to cover their position in response to an uptick in investors buying the stock. The net result, more often than not, is a brief, parabolic-like move higher in the stock in question.</p>\n<p>Last month, short-sellers seemingly took advantage of the widespread weakness across the biopharma space. As a result, scores of biopharma equities sport sizable short positions as a percentage of the outstanding shares. The Alzheimer's&nbsp; specialist <b>Cortexyme</b> (NASDAQ:CRTX) and the commercial-stage biotech <b>Heron Therapeutics</b> (NASDAQ:HRTX) were two of the most heavily shorted pharma stocks at last count. These two drugmakers, however, could prove to be terrible stocks to bet against. Here's why.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6841093892c649c73d00f9f0f9f2663\" tg-width=\"700\" tg-height=\"533\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Cortexyme: Alzheimer's drugs are too risky to short</h2>\n<p>Cortexyme, a small-molecule drug developer, became a huge target for short-sellers after its experimental Alzheimer's disease treatment atuzaginstat flopped in a late-stage trial toward the end of October. In fact, the biotech's shares were <i>the</i> most heavily shorted equity among biopharmas at last count, a little over two weeks ago. Short-sellers are clearly betting that atuzaginstat is basically dead on arrival. That rather dire take might not be the case, however.</p>\n<p>During a recent conference call, Cortexyme management said that the drug does appear to show a worthwhile clinical benefit for Alzheimer's patients who also tested positive for the gum-disease bacteria Porphyromonas gingivalis. While this analysis is far from definitive, it may help the company identify the correct patient population to evaluate atuzaginstat in, via another late-stage trial. Cortexyme intends to do just that. Almost immediately after the drug disappointed in this all-comer study, management announced plans to target a more-focused group of patients in another pivotal study.</p>\n<p>Why is Cortexyme an outstanding short-squeeze candidate? Even as a drug exclusively for Alzheimer's disease patients with an active P. gingivalis infection, it should still generate mega-blockbuster sales (greater than $5 billion). That's a massive revenue stream for a company with a $420 million market cap at present. Cortexyme plans to provide an update to investors on this upcoming clinical trial in the first quarter of 2022. This update could very well spark a short squeeze in the biotech's stock.</p>\n<h2>Heron Therapeutics: Down but not out</h2>\n<p>Heron Therapeutics has been a top short-seller target for well over a year now. As a result, the biotech's stock is currently <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most heavily shorted within its immediate peer group. Bears have bet against this small-cap pharma stock for two clear reasons. First, Heron's chemotherapy-induced nausea and vomiting franchise has underwhelmed from a commercial standpoint.</p>\n<p>Second, the biotech's highly anticipated acute pain medication Zynrelef didn't get the type of broad label from the Food and Drug Administration (FDA) that would have allowed it to become a major growth driver right off the bat.&nbsp;Heron is working with the FDA to expand Zynrelef's label, but this process will take a while to work through.</p>\n<p>The good news is that Zynrelef still holds the potential to rake in upward of $500 million in sales by the middle of the decade. That's a nice chunk of change for a biotech with a sub-$1 billion market cap.</p>\n<p>Why might Heron be gearing up for a noteworthy short squeeze? It is expected to announce important commercial and regulatory updates for Zynrelef before the end of February 2022. If the drug's commercial launch continues to show promise and its label-expansion plans remain on track, the stock should reverse course. The biotech's shares, after all, are currently trading at under 3 times 2023 sales, which is a dirt cheap valuation for a commercial-stage biotech.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Short-Squeeze Candidates That Could Go Parabolic Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Short-Squeeze Candidates That Could Go Parabolic Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 23:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/09/2-short-squeeze-stock-candidates-that-could-go-par/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called \"meme stocks\" generated jaw-dropping gains for investors earlier this year due to this phenomenon.\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/09/2-short-squeeze-stock-candidates-that-could-go-par/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","HRTX":"Heron Therapeutics Inc."},"source_url":"https://www.fool.com/investing/2021/12/09/2-short-squeeze-stock-candidates-that-could-go-par/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190617302","content_text":"Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called \"meme stocks\" generated jaw-dropping gains for investors earlier this year due to this phenomenon.\nThe mechanics of a short squeeze are fairly straightforward. Short-sellers, or investors betting against an equity, are essentially forced to cover their position in response to an uptick in investors buying the stock. The net result, more often than not, is a brief, parabolic-like move higher in the stock in question.\nLast month, short-sellers seemingly took advantage of the widespread weakness across the biopharma space. As a result, scores of biopharma equities sport sizable short positions as a percentage of the outstanding shares. The Alzheimer's  specialist Cortexyme (NASDAQ:CRTX) and the commercial-stage biotech Heron Therapeutics (NASDAQ:HRTX) were two of the most heavily shorted pharma stocks at last count. These two drugmakers, however, could prove to be terrible stocks to bet against. Here's why.\nImage source: Getty Images.\nCortexyme: Alzheimer's drugs are too risky to short\nCortexyme, a small-molecule drug developer, became a huge target for short-sellers after its experimental Alzheimer's disease treatment atuzaginstat flopped in a late-stage trial toward the end of October. In fact, the biotech's shares were the most heavily shorted equity among biopharmas at last count, a little over two weeks ago. Short-sellers are clearly betting that atuzaginstat is basically dead on arrival. That rather dire take might not be the case, however.\nDuring a recent conference call, Cortexyme management said that the drug does appear to show a worthwhile clinical benefit for Alzheimer's patients who also tested positive for the gum-disease bacteria Porphyromonas gingivalis. While this analysis is far from definitive, it may help the company identify the correct patient population to evaluate atuzaginstat in, via another late-stage trial. Cortexyme intends to do just that. Almost immediately after the drug disappointed in this all-comer study, management announced plans to target a more-focused group of patients in another pivotal study.\nWhy is Cortexyme an outstanding short-squeeze candidate? Even as a drug exclusively for Alzheimer's disease patients with an active P. gingivalis infection, it should still generate mega-blockbuster sales (greater than $5 billion). That's a massive revenue stream for a company with a $420 million market cap at present. Cortexyme plans to provide an update to investors on this upcoming clinical trial in the first quarter of 2022. This update could very well spark a short squeeze in the biotech's stock.\nHeron Therapeutics: Down but not out\nHeron Therapeutics has been a top short-seller target for well over a year now. As a result, the biotech's stock is currently one of the most heavily shorted within its immediate peer group. Bears have bet against this small-cap pharma stock for two clear reasons. First, Heron's chemotherapy-induced nausea and vomiting franchise has underwhelmed from a commercial standpoint.\nSecond, the biotech's highly anticipated acute pain medication Zynrelef didn't get the type of broad label from the Food and Drug Administration (FDA) that would have allowed it to become a major growth driver right off the bat. Heron is working with the FDA to expand Zynrelef's label, but this process will take a while to work through.\nThe good news is that Zynrelef still holds the potential to rake in upward of $500 million in sales by the middle of the decade. That's a nice chunk of change for a biotech with a sub-$1 billion market cap.\nWhy might Heron be gearing up for a noteworthy short squeeze? It is expected to announce important commercial and regulatory updates for Zynrelef before the end of February 2022. If the drug's commercial launch continues to show promise and its label-expansion plans remain on track, the stock should reverse course. The biotech's shares, after all, are currently trading at under 3 times 2023 sales, which is a dirt cheap valuation for a commercial-stage biotech.","news_type":1},"isVote":1,"tweetType":1,"viewCount":275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853051120,"gmtCreate":1634744393194,"gmtModify":1634744394346,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/853051120","repostId":"1181418547","repostType":4,"repost":{"id":"1181418547","pubTimestamp":1634744179,"share":"https://www.laohu8.com/m/news/1181418547?lang=&edition=full","pubTime":"2021-10-20 23:36","market":"us","language":"en","title":"PayPal Said to Explore Purchase of Social Media Firm Pinterest","url":"https://stock-news.laohu8.com/highlight/detail?id=1181418547","media":"Bloomberg","summary":"PayPal Holdings Inc. is exploring an acquisition of social media company Pinterest, Inc., people wit","content":"<p><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings Inc.&nbsp;is exploring an acquisition of social media company&nbsp;<b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b>, people with knowledge of the matter said.</p>\n<p>San Jose, California-based PayPal has recently approached Pinterest about a potential deal, the people said, asking not to be identified because the talks are private, Bloomberg <a href=\"https://laohu8.com/S/NWS\">News</a> reports.</p>\n<p>Pinterest shares soar&nbsp;over&nbsp;9%</p>\n<p><img src=\"https://static.tigerbbs.com/35eebc7272c61243c6b3b90c7d4e41da\" tg-width=\"1045\" tg-height=\"562\" referrerpolicy=\"no-referrer\"></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PayPal Said to Explore Purchase of Social Media Firm Pinterest</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPayPal Said to Explore Purchase of Social Media Firm Pinterest\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-20 23:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-20/paypal-weighs-purchase-of-social-media-firm-pinterest><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PayPal Holdings Inc. is exploring an acquisition of social media company Pinterest, Inc., people with knowledge of the matter said.\nSan Jose, California-based PayPal has recently approached Pinterest ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-20/paypal-weighs-purchase-of-social-media-firm-pinterest\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PINS":"Pinterest, Inc.","PYPL":"PayPal"},"source_url":"https://www.bloomberg.com/news/articles/2021-10-20/paypal-weighs-purchase-of-social-media-firm-pinterest","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181418547","content_text":"PayPal Holdings Inc. is exploring an acquisition of social media company Pinterest, Inc., people with knowledge of the matter said.\nSan Jose, California-based PayPal has recently approached Pinterest about a potential deal, the people said, asking not to be identified because the talks are private, Bloomberg News reports.\nPinterest shares soar over 9%","news_type":1},"isVote":1,"tweetType":1,"viewCount":140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859369475,"gmtCreate":1634656181662,"gmtModify":1634656214034,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859369475","repostId":"1183104478","repostType":4,"repost":{"id":"1183104478","pubTimestamp":1634654982,"share":"https://www.laohu8.com/m/news/1183104478?lang=&edition=full","pubTime":"2021-10-19 22:49","market":"us","language":"en","title":"Morgan Stanley’s Kushma Says Bond Yields Climbing Too Quickly","url":"https://stock-news.laohu8.com/highlight/detail?id=1183104478","media":"Bloomberg","summary":"The recent spike in Treasury yields is likely overdone as global demand for “risk-free” assets remai","content":"<p>The recent spike in Treasury yields is likely overdone as global demand for “risk-free” assets remains strong, according to Morgan Stanley Investment Management’s Michael Kushma.</p>\n<p>“Everyone is worried about tapering from the Fed, but the U.S. fiscal deficit should shrink dramatically next year,” Kushma, the firm’s chief investment officer for global fixed income, told Bloomberg TV’s Surveillance Tuesday. “I don’t see a supply-side issue on Treasuries right now. Treasuries are the world’s risk-free asset. That’s not going away. The level of U.S. yields relative to the rest of the world is also very high, meaning the U.S. is a high-yielding alternative.”</p>\n<p>Benchmark 10-year yields hovered near 1.61% on Tuesday. They reached 1.63% last week, the highest since mid-year.</p>\n<p>Markets globally are reckoning with an elevated pace of inflation that’s testing the Federal Reserve’s resolve to keep borrowing costs low until the labor-market recovery progresses further. The allocation to bonds tumbled to the lowest level ever as inflation woes drove expectations for higher rates, according to the latest Bank of America Corp. monthly fund manager survey, conducted in the week through Oct. 14.</p>\n<p>For Kushma, most countries are probably “overpredicting” how fast rates are going to rise.</p>\n<p>“The cyclical bounce in recovery next year will be strong. From a credit perspective, we’ll be fine,” Kushma noted. “We will have continued strong labor markets, strong inflationary pressures at the margin.” But he said, “there is no doubt that inflation is going to slow over the next 12 months.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley’s Kushma Says Bond Yields Climbing Too Quickly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley’s Kushma Says Bond Yields Climbing Too Quickly\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 22:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/morgan-stanley-kushma-says-bond-140757982.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The recent spike in Treasury yields is likely overdone as global demand for “risk-free” assets remains strong, according to Morgan Stanley Investment Management’s Michael Kushma.\n“Everyone is worried ...</p>\n\n<a href=\"https://finance.yahoo.com/news/morgan-stanley-kushma-says-bond-140757982.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MS":"摩根士丹利"},"source_url":"https://finance.yahoo.com/news/morgan-stanley-kushma-says-bond-140757982.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183104478","content_text":"The recent spike in Treasury yields is likely overdone as global demand for “risk-free” assets remains strong, according to Morgan Stanley Investment Management’s Michael Kushma.\n“Everyone is worried about tapering from the Fed, but the U.S. fiscal deficit should shrink dramatically next year,” Kushma, the firm’s chief investment officer for global fixed income, told Bloomberg TV’s Surveillance Tuesday. “I don’t see a supply-side issue on Treasuries right now. Treasuries are the world’s risk-free asset. That’s not going away. The level of U.S. yields relative to the rest of the world is also very high, meaning the U.S. is a high-yielding alternative.”\nBenchmark 10-year yields hovered near 1.61% on Tuesday. They reached 1.63% last week, the highest since mid-year.\nMarkets globally are reckoning with an elevated pace of inflation that’s testing the Federal Reserve’s resolve to keep borrowing costs low until the labor-market recovery progresses further. The allocation to bonds tumbled to the lowest level ever as inflation woes drove expectations for higher rates, according to the latest Bank of America Corp. monthly fund manager survey, conducted in the week through Oct. 14.\nFor Kushma, most countries are probably “overpredicting” how fast rates are going to rise.\n“The cyclical bounce in recovery next year will be strong. From a credit perspective, we’ll be fine,” Kushma noted. “We will have continued strong labor markets, strong inflationary pressures at the margin.” But he said, “there is no doubt that inflation is going to slow over the next 12 months.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826719801,"gmtCreate":1634052671682,"gmtModify":1634052672014,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/826719801","repostId":"1160581040","repostType":4,"repost":{"id":"1160581040","pubTimestamp":1634042129,"share":"https://www.laohu8.com/m/news/1160581040?lang=&edition=full","pubTime":"2021-10-12 20:35","market":"us","language":"en","title":"Another Earnings Season Is Here. What to Expect This Time.","url":"https://stock-news.laohu8.com/highlight/detail?id=1160581040","media":"Barrons","summary":"Earnings season kicks off this week—and it may take some unusually impressive results for stocks to ","content":"<p>Earnings season kicks off this week—and it may take some unusually impressive results for stocks to rise after them.</p>\n<p>Reports from&nbsp;S&amp;P 500&nbsp;companies have been trickling in—only 21 companies in the index had reported through Monday—but this week marks the beginning of what is known as earnings season. Investors will hear from&nbsp;Delta Air Lines&nbsp;(DAL),<a href=\"https://laohu8.com/S/WBA\">Walgreens Boots Alliance</a>&nbsp;(WBA), and UnitedHealth Group (UNH), plus, banking heavyweights JPMorgan Chase &amp; Co. (JPM), Bank of America(BAC). It will provide a view of how businesses performed during the third quarter of 2021, and offer a glimpse into coming quarters as well.</p>\n<p>Analysts are forecasting aggregate earnings per share on the S&amp;P 500 to grow 24.5%, according to S&amp;P Global Market Intelligence. Some of the most economically sensitive sectors are still expecting the largest rebound in EPS, as last year’s third quarter was still ravaged by partial lockdowns. S&amp;P 500 industrial and material companies are expected to see 73% and 90% year-over-year growth, respectively, with energy expected to go from losses to profits. Two of the slowest growing sectors will be the traditionally non-volatile and highly stable consumer staples and utility sectors, expected to see EPS grow 3% and fall 2.9%, respectively.</p>\n<p>No matter the predicted growth, companies need to post big earnings beats in order for their shares to gain much. The S&amp;P 500 has already risen 17.9% this year, as companies benefited from the unprecedented reopening following Covid-19 shutdowns and trillions of dollars of fiscal stimulus. As a result, valuations already reflect a large earnings stream, with the average S&amp;P 500 stock trading at around 20.5 times 12-month forward earnings estimates, above the long-term average in the mid-teens. For the market to live up to those valuations, the index needs to beat expectations by at least 10% in order to rally into year-end, writes Nicholas Colas, co-founder of DataTrek.</p>\n<p>That won’t be easy. Nike (NKE) and FedEx (FDX), for example, posted mixed results as supply chain constraints and rising costs ate into sales and profit margins, causing the stocks to fall 6% and 9%, respectively, the trading day after their earnings reports. The size of earnings beats from early reporters has been shrinking as well. So far, early reporters have topped earnings forecasts by just 4%, well below the 23.2% and 15.5% during the second quarter in 2020 and 2021.</p>\n<p>“We believe that economic headwinds will mitigate the benefits from pricing power and operating leverage, leading to less robust surprises in the third quarter,” writes Jonathan Golub, chief U.S. equity strategist at Credit Suisse.</p>\n<p>Earnings estimates have begun to reflect those headwinds. Third-quarter forecasts have fallen about 0.8% since the beginning of September. That may not seem like much, but if companies say they expect more difficulty accessing supplies and that higher costs are persisting, analysts could revise 2022 estimates lower. “This sets up the first earnings season in the recovery where earnings risk clearly exists,” writes Tavis McCourt, institutional equity strategist at Raymond James.</p>\n<p>The good news? The S&amp;P 500 is down 3.8% from its Sept. 2 all-time high, so there’s a chance that some of the earnings risks are already reflected in the market.</p>\n<p>The question is whether it’s enough.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Another Earnings Season Is Here. What to Expect This Time.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnother Earnings Season Is Here. What to Expect This Time.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 20:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stock-market-earnings-season-preview-51633995452?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earnings season kicks off this week—and it may take some unusually impressive results for stocks to rise after them.\nReports from S&P 500 companies have been trickling in—only 21 companies in the ...</p>\n\n<a href=\"https://www.barrons.com/articles/stock-market-earnings-season-preview-51633995452?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.barrons.com/articles/stock-market-earnings-season-preview-51633995452?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160581040","content_text":"Earnings season kicks off this week—and it may take some unusually impressive results for stocks to rise after them.\nReports from S&P 500 companies have been trickling in—only 21 companies in the index had reported through Monday—but this week marks the beginning of what is known as earnings season. Investors will hear from Delta Air Lines (DAL),Walgreens Boots Alliance (WBA), and UnitedHealth Group (UNH), plus, banking heavyweights JPMorgan Chase & Co. (JPM), Bank of America(BAC). It will provide a view of how businesses performed during the third quarter of 2021, and offer a glimpse into coming quarters as well.\nAnalysts are forecasting aggregate earnings per share on the S&P 500 to grow 24.5%, according to S&P Global Market Intelligence. Some of the most economically sensitive sectors are still expecting the largest rebound in EPS, as last year’s third quarter was still ravaged by partial lockdowns. S&P 500 industrial and material companies are expected to see 73% and 90% year-over-year growth, respectively, with energy expected to go from losses to profits. Two of the slowest growing sectors will be the traditionally non-volatile and highly stable consumer staples and utility sectors, expected to see EPS grow 3% and fall 2.9%, respectively.\nNo matter the predicted growth, companies need to post big earnings beats in order for their shares to gain much. The S&P 500 has already risen 17.9% this year, as companies benefited from the unprecedented reopening following Covid-19 shutdowns and trillions of dollars of fiscal stimulus. As a result, valuations already reflect a large earnings stream, with the average S&P 500 stock trading at around 20.5 times 12-month forward earnings estimates, above the long-term average in the mid-teens. For the market to live up to those valuations, the index needs to beat expectations by at least 10% in order to rally into year-end, writes Nicholas Colas, co-founder of DataTrek.\nThat won’t be easy. Nike (NKE) and FedEx (FDX), for example, posted mixed results as supply chain constraints and rising costs ate into sales and profit margins, causing the stocks to fall 6% and 9%, respectively, the trading day after their earnings reports. The size of earnings beats from early reporters has been shrinking as well. So far, early reporters have topped earnings forecasts by just 4%, well below the 23.2% and 15.5% during the second quarter in 2020 and 2021.\n“We believe that economic headwinds will mitigate the benefits from pricing power and operating leverage, leading to less robust surprises in the third quarter,” writes Jonathan Golub, chief U.S. equity strategist at Credit Suisse.\nEarnings estimates have begun to reflect those headwinds. Third-quarter forecasts have fallen about 0.8% since the beginning of September. That may not seem like much, but if companies say they expect more difficulty accessing supplies and that higher costs are persisting, analysts could revise 2022 estimates lower. “This sets up the first earnings season in the recovery where earnings risk clearly exists,” writes Tavis McCourt, institutional equity strategist at Raymond James.\nThe good news? The S&P 500 is down 3.8% from its Sept. 2 all-time high, so there’s a chance that some of the earnings risks are already reflected in the market.\nThe question is whether it’s enough.","news_type":1},"isVote":1,"tweetType":1,"viewCount":235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864749917,"gmtCreate":1633153866406,"gmtModify":1633153866700,"author":{"id":"3576377533433583","authorId":"3576377533433583","name":"llipinggg","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/864749917","repostId":"1134305481","repostType":4,"repost":{"id":"1134305481","pubTimestamp":1633152909,"share":"https://www.laohu8.com/m/news/1134305481?lang=&edition=full","pubTime":"2021-10-02 13:35","market":"us","language":"en","title":"3 Stocks That Can Double Again in the Fourth Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=1134305481","media":"The motley fool","summary":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this mo","content":"<p>Key Points</p>\n<ul>\n <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>\n <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>\n <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li>\n</ul>\n<p></p>\n<p>It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p>\n<p><b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p>\n<p>1. Crocs</p>\n<p>Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p>\n<p>The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p>\n<p>The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p>\n<p>Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p>\n<p>2. AMC Entertainment</p>\n<p>You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p>\n<p>However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p>\n<p>Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p>\n<p>3. Upstart</p>\n<p>I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p>\n<p>Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p>\n<p>With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Can Double Again in the Fourth Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Can Double Again in the Fourth Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-02 13:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CROX":"卡骆驰","UPST":"Upstart Holdings, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134305481","content_text":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.\nUpstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.\n\n\nIt's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?\nCrocs (NASDAQ:CROX),AMC Entertainment(NYSE:AMC), andUpstart (NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.\n1. Crocs\nRemember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.\nThe comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.\nThe year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?\nDespite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.\n2. AMC Entertainment\nYou may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.\nHowever, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?\nFundamentally speaking, the catalysts are also there.Shang-Chi and the Legend of the Ten Ringsshattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.\n3. Upstart\nI love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.\nGrowth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.\nWith Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}